•xŽR‘åŠwˆćŠw•”—Տ°•ŖŽq•a‘ŌŒŸøŠw

Œ¤‹†‹ĘŃ

2015”N

’˜‘

  1. –k“‡ŒM. —Տ°ŒŸøƒf[ƒ^ƒuƒbƒN2015-2016. •ģ“, t“ś³‰ė, –k‘ŗ¹•Ņ. “Œ‹ž:ˆćŠw‘‰@;2015. ƒvƒƒgƒƒ“ƒrƒ“, ƒvƒƒgƒƒ“ƒrƒ“ƒtƒ‰ƒOƒƒ“ƒgiPF1+2j, ‘ęVˆöŽq, ‘ęVIIˆöŽq, ‘ęVIIIˆöŽq, von Willebrand ˆöŽq, von WillenrandˆöŽqƒ}ƒ‹ƒ`ƒ}[‰šĶ, VWF Ų’fy‘fiADAMTS13j, ‘ęIXˆöŽq, ‘ęXˆöŽq, ‘ęXIˆöŽq, ‘ęXIIˆöŽq, ‘ęXIIIˆöŽq;p.378-91.
  2. –k“‡ŒM. —Տ°ŒŸøƒf[ƒ^ƒuƒbƒN2015-2016. •ģ“Ct“ś³‰ė,–k‘ŗ ¹•Ņ. “Œ‹ž:ˆćŠw‘‰@;2015. ‹ĆŒÅˆöŽqƒCƒ“ƒqƒrƒ^[’萫iƒNƒƒXƒ~ƒLƒVƒ“ƒOŽŽŒ±j,‘ęVIIIˆöŽqƒCƒ“ƒqƒrƒ^[, ‘ęIXˆöŽqƒCƒ“ƒqƒrƒ^[, ‘gDˆöŽqi‘gDƒgƒƒ“ƒ{ƒvƒ‰ƒXƒ`ƒ“j, ‘‘gDˆöŽqŒo˜HƒCƒ“ƒqƒrƒ^[i‘TFPIj. ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“iATj, ƒgƒƒ“ƒrƒ“EƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“•”‡‘ĢiTATj;p.391-5.
  3. –k“‡ŒM. —Տ°ŒŸøƒf[ƒ^ƒuƒbƒN2015-2016. •ģ“, t“ś³‰ė, –k‘ŗ¹•Ņ. “Œ‹ž:ˆćŠw‘‰@;2015. ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“, ƒvƒƒeƒCƒ“C, ƒvƒƒeƒCƒ“S, ‘gDƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^it-PAj, ƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^ƒCƒ“ƒqƒrƒ^[1iPAI-1j, t-PAEPAI-1 •”‡‘Ģ, ƒvƒ‰ƒXƒ~ƒmƒQƒ“, α2|ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[, ƒvƒ‰ƒXƒ~ƒ“Eα2|ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[•”‡‘ĢiPIC ƒeƒXƒgj;p.395-403.
  4. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ƒAƒ“ƒrƒIƒeƒ“ƒVƒ“1•ĻŠ·y‘f‘Ŗ’č;p.82.
  5. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ƒAƒ“ƒ`ƒvƒ‰ƒXƒ~ƒ“ŒŸø;p.85.
  6. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ƒGƒ‰ƒXƒ^[ƒ[1‘Ŗ’č;p.252.
  7. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ‹ĆŒÅˆöŽq‘Ŗ’č, ‹ĆŒÅˆöŽqƒCƒ“ƒqƒrƒ^[‘Ŗ’č;p.558.
  8. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ŒŒ¬”Ā‹@”\ŒŸø;p.696.
  9. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. C1ƒCƒ“ƒAƒNƒ`ƒx[ƒ^[;p.1187.
  10. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ‘gDƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^;p.1482.
  11. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ‘ęVIIIˆöŽq—lRŒ“’č—Ź;p.1522.
  12. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. D-ƒ_ƒCƒ}[;p.1676.
  13. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ƒgƒƒ“ƒrƒ“EƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“•”‡‘Ģ‘Ŗ’č;p.1792-3.
  14. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ƒtƒHƒ“ƒEƒCƒ‹ƒuƒ‰ƒ“ƒhˆöŽq’č—Ź;p.2125.
  15. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ƒtƒBƒuƒŠƒmƒQƒ“EƒtƒBƒuƒŠƒ“•Ŗ‰šŽY•Ø‘Ŗ’č;p.2114-5.
  16. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ƒvƒ‰ƒXƒ~ƒmƒQƒ“‘Ŗ’č;p.2171.
  17. –k“‡ŒM. “ģŽR“°ˆćŠw‘厫“T. ‘ę20”Å. “Œ‹ž:“ģŽR“°;2015. ƒvƒƒgƒƒ“ƒrƒ“ƒtƒ‰ƒOƒƒ“ƒg1+2 ‘Ŗ’č;p.2200.
  18. ˆĄ‘ŗ•q, “n•Ó–¾Ž”. –Ś‚Å‚Ż‚é—Տ°‰h—{ŠwUPDATED‘ę2”ŁDˆćŽ•–ņo”Å•ŅD“Œ‹ž:ˆćŽ•–ņo”Å;2015DŠĢŽ¾Š³i2j|—Տ°ŒŸøEf’f, ŠĢŽ¾Š³‚Ģ•Ŗ—Ž;p.26-33.

Œ“’˜

  1. Ichinose A, Souri M, Osaki T, Matsushita T, Urano T, Ieko M, Tamai Y, Ito T, Kawamae K, Yamamoto M, Madoiwa S, Kurosawa H, Ogawa Y, Yatomi Y, Hanafusa N, Kawasugi K, Ishida F, Kitajima I, Asakura H, Hosono N, Mouri H, Kobayashi T, Wada H, Miyata S, Kashiwagi H, Ikeda M, Yukawa M, Higasa S, Hato T, Okamoto K, Okamura T, Uchiba M, Hashiguchi T, Maruyama I. On AH13 Hemorrhagic Acquired Coagulopathies. Inhibitors of Factor XIII/13 in older patients. Semin Thromb Hemost. 2014 Sep;40(6):704-11. DOI:10.1055/s-0034-1390151.PMID:25215637i2014 ”N–¢ŒfŚ•Ŗj
  2. Ihara H, Hirota K, Miura M, Kitajima I, Yamashita M, Nomura F, Nishumura M, Kamioka K, Onda K, Sunahara S, Suzuki T, Itabashi M, Ishibashi M, Ito S, Ohashi K, Ohta Y, Nobori T, Fujishiro K, Maekawa M, Miyano H, Ando T, Nishumura K, Tsugawa N, Okano T. National Institute of standards and technology SRM 972 as a reference material for serum total 25-hydroxyvitamin D measurements. Int J Anal Bio-Sci. 2014 Mar 31;2(1):1-6.2014 ”N–¢ŒfŚ•Ŗj
  3. Nakamura M, Nishikawa M, Komuro I, Kitajima I, Uetsuka Y, Yamagami T, Minamiguchi H, Yoshimatsu R, Tanabe K, Matsuoka N, Kanmuri K, Ogawa H. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study). Circ J. 2015;79(6):1230-6. DOI:10.1253/circj.CJ-15-0195.PMID:25912695
  4. Ueno T, Niimi H, Yoneda N, Yoneda S, Mori M, Tabata H, Minami H, Saito S, Kitajima I. Eukaryote-Made Thermostable DNA Polymerase Enables Rapid PCR-Based Detection of Mycoplasma, Ureaplasma and Other Bacteria in the Amniotic Fluid of Preterm Labor Cases. PLoS One. 2015 Jun 4;10(6):e0129032. DOI:10.1371/journal.pone.0129032.PMID:26042418
  5. Niimi H, Ueno T, Hayashi S, Abe A, Tsurue T, Mori M, Tabata H, Minami H, Goto M, Akiyama M, Yamamoto Y, Saito S, Kitajima I. Melting Temperature Mapping Method: A Novel Method for Rapid Identification of Unknown Pathogenic Microorganisms within Three Hours of Sample Collection. Sci Rep. 2015 Jul 28;5:12543. DOI:10.1038/srep12543.PMID:26218169
  6. Tajiri K, Kawai K, Minemura M, Yasumura S, Hosokawa A, Kawabe H, Tomizawa G, Sugiyama T. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res. 2015 Jul;45(7):755-63.PMID:25196816

‘ą

  1. –k“‡ŒM. NOACs‚É‘Ī‚·‚郂ƒjƒ^ƒŠƒ“ƒO‚Ģ—L—p«. Int Rev Thromb. 2015 Mar;10(1):22-7.
  2. –k“‡ŒM. NOAC‚ɂ؂Ƃ郂ƒjƒ^ƒŠƒ“ƒO‚Ģ•K—v«. “ś–{ˆćŽ–V•ńD2015 Apr;4748:61-2.
  3. mˆäŒ©‰pŽ÷. ŒŒ‰tŒŸ‘Ģ‚©‚ē‚Ģ‹N‰Š‹Ū‚Ģ’¼ŚŒŸoE“Æ’č•ū–@‚ĢŠJ”­i‰šąE“ĮWj. ‰»Šw—Ć–@‚Ģ—Ģˆę. 2015 Apr;31(Suppl.1):1089-97.
  4. –k“‡ŒM. ‚Ž‰ŒŒĒ‚Ę‚±‚Ž‚ē•Ō‚č. ˆć•ń‚Ę‚ā‚Ü. 2015 Apr;1620:22-3.
  5. –k“‡ŒM. ŒoŒūR‹ĆŒÅ–ņŽg—pć‚ĢŠī‘b’mŽÆ. ”]‚ʏzŠĀ. 2015 May;20(2):117-21.
  6. –k“‡ŒM, –Ų‘ŗ˜a”ü, ‘–ģŒ’Œį, ‚‹“®•F, ŽO“c‘ŗG—Y. S–[×“®‚ĢR‹ĆŒÅ—Ć–@up-to-date. ˆćŠwƒWƒƒ[ƒiƒ‹. 2015 Aug;51(8):1954-65.
  7. ˜a“c‰p•v, –k“‡ŒM. “KŲ‚ȍR‹ĆŒÅ—Ć–@^ƒ‚ƒjƒ^[–@‚ʩ󏭏oŒŒ«Ž¾Š³. “śŒŒšŽ~ŒŒ‰ļŽ. 2015 Nov;26(4):480-1.

Šw‰ļ•ń

  1. Kitajima I. Pharmacological characteristic of Novel oral anticoagulants. The 79th Annual Meeting of the Japanese Circulation Society; 2015 Apr 24; Osaka.
  2. Nishida K, Sakamoto T, Nakatani Y, Kataoka N, Wada O, Mizumaki K, Kitajima I, Inoue H. Chromogenic anti-factor Xa assay and routin coagulation tests in patients with atrial fibrillation treated with apixaban and rivaroxaban. The 79th Annual Meeting of the Japanese Circulation Society; 2015 Apr 24; Osaka.
  3. Tajiri K, Kawai K, Minemura M, Yasumura S, Takahara T, Sugiyama T. Neutrophil/lymphocyte ratio does not predict the recurrence after curative treatment with radiofrequency ablation for small hepatocellular carcinoma. The 6th Asia-Pacific Primary Liver Cancer Expert Meeting(APPLE); 2015 Jul 3-5; Osaka.
  4. –k“‡ŒM. _Œoø_’x‘Ų‚š’ę‚·‚éATRX ĒŒóŒQ‚Ģƒ‚ƒfƒ‹“®•Øģ¬‚É‚ę‚é•a‘Ō‰šĶ.ˆ¤•Q‘åŠw_ŒoƒZƒ~ƒi[;2015 Jan 28;¼ŽR.
  5. –k“‡ŒM. ŒŒšĒf’f‚ĘŽ”—Ć‚Ģi•ą.¼ŽR’ß—Ė‰ļu‰‰‰ļ;2015 Jan 28;¼ŽR.
  6. “ąŽRŒ«Žq, –k“‡ŒM, ¬‘ņˆ»‰Ą, Žs“c•™Žq, –q–{—D”ü, ‹g“cär, •Ä“c“N, Ä“”Ž .“–‰@‚É‚Ø‚Æ‚é‘ŁŽ™f’f‚³‚ź‚½18ƒgƒŠƒ\ƒ~[‚Ģ‡•¹SŠļŒ`‚Ę—\Œć.‘ę21‰ń“ś–{‘ŁŽ™S‘Ÿ•aŠw‰ļŠwpW‰ļ;2015 Feb 13;“Œ‹ž.
  7. –k“‡ŒM.ŒŒšŽ~ŒŒŠw‚©‚ē‚Ż‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ—L—p«.BRAIN Prorection Core Member Meeting in Owari;2015 Feb 23;–¼ŒĆ‰®.
  8. Ż“cK‘¾˜Y, ‘ŗćƒ, ˜a“c‹Å–@, ‹{‰€‘ģ‹X, ˆĄ‘ŗ•q, ™ŽR•q˜Y.RƒŠƒ“Ž‰ŽæR‘ĢĒŒóŒQ‡•¹SLEŠ³ŽŅ‚ɐ¶‚¶‚½‹}«œ‘«”’ŒŒ•a‚É‘Ī‚·‚é“ÆŽķ‘¢ŒŒŠ²×–EˆŚA.‘ę37‰ń“ś–{‘¢ŒŒ×–EˆŚAŠw‰ļ‘‰ļ;2015 Mar 5-7;_ŒĖ.
  9. “‡‹žŽq, ˆĄ‘ŗ•q.“–‰@‚É‚Ø‚Æ‚é5”NŠŌ‚ĢŽ©ŒČŒŒ’™ŒŒó‹µ‚Ę’™ŒŒ‘OŒć‚ĢHb•Ļ“®‚ĢŒŸ“¢.‘ę28‰ń“ś–{Ž©ŒČŒŒ—AŒŒŠw‰ļŠwp‘‰ļ;2015 Mar 6-7;“Œ‹ž.
  10. ‰”“cˆ», ‘åŠp—F‹I, Šp“c”ü—é, ’·“c‘ńĘ, ’Ė“cˆź”Ž, –k“‡ŒM. “ū–[’“‰¹”gŒŸø‚Å‚Ģ‚Ż„‘Ŗ‚µ“¾‚½“ū–[“ą“]ˆŚ‚Ģˆź—į.‘ę54‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļ, ‘ę329‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠCE–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ;2015 Mar 8;–¼ŒĆ‰®.
  11. ć–ģ’q_, mˆäŒ©‰pŽ÷, •Ä“c“æŽq, •Ä“c“N, X³”V, ‘½—t“c—_, “ģ _, āV“”Ž , –k“‡ŒM. eukaryote-made Taq polymerase‚š—p‚¢‚½v‘¬E³Šm‚ČŽq‹{“ąŠ“õĒ‹N‰Š‹ŪŒŸo–@‚Ģ\’z.‘ę54‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļ, ‘ę329‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠCE–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ;2015 Mar 8;–¼ŒĆ‰®.
  12. “cK˜al, ‰Ķ‡Œ’Œį, •õ‘ŗ³ŽĄ, ˆĄ‘ŗ•q, ‚Œ“Ę”ü, ™ŽR•q˜Y.“ļŽ”«• …ŠĒ—‚É‚Ø‚Æ‚éƒgƒ‹ƒoƒvƒ^ƒ“‚Ģ—L—p«‚Ę‚»‚ĢŒų‰Ź—\‘Ŗ‚É‚Ā‚¢‚Ä.‘ę51‰ń“ś–{ŠĢ‘ŸŠw‰ļ‘‰ļ;2015 May 21-22;ŒF–{.
  13. ‰Ķ‡Œ’Œį, “cK˜al, ˆĄ‘ŗ•q, •õ‘ŗ³ŽĄ, ‚Œ“Ę”ü, ™ŽR•q˜Y.DAA‘Ļ«•ĻˆŁ‚š—L‚·‚éHCVƒEƒCƒ‹ƒX‚ĘIL-28B‚Ø‚ę‚ŃIP-10‚ĢŠÖ˜A.‘ę51‰ń“ś–{ŠĢ‘ŸŠw‰ļ‘‰ļ;2015 May 21-22;ŒF–{.
  14. –k“‡ŒM.ŒŒ‰t‹ĆŒÅŒŸø‚ĢÅ‹ß‚Ģ˜b‘č‚ĘŒŸø‹ZpŠJ”­.•½¬26”N“x“ś—§ƒnƒCƒeƒNƒmƒƒW[ƒYŠwpu‰‰‰ļ;2015 Mar 25;‚Š‚½‚æ‚Č‚©.
  15. ‰–ś±^‹|, ‘åŠp—F‹I, ŽRŠŻ“ŽX, ¬£—¢Œb, “ąŽRŒ«Žq, Šp“c”ü—é, ‰”“cˆ», •½ˆä’‰M, Žs“c•™Žq, ˆäć”Ž, –F‘ŗ’¼Ž÷, –k“‡ŒM.ƒtƒ@ƒ|Žl’„ĒC•œpŒć‚Ģ”DPoŽY—į‚É‚Ø‚Æ‚éSƒGƒR[}ŠŒ©‚É‚Ā‚¢‚Ä.‘ę26 ‰ń“ś–{SƒGƒR[}Šw‰ļ;2015 Mar 27;–k‹ćB.
  16. ˆĄ‘ŗ•q, “‡‹žŽq, “¹–ģ~Žq.“K³‚ňĄ‘S‚ČŽ©ŒČŒŒ—AŒŒ„i‚ÉŒü‚Æ‚Ä‚ĢˆćŽtAŠÅŒģŽtA—Տ°ŒŸø‹ZŽt‚Ģ‹¦—Ķ‘Ģ§.‘ę63‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ‘‰ļ(ƒVƒ“ƒ|ƒWƒEƒ€);2015 May 28-30;“Œ‹ž.
  17. “‡‹žŽq, ˆĄ‘ŗ•q.ƒ`[ƒ€ˆć—Ć‚Ę‚µ‚Ä‚ĢPBM|ŠÅŒģŽt‚Ģ–šŠ„‚ĘŠˆ“®|.‘ę63‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ‘‰ļ(ƒVƒ“ƒ|ƒWƒEƒ€);2015 May 28-30;“Œ‹ž.
  18. ˆĄ‘ŗ•q.ƒAƒ‹ƒuƒ~ƒ“Ž”—Ć‚ĢƒGƒrƒfƒ“ƒX‰šĶ‚ĘŽg—pŽwjō’č‚É‚Ā‚¢‚Ä.‘ę63‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ‘‰ļ(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[);2015 May 28-30;“Œ‹ž.
  19. •xŽR—²‰ī, ˆĄ‘ŗ•q, ²’|ˆÉ’ĆŽq, ’†oĖ‘ć, “¹–ģ~Žq, “‡‹žŽq.“–‰@‚É‚Ø‚Æ‚éƒtƒBƒuƒŠƒmƒQƒ“»Ü‚ĢŽg—pó‹µ.‘ę63‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ‘‰ļ;2015 May 28-30;“Œ‹ž.
  20. mˆäŒ©‰pŽ÷, ŽR–{‘P—T, ć–ģ’q_, āV“”Ž , –k“‡ŒM.Tm mapping –@iŠ“õĒ‹N‰Š‹Ūv‘¬“Æ’č–@j‚Ģ‰@“ąŽŽŒ±‰^—pŒ‹‰Ź‚ʐ³Šm«‚Ģ•]‰æ.‘ę89‰ń“ś–{Š“õĒŠw‰ļŠwpu‰‰‰ļ;2015 Apr 16;‹ž“s.
  21. –k“‡ŒM.ƒƒŠƒtƒ@ƒŠƒ“‚ĘNOAC, NOAC ŠŌ‚É‚Ø‚Æ‚é–ņ—ģ—p‚Ģ‘Šˆį‚Ę“Į’„.‘ę37‰ń“ś–{ŒŒšŽ~ŒŒŠw‰ļŠwpW‰ļƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[;2015 May 22;b•{.
  22. –k“‡ŒM.ŒŒšŽ~ŒŒŠw‚©‚ē‚Ż‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ—L—p«.•l–kR‹ĆŒÅ–ņ•×‹­‰ļ;2015 Jun 9;•l¼.
  23. –k“‡ŒM.RCPC ŒŸø’l‚Ģ“Ē‚Ż•ū.Œ¤CƒZƒ“ƒ^[ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[;2015 Jun 16;•xŽR.
  24. –k“‡ŒM.‚Š““xv‘¬‹Nˆö‹Ū“Æ’č‚ĘNF-κB Šˆ«‰»’č—Ź‰šĶ–@‚É‚ę‚é”sŒŒĒŒŸøƒVƒXƒeƒ€ŠJ”­.“Œ–k‘åŠw–ņŠwŒ¤‹†‰Č–ņŠwƒZƒ~ƒi[;2015 Jun 29;å‘ä.
  25. mˆäŒ©‰pŽ÷.Tm mapping –@:ŒŒ‰tŒŸ‘Ģ‚©‚ē‚Ģ‹N‰Š‹Ū‚Ģ’¼ŚŒŸoE“Æ’č•ū–@‚ĢŠJ”­.‘ę27‰ń—Տ°”÷¶•Øv‘¬f’fŒ¤‹†‰ļ‘‰ļ;2015 Jul 4;‹ą‘ņ.
  26. “cK˜al, ‰Ķ‡Œ’Œį, •õ‘ŗ³ŽĄ, ˆĄ‘ŗ•q, ‚Œ“Ę”ü, ™ŽR•q˜Y.‰”­ŠĢ×–EŠą‚É‘Ī‚·‚郉ƒWƒI”gÄŽÜ—Ć–@Œć‚Ģ’·Šś¶‘¶‚ÉŠÖ‚ķ‚éˆöŽq‚ĢŒŸ“¢.‘ę51‰ń“ś–{ŠĢŠąŒ¤‹†‰ļ;2015 Jul 23-24;‹ž“s.
  27. –k“‡ŒM.ŒŒšŽ~ŒŒŠw‚©‚ē‚Ż‚½NOAC ‚Ģˆį‚¢.–L’†ŒŒšŽ”—ĆNetwork Meeting;2015 Jul 25;–L’†.
  28. –k“‡ŒM.ŒŒšĒ‚É‚Ø‚Æ‚é‹ĆŒÅEü—nƒ}[ƒJ[‚Ģ—Տ°“I‰ž—p.ƒVƒXƒƒbƒNƒXƒZƒ~ƒi[in ‚³‚¢‚½‚Ü;2015 Aug 29;‚³‚¢‚½‚Ü.
  29. ć–ģ’q_, mˆäŒ©‰pŽ÷, •Ä“c“æŽq, •Ä“c“N, X³”V, ‘½—t“c—_, “ģ—m, āV“”Ž , –k“‡ŒM.eukaryote-made Taq polymerase‚š—p‚¢‚½v‘¬‚Ő³Šm‚ČŽq‹{Š“õĒ‹N‰Š‹Ū‚ĢŒŸo‚ʐŲ”—‘ŽY‚É‹y‚Ś‚·‰e‹æ.‘ę40 ‰ń–k—¤—Տ°•a—W’k‰ļ;2015 Sep 12;‹ą‘ņ.
  30. ŽRŠŻ“ŽX, “ąŽRŒ«Žq, ‹{”ö¬–¾, ˆÉŒ\ˆź˜Y, ¬ąVˆ»‰Ą, œA–ģŒbˆź, Žs“c•™Žq, –k“‡ŒM.SŽG‰¹øø–Ś“I‚ĢSƒGƒR[‚Å”­Œ©‚³‚ź‚½¶Š„“®–¬”x“®–¬‹NŽnĒiBland-White-Garland ĒŒóŒQj‚Ģ1—į.‘ę40 ‰ń–k—¤—Տ°•a—W’k‰ļ;2015 Sep 12;‹ą‘ņ.
  31. ŽŒ“N—T, ŠÖŒūŒh•¶, X“c”ü, ā–{ƒŽq, –ģŽč—Ē„, ŽR–{‘P—T, –k“‡ŒM.•xŽR‘åŠw•‘®•a‰@‚ɂ؂Ƃ錌‰t”|—{‚Ģ“śķ‹Ę–±ŽžŠŌŠO’ńoó‹µ‚Ę‚»‚Ģ‘Ī‰žŒų‰Ź‚ĢlŽ@.‘ę40 ‰ń–k—¤—Տ°•a—W’k‰ļ;2015 Sep 12;‹ą‘ņ.
  32. •xŽR—²‰ī*, –ģŽč—Ē„, –k“‡ŒM.ƒRƒAƒvƒŒƒXƒ^2000 ‚š—p‚¢‚½ƒvƒƒeƒCƒ“S‘Ŗ’莎–ņ‚ĢŒŸ“¢.“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę47‰ń‘å‰ļ;2015 Oct 9;‰”•l.
  33. –k“‡ŒM.ŒuŒõ‘ŠŠÖ•ŖŒõ–@‚É‚ę‚é“]ŽŹˆöŽqNF-κB‚ĢƒnƒCƒXƒ‹[ƒvƒbƒg’č—Ź–@ŠJ”­‚Ę‚»‚Ģ—Տ°‰ž—p.Ž­Ž™“‡‘åŠwŒŒŠĒ‘ćŽÓ•a‘ŌƒZƒ~ƒi[;2015 Oct 13;Ž­Ž™“‡.
  34. mˆäŒ©‰pŽ÷.Melting Temperature (Tm) mapping –@:ŒŸ‘ĢĢŽęŒć3ŽžŠŌˆČ“ą‚Å‚Ģ”sŒŒĒ‹N‰Š‹Ūv‘¬“Æ’č–@.‘ę58‰ń“ś–{Š“õĒŠw‰ļ’†“ś–{’n•ū‰ļŠwpW‰ļ;2015 Oct 16;“Ž—Ē.
  35. “‡‹žŽq.—AŒŒ‚ÉŠÖ‚ķ‚éŠÅŒģŽt‚Ģ–šŠ„‚ĘŠˆ“®iƒZƒ~ƒi[j.‘ę22‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļH‹GƒVƒ“ƒ|ƒWƒEƒ€;2015 Oct 23;Œyˆä‘ņ.
  36. ć–ģ’q_, mˆäŒ©‰pŽ÷, –k“‡ŒM.eukayote-made Taq polymerase ‚š—p‚¢‚½v‘¬E‚Š““xE³Šm‚ČŽq‹{“ąŠ“õĒ‹N‰Š‹ŪŒŸo–@‚Ģ\’z.‘ę55‰ń—Տ°‰»Šw”NŽŸŠwpW‰ļ;2015 Oct 30;‘åć.
  37. ˆĄ‘ŗ•q, “‡‹žŽq, “¹–ģ~Žq, •xŽR—²‰ī, ’†oĖ‘ć, ²’|ˆÉ’ĆŽq, –k“‡ŒM.“–‰@‚ɂ؂Ƃ鎩ŒČŒŒ—AŒŒ‚ĢŒ»ó‚ʉŪ‘č.‘ę33‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ–k—¤Žx•”—į‰ļ(ƒVƒ“ƒ|ƒWƒEƒ€);2015 Nov 7;•xŽR.
  38. “‡‹žŽq, ˆĄ‘ŗ•q, “¹–ģ~Žq, •xŽR—²‰ī, ’†oĖ‘ć, ²’|ˆÉ’ĆŽq, –k“‡ŒM.Ž©ŒČŒŒ—AŒŒ‚É‚Ø‚Æ‚éŠÅŒģŽt‚Ģ–šŠ„‚Ø‚ę‚Ń–ā‘č“_.‘ę33‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ–k—¤Žx•”—į‰ļ(ƒVƒ“ƒ|ƒWƒEƒ€);2015 Nov 7;•xŽR.
  39. ²’|ˆÉ’ĆŽq, ˆĄ‘ŗ•q, •xŽR—²‰ī, ’†oĖ‘ć, “¹–ģ~Žq, “‡‹žŽq, –k“‡ŒM.“–‰@‚ɂ؂Ƃ鎩ŒČR‘Ģ•Ū—LŠ³ŽŅ‚Ö‚Ģ‘Ī‰ž.‘ę33‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ–k—¤Žx•”—į‰ļ;2015 Nov 7;•xŽR.
  40. •xŽR—²‰ī*, ˆĄ‘ŗ•q, ²’|ˆÉ’ĆŽq, ’†oĖ‘ć, “¹–ģ~Žq, “‡‹žŽq, –k“‡ŒM.—AŒŒŒć‚Ɍċz•s‘S‚ŖoŒ»‚µ, TACO‚Ŗ‹^‚ķ‚ź‚½Ē—į.‘ę33‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ–k—¤Žx•”—į‰ļ;2015 Nov 7;•xŽR.
  41. “¹–ģ~Žq, ˆĄ‘ŗ•q, •xŽR—²‰ī, ’†oĖ‘ć, ²’|ˆÉ’ĆŽq, “‡‹žŽq, –k“‡ŒM.“–‰@‚ɂ؂Ƃ鑽ŒŒ¬”ĀŒŒŸ÷iPRPj—Ć–@‚É‘Ī‚·‚é“–•”‚Å‚Ģ‹Zp‹¦—Ķ.‘ę33 ‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ–k—¤Žx•”—į‰ļ;2015 Nov 7;•xŽR.
  42. ’·“cI•½, “cK˜al, ‰Ķ‡Œ’Œį, ‹{‰€‘ģ‹X, •õ‘ŗ³ŽĄ, ˆĄ‘ŗ•q, ‚Œ“Ę”ü, ŽO—֏dŽ”, ™ŽR•q˜Y.‰©įt‚Ŗ‘J‰„‚µ‚½–ņ•Ø«ŠĢįŠQ‚Ģ1—į.“ś–{Į‰»Šķ•aŠw‰ļ–k—¤Žx•”‘ę121 ‰ń—į‰ļ;2015 Nov 8;‹ą‘ņ.
  43. –k“‡ŒM.ŒŒ‰t‹ĆŒÅŠw‚©‚ē‚Ż‚½Xa‘jŠQ–ņ‚Ģ—L—p«.R‹ĆŒÅ–ņ‚Ģ“K³Žg—p‚šl‚¦‚é‰ļ;2015 Nov 18;•xŽR.
  44. –k“‡ŒM.”ńƒrƒ^ƒ~ƒ“KŒoŒūR‹ĆŒÅ–ņiNOACj‚Ģ–ņ—ģ—p‚Ę—Õ°ŒŸø.—Տ°ŒŸøˆćŠwCatch upƒZƒ~ƒi[, ‘ę62‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2015 Nov 20;Šņ•Œ.
  45. ć–ģ’q_, mˆäŒ©‰pŽ÷, •Ä“c“æŽq, •Ä“c“N, X³”V, ‘½—t“c—_, “ģ—m, āV“”Ž , –k“‡ŒM.eukaryote-made Taq polymerase ‚š—p‚¢‚½v‘¬‚Ő³Šm‚ČŽq‹{“ąŠ“õĒ‹N‰Š‹Ū‚ĢŒŸo‚ʐŲ”—‘ŽY‚É‹y‚Ś‚·‰e‹æ.‘ę62‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2015 Nov 20;Šņ•Œ.
  46. –ģŽč—Ē„, ŽO‘ŗ‘וF, –Ā‰Ķ@‘, ŽR–{‘P—T, –k“‡ŒM.“–‰@‚É‚Ø‚Æ‚éMRSA ‚Ģ•Ŗ—£ó‹µ‚Ę–ņÜŠ“Žó«‚Ģ„ˆŚ.‘ę62‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2015 Nov 20;Šņ•Œ.
  47. •õ‘ŗ³ŽĄ, “cK˜al, ‰Ķ‡Œ’Œį, “‡“c“‘¾˜Y, ‚–ŲG–¾, ˆĄ‘ŗ•q, ‚Œ“Ę”ü, ™ŽR•q˜Y.B Œ^–«ŠĢ‰Š‚É‘Ī‚·‚éPeg-IFNα2a “Š—^Ē—į‚ĢŒŸ“¢.‘ę41‰ń“ś–{ŠĢ‘ŸŠw‰ļ¼•”‰ļ;2015 Dec 3-4;–¼ŒĆ‰®.
  48. “cK˜al, ‰Ķ‡Œ’Œį, •õ‘ŗ³ŽĄ, ˆĄ‘ŗ•q, ‚Œ“Ę”ü, ™ŽR•q˜Y.Elastography‚š—p‚¢‚½ŠĢüˆŪ‰»•]‰æ‚Ģ—L—p«‚ĢŒŸ“¢.‘ę41‰ń“ś–{ŠĢ‘ŸŠw‰ļ¼•”‰ļ;2015 Dec 3-4;–¼ŒĆ‰®.
  49. –k“‡ŒM.ŒŒ‰t‹ĆŒÅŠw‚©‚ē‚Ż‚½ŒoŒūR‹ĆŒÅ–ņ‚Ģ–ņ—ģ—p.CVMW2015 SŒŒŠĒ‘ćŽÓ, ‘ę23‰ń“ś–{ŒŒŠĒ¶•ØˆćŠw‰ļŠwpW‰ļ, ‘ę19‰ń“ś–{SŒŒŠĒ“ą•Ŗ”åŠwp‘‰ļ, ‘ę32‰ń‘ŪS‘ŸŒ¤‹†‰ļ“ś–{•”‰ļ, ‘ę37‰ńS‹Ų¶ŒŸŒ¤‹†‰ļ˜A‡ƒZƒ~ƒi[;2015 Dec 11;_ŒĖ.

‚»‚Ģ‘¼

  1. –k“‡ŒM. RVWFŽ©ŒČR‘ĢŒŸo‚Ģ‚½‚ß‚ĢƒCƒ€ƒmƒNƒƒ}ƒg–@‚É—p‚¢‚éRŒ“‚Ę“ĮˆŁR‘Ģ‚ĢŒŸõ.Œś¶˜J“­‰ČŠwŒ¤‹†“ļŽ”«Ž¾Š³“™ŽĄ—p‰»Œ¤‹†Ž–‹Ę”Ē‰ļ‹ciˆź£”Ēj;2015 Jan 25;“Œ‹ž.
  2. mˆäŒ©‰pŽ÷. ˆā“`ŽqŒŸøƒrƒWƒlƒX ŒŸø‹Zp‚ĢŒ»ó‚Ę–ā‘č“_. —Տ°‰»Šw. 2015 Jan;44(1):76
  3. ˆĄ‘ŗ•q. ƒAƒ‹ƒuƒ~ƒ“Ž”—Ć‚ĢƒGƒrƒfƒ“ƒX‰šĶ‚ĘŽg—pŽwjō’č‚É‚Ā‚¢‚Ä. ‘ę18‰ń•Ÿ‰ŖŒ§—AŒŒ‡“ƈĻˆõ‰ļ;2015 Jan 30;•Ÿ‰Ŗ.
  4. ¼ˆäĖŽq,‚‘qˆźŒb,–ģŒūŽõŒb,–k“‡ŒM. ‘åŠw¶‚É‚Ø‚Æ‚é–ƒ]E•—]R‘Ģ‰æ‚Ģ„ˆŚ. Šw‰€‚Ģ—Տ°Œ¤‹†. 2015 Mar;14:1-4.
  5. –q–ģ–Ī‹`,¼‰ŗ³,•Ä‘ŗ—YŽm,ˆĄ‘ŗ•q,‹I–ģCˆź,‰Ķ–ģ•O,“c’†’©Žu,¼–{‰ė‘„,˜eā–¾”ü,“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļƒKƒCƒhƒ‰ƒCƒ“ˆĻˆõ‰ļƒAƒ‹ƒuƒ~ƒ“»Ü‚ĢŽg—pŽwjō’č‚ÉŠÖ‚·‚éƒ^ƒXƒNƒtƒH[ƒX. ‰ČŠw“IŖ‹’‚ÉŠī‚Ć‚¢‚½ƒAƒ‹ƒuƒ~ƒ“»Ü‚ĢŽg—pƒKƒCƒhƒ‰ƒCƒ“i2015”N6ŒŽ1“ś‘ę1”Łj. “ś–{—AŒŒ×–EŽ”—ĆŠw‰ļŽ. 2015 Jun;61(3):ŠŖ––3-22.
  6. ¼‰ŗ³,¼–{‰ė‘„,‹{“c–ĪŽ÷,‰H“”‚–¾,‹I–ģCˆź,ˆĄ‘ŗ•q,‰Ŗčm. ‰ČŠw“IŖ‹’‚ÉŠī‚Ć‚­—AŒŒƒKƒCƒhƒ‰ƒCƒ“‚Ģō’č“™‚ÉŠÖ‚·‚錤‹† •½¬26”N“x‘Š‡E•Ŗ’SŒ¤‹†•ń‘ Œś¶˜J“­‰ČŠwŒ¤‹†”ļ•ā•‹ąˆć–ņ•iEˆć—Ć‹@Šķ“™ƒŒƒMƒ…ƒ‰ƒgƒŠ[ƒTƒCƒGƒ“ƒX‘‡Œ¤‹†Ž–‹Ę. –¼ŒĆ‰®:¼‰ŗ³;2015. p.78
  7. ˆĄ‘ŗ•q. ƒAƒ‹ƒuƒ~ƒ“Ž”—Ć‚ĢƒGƒrƒfƒ“ƒX‰šĶ‚ĘŽg—pŽwjō’č‚É‚Ā‚¢‚Ä. ‘ę18‰ń•Ÿ‰ŖŒ§—AŒŒ‡“ƈĻˆõ‰ļ•ń‘. 2015 Mar:23-44.
  8. ˆĄ‘ŗ•q. —AŒŒ—Ć–@‚Ģl‚¦•ū‚Ę“ą‰Č‚Ģ—AŒŒ. ‘ę14‰ńŠw‰ļ”F’čEŽ©ŒČŒŒ—AŒŒŠÅŒģŽt§“x‡“ÆŒ¤C‰ļ;2015 Mar 6;“Œ‹ž.
  9. ˆĄ‘ŗ•q. —AŒŒ‚š‚ß‚®‚éÅ‹ß‚Ģ˜b‘č. Ļ¶‰ļ•xŽR•a‰@—AŒŒ—Ć–@Œ¤C‰ļ;2015 Mar 17;•xŽR.
  10. ˆĄ‘ŗ•q. ƒAƒ‹ƒuƒ~ƒ“Ž”—Ć‚ĢƒGƒrƒfƒ“ƒX‰šĶ‚ĘŽg—pŽwjō’č‚É‚Ā‚¢‚Ä. ŒŒŸ÷•Ŗ‰ę»ÜƒtƒH[ƒ‰ƒ€;2015 Mar 26;–¼ŒĆ‰®.
  11. –k“‡ŒM. f—ĆŽQ‰ĮŒ^—Տ°ŽĄKŽĄŽ{ƒKƒCƒhƒ‰ƒCƒ“f—ĆŽQ‰ĮŒ^—Տ°ŽĄK‚É‚Ø‚Æ‚éˆć—ĆˆĄ‘S. ‘ę1‰ń•xŽR‘åŠw•‘®•a‰@ˆć—ĆˆĄ‘SuK‰ļ;2015 Apr 23;•xŽR.
  12. ˆĄ‘ŗ•q. ƒCƒ“ƒ^[ƒtƒFƒƒ“ƒtƒŠ[‚ĢCŒ^ŠĢ‰ŠŽ”—Ć ŠŌ‹ß‚É”—‚Į‚½HCV‚Ģ–o–Å. ‘ę29‰ńŠĢŽõ‰ļu‰‰‰ļ;2015 Apr 25;•xŽR.
  13. ˆĄ‘ŗ•q. ƒAƒ‹ƒuƒ~ƒ“Ž”—Ć‚ĢƒGƒrƒfƒ“ƒX‰šĶ‚ĘŽg—pŽwjō’č‚É‚Ā‚¢‚Ä. ‘ę1‰ń‹}«Šś—A‰tŠĒ—Œ¤‹†‰ļ;2015 Aug 1;“Œ‹ž.
  14. mˆäŒ©‰pŽ÷. CHIPS –@iˆā“`Žq•ĻˆŁƒXƒNƒŠ[ƒjƒ“ƒO–@j‚Ķˆā“`ŽqŒŸø‚ĢŠČ•Ö‰»E’įƒRƒXƒg‰»‚É–š—§‚Ā. —Տ°‰»Šw. 2015 Oct;44(4):326.
  15. –k“‡ŒM. R-CPC ‰‹‰ƒŒƒxƒ‹. •½¬26”N“xŒŸøą–¾E‘Š’k‚Ŗ‚Å‚«‚é—Տ°ŒŸø‹ZŽtˆē¬uK‰ļ;2015 Mar 15;•xŽR.
  16. Œ““cŒ’‰E. ŒŸøą–¾‚ĢŽĄŪA‰‹‰ƒŒƒxƒ‹. •½¬26”N“xŒŸøą–¾E‘Š’k‚Ŗ‚Å‚«‚é—Տ°ŒŸø‹ZŽtˆē¬uK‰ļ;2015 Mar 15;•xŽR.
  17. –k“‡ŒM. R-CPCq‰‹‰ƒŒƒxƒ‹r. •½¬27”N“xŒŸøą–¾E‘Š’k‚Ŗ‚Å‚«‚é—Տ°ŒŸø‹ZŽtˆē¬uK‰ļ;2015 Oct 25;•xŽR.
  18. Œ““cŒ’‰E. ŒŸøą–¾‚ĢŽĄŪq‰‹‰ƒŒƒxƒ‹r. •½¬27”N“xŒŸøą–¾E‘Š’k‚Ŗ‚Å‚«‚é—Տ°ŒŸø‹ZŽtˆē¬uK‰ļ;2015 Oct 25;•xŽR.
  19. –k“‡ŒM. —Տ°ŒŸøø“xŠĒ—‚Ģd—v«‚šÄŠm”F‚µ‚Ü‚µ‚傤. —Տ°ŒŸøø“xŠĒ—’²ø•ń‘. 2015;27:1.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2014”N

’˜‘

  1. –k“‡ŒM. ƒXƒ^ƒ“ƒ_[ƒhŒŸøŒŒ‰tŠw‘ę3”Å. “ś–{ŒŸøŒŒ‰tŠw‰ļ•Ņ. “Œ‹ž:ˆćŽ•–ņo”Å;2014. ŒŒŠĒ‚ĢˆŁķ;p.345-9.
  2. mˆäŒ©‰pŽ÷ŠÄC. ?‚Ŗ!‚É‚Č‚éˆā“`ŽqŒŸøVol.2 ˆā“`Žq. Sysmex. 2014 10.

Œ“’˜

  1. Hirono K, Sekine M, Shiba N, Hayashi S, Nakaoka H, Ibuki K, Saito K, Watanabe K, Ozawa S, Higuma T, Yoshimura N, Kitajima I. Ichida F. N-terminal pro-brain natriuretic peptide as a predictor of reoperation in children with surgically corrected tetralogy of fallot. Circulation Jurnal. 2014;78(3):693-700.PMID:24334564
  2. Shirahata A, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, Kajiki M, Honda G, Sataka Y. Recombinant soluble human thrombomodulin (thrombomojurin Alfa) in the treatment of neonatal disseminated intravascular coagulation. European Journal of Pediatrics. 2014;173(3):303-11.PMID:24005342
  3. Shirahata A, Mimuro J, Takahashi, H, Tsuji H, Kitajima I, Matsushita T, Eguchi Y, MD, Kitamura N8, Honda G, Sakata Y:Post-Marketing Surveillance of Recombinant Human Soluble Thrombomodulin (Thrombomodulin Alfa) in Pediatric Patients with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis. 2014;20(5):465-72.PMID:24563247
  4. Asakura H, Takahashi H, Matsushita T, Ninomya H, Honda G, Mimuro J, Eguchi Y, Kitajima I, Sakata Y. Post-maketing surveillance of thrombomodulin alfa, a novel drug for treatment of disseminated intravascular coagulation treatment- Safety and efficacy in 1,032 patients assosiated with hematologic makignancy. Thromb Res. 2014;133:364-70.PMID:24440141
  5. Mastusita T, Watanabe J, Honda G, Mimuro J, Tsuji H, Eguchi Y, Kitajima I, Sakata Y. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of a open label multicenter postmarketing surveillance study cohort. Thromb Res. 2014;133(5):772-81.PMID:24636871
  6. Eguchi Y, Gando S, Ishikura H, Saitoh D, Mimuro J, Takahashi H, Kitajima I, Tshuji H, Matsushita T, Tsujita R, Nagao O, Sakata Y. Post-marketing surveillance data of the thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J Intensive Care. 2014 Apr 30;2(1):30.PMID:25520842
  7. Takiwaki M, Tomoda F, Koike T, Taki T, Inoue H, Kigawa M, Kitajima I, Uji Y. Increased level of small dense low-density lipoprotein cholesterol associated with hemorheological abnormalities in untreated early stage essential hypertensive. Hypertens Res. 2014 Nov;37(11):1008-13.PMID:24990092

‘ą

  1. –k“‡ŒM. V‹KŒoŒūR‹ĆŒÅ–ņ(NOAC)‚Ģƒ‚ƒjƒ^[–@. ˆć–ņƒWƒƒ[ƒiƒ‹. 2014;50(2):97-102.
  2. –k“‡ŒM. V‹KŒoŒūR‹ĆŒÅ–ņ‚Ģ–ņ—Šw“I“Į’„.zŠĀŠķ“ą‰Č.2014;75(5):542-8.
  3. –k“‡ŒM, ‹“ŒūĘl, X‰ŗ‰p—¢Žq. V‹KŒoŒūR‹ĆŒÅ–ņNOAC‚Ģƒ‚ƒjƒ^ƒŠƒ“ƒOŒŸø‚Ģ‰Ā”\«‚Ę‚»‚Ģ•W€‰»‚ÉŒü‚Æ‚Ä. “ś–{ŒŒšŽ~ŒŒŠw‰ļŽ. 2014;25(4):552-3.
  4. –k“‡ŒM. S–[×“®Š³ŽŅ‚ɂ؂Ƃ錌‰t‹ĆŒÅ˜“i‚ĢƒƒJƒjƒYƒ€‚ĘŒoŒūR‹ĆŒÅ–ņ‚ĢŒŒšŽ~ŒŒŠw“IlŽ@. “ś–{S“dŠw‰ļŽ. 2014;34(4):S4-3-10.
  5. z–K•”Ķ, ‘Oģ^l, ¬ŽÄŒ«—m, ”nź®Žu, ”яĄ—RŽk, ˆäŒ“Œ«Ž”, ŒĆģ‘׎i, “c’†–õl, ŒĆŽsŒ«Œį, ˜a“c—²Žu, ‹g“c”Ž, ’£‘֏G˜Y, “nē³’¼Ž÷, –k“‡ŒM. —Տ°ŒŸø‚ĢƒKƒCƒhƒ‰ƒCƒ“JSLM2012‚ĢŠˆ—p|‰ü’ł‚Ģƒ|ƒCƒ“ƒg‚šˆź“—¼’f|. —Տ°•a—. 2014;62(7):702-9.
  6. –īā³O, ‘–ģŒ¤Œį, –k“‡ŒM, •½–ģĘ”V, ‰r“cįĮŽ”, R‹ĆŒÅ—Ć–@‚É”ŗ‚¤“ŖŠW“ąoŒŒ, Cardio-Coagulation, 2014;1(3):6-14.

Šw‰ļ•ń

  1. Niimi H, Ueno T, Kitajima I. The Melting Temperature (TM) Mapping Method: A Novel Method That Enables Rapid Identification of Unknown Pathogenic Microorganisms within Three Hours of Patient Sample Collection. The 9th International Conference of Clinical Laboratory Automation and Robotics; 2014 Apr 19; Yokohama.
  2. Niimi H, Ueno T, Hayashi S, Abe A, Tsurue T, Mori M, Tabata H, Minami H, Goto M, Saito S Kitajima I. The Melting Temperature (Tm) Mapping Method: A Novel Method That Enables Rapid Identification of Unknown Pathogenic Bacteria In Sepsis Within Three Hours of Whole Blood Collection. ECCMID 2014; 2014 May 10-13; Barcelona.
  3. Niimi H, Kitajima I. The Tm mapping method. A noel rapid, easy, and cost-effective method that identifies unknown pathogenic microorganisms within 3 hours of patients sample collection. Microbiology and Infectious Diseases Asia Congress; 2014 Jun 10-11; Singapore.
  4. mˆäŒ©‰pŽ÷. Tm mapping–@Š³ŽŅŒŸ‘ĢĢŽęŒć3ŽžŠŌˆČ“ą‚Å‚Ģ‹N‰Š‹Ūv‘¬“Æ’č–@D‘ę25‰ń“ś–{—Տ°”÷¶•ØŠw‰ļ‘‰ļ; 2014 Feb 1; –¼ŒĆ‰®.
  5. –k“‡ŒM. Novel Oral Anticoagulant(NOAC)‚É‘Ī‚·‚é‹ĆŒÅEü—nŒŸø•W€‰»‚Ģ“®ŒüD‘ę8‰ń“ś–{ŒŒšŽ~ŒŒŠw‰ļŠwp•W€‰»ˆĻˆõ‰ļƒVƒ“ƒ|ƒWƒEƒ€;2014 Feb 22;“Œ‹ž.
  6. mˆäŒ©‰pŽ÷. V‹Kˆā“`Žq•ĻˆŁƒXƒNƒŠ[ƒjƒ“ƒO–@‚Ģ”­–¾‚Ęˆā“`Žqf’f‚Ö‚Ģ‰ž—pD‘ę68‰ń•xŽRŒ§ˆćŠw‰ļ;2014 Feb 22;•xŽR.
  7. –k“‡ŒM. ŒŒšŽ~ŒŒ§Œä‚ĢŽå–šƒgƒƒ“ƒrƒ“‚š„‚éÅ‹ß‚Ģ˜b‘č. ‘ę43‰ńV“sŽsŒŒšŽ~ŒŒŒ¤‹†‰ļ;2014 Mar 7;“Œ‹ž.
  8. –k“‡ŒM. ŒŒšŽ~ŒŒŠw‚©‚ē‚Ż‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ—L—p«Dƒvƒ‰ƒUƒLƒT”­”„3Žü”N‹L”Ou‰‰ in ē—t;2014 Apr 15;ē—t.
  9. –k“‡ŒM. ƒgƒƒ“ƒrƒ“ģ—p‚Ģ‘½–Ź«‚Ęƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ—L—p«. S–[×“®Š³ŽŅ‚³‚ń‚Ģ”]‚šŒģ‚錤‹†‰ļ;2014 Apr 19;_ŒĖ.
  10. –k“‡ŒM. ’¼Śƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ–ņ—ģ—p‚Ę—L—p«. R‹ĆŒÅ—Ć–@VŽž‘ć ‘ę2‰ńŒŒšĒšŠwpW‰ļ;2014 May 23;‰”•l.
  11. mˆäŒ©‰pŽ÷. Tm mapping–@:Š³ŽŅŒŸ‘ĢĢŽęŒć3ŽžŠŌˆČ“ą‚Å‚ĢŠ“õĒ‹N‰Š‹Ūv‘¬“Æ’č–@. ‘ę79‰ń“ś–{ƒCƒ“ƒ^[ƒtƒFƒƒ“EƒTƒCƒgƒJƒCƒ“Šw‰ļŠwpW‰ļ;2014 Jun 19;ŽD–y.
  12. –k“‡ŒM. V‹KŒoŒūR‹ĆŒÅ–ņ‚ĢˆĄ‘S«‚Ę—LŒų«‚Ģƒ‚ƒjƒ^ƒŠƒ“ƒO. ‘ę4‰ńŒŒšŽ~ŒŒŒŸøŒ¤‹†‰ļ in Tokyo; 2014 Jun 28;“Œ‹ž.
  13. –k“‡ŒM. ŒŒšŽ~ŒŒŠw‚©‚ē‚Ż‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ—L—p«. Core Member Meeting;2014 Jul 24;L“‡.
  14. –k“‡ŒM. Novel Oral Anticoagulant (NOAC)‚Ģƒ‚ƒjƒ^ƒŠƒ“ƒOŒŸø‚ĢŒ»ó‚Ę‚»‚Ģ‰Ā”\«. ‘ę15‰ń“ś–{ŒŸøŒŒ‰tŠw‰ļŠwpW‰ļ;2014 Jul 20;å‘ä.
  15. –k“‡ŒM. ŒŒšŽ~ŒŒ§Œä‚ĢŽå–šƒgƒƒ“ƒrƒ“‚š„‚é˜b‘č|‹ĆŒŒ•ŖŽqƒ}[ƒJ[‚š’†S‚Ɂ|;2014 Sep 27;•xŽR.
  16. –k“‡ŒM. R‹ĆŒÅ—Ć–@‚É‚Ø‚Æ‚é“ŖŠW“ąoŒŒ. Toyama Network Meeting;2014 Nov 26;•xŽR.
  17. –k“‡ŒM. ŒŒ‰t‹ĆŒÅŠw‚©‚ē‚Ż‚½V‹KŒoŒūR‹ĆŒÅ–ņ‚Ģ–ņ—Šw“I“Į’„. ‘ę35‰ń“ś–{—Տ°–ņ—Šw‰ļŠwp‘‰ļ;2014 Dec 4;¼ŽR.
  18. mˆäŒ©‰pŽ÷. ŒŒ‰t’†‚Ģ‹Ū”‚š”sŒŒĒdĒ“x‚āŽ”—ĆŒų‰Ź‚ĢV‚½‚ČŽw•W‚Ę‚·‚錟ø‹Zp‚ĢŠJ”­. ‘ę61‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļŠwp„iƒvƒƒWƒFƒNƒg1;2014 Nov 25;•Ÿ‰ŖD
  19. X“c–¢, ŠÖŒūŒh•¶, ā–{ƒŽq, –ģŽč—Ē„, –Ā‰Ķ@‘, ŽR–{‘P—T. “–‰@‚É‚Ø‚Æ‚é‰ß‹Ž10”NŠŌ‚ĢPseudomonas aeruginosa‚Ģ•Ŗ—£ó‹µ‚Ø‚ę‚Ń–ņÜŠ“Žó«‚Ģ„ˆŚ. ‘ę25‰ń“ś–{—Տ°”÷¶•ØŠw‰ļ‘‰ļ;2014 Feb 1-2;–¼ŒĆ‰®.
  20. ŽĀŒ“Š°–¾, —é–Ų³N, ‰““c_Ži, –k“‡ŒMDˆćH‚Ŗ˜AŒg‚·‚鉻ŠwEƒoƒCƒIƒZƒ“ƒT‚ĢŠJ”­‚Ę—Õ°ŒŸø‚Ģ‰Ū‘艚Œˆ‚Ö‚Ģ‰ž—pD2014 •xŽR‘åŠwŠwpŒš—¬‰ļ;2014 Mar 10;•xŽRD 21) ŽR‰ŗ•ō*D”Ä—p‹@‚É‚ę‚éCK-MB mass –@‚É—L—p«DĪģŒ§ˆćŠwŒŸøŠw‰ļƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[;2014 Mar 23;‹ą‘ņD
  21. ć–ģ’q_, mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ģ—m, āV“”Ž , –k“‡ŒMDEukaryote-made Taq polymerase ‚š—p‚¢‚½v‘¬‚Ő³Šm‚ČŽq‹{“ąŠ“õĒ–@‚Ģ\’zD‘ę53‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļ ‘ę328‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠCE–k—¤Žx•”—į‰ļ;2014 Mar 9;•ŸˆäD
  22. ‰”“cˆ»*, ģ“Y—F‹I, –ģŽč—Ē„, –k“‡ŒMD’¼Śƒgƒƒ“ƒrƒ“‘jŠQ–ņƒ_ƒrƒKƒgƒ‰ƒ“ƒ‚ƒjƒ^ƒŠƒ“ƒOŒŸø‚ÉŠÖ‚·‚錟“¢D‘ę53‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļ ‘ę328‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠCE–k—¤Žx•”—į‰ļ;2014 Mar;•ŸˆäD
  23. Žß‰i“Žu, Œ““cŒ’‰E, •ž•”’[Ž÷, ‹v•Ū“c—ŗ•½, –k“‡ŒM, ŽRčŒõĶD‰“Šu‹•ŒŒƒvƒŒƒRƒ“ƒfƒVƒ‡ƒiƒ‹‚É‚ę‚錌š—\–hŒų‰ŹD“ś–{–ƒŒ‰ČŠw‰ļ‘ę61‰ńŠwpW‰ļ;2014 May 16;‰”•lD
  24. ŽR‰ŗ•ō*, ‘å’ĪW–ē, –ģŽč—Ē„, –k“‡ŒMDƒ‰ƒeƒbƒNƒX‹ĆW”ä‘÷–@‚É‚ę‚éV‹KCK-MB’`”’‘Ŗ’莎–ņ‚ĢŠī‘b“IŒŸ“¢‚Ø‚ę‚Ń“d‹C‰j“®–@‚É‚ę‚鉚ĶD‘ę25‰ń“ś–{—Տ°‰»Šw“ŒŠC–k—¤Žx•”‘‰ļ ‘ę33 ‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ;2014 Aug 2;–¼ŒĆ‰®D
  25. mˆäŒ©‰pŽ÷, ć–ģ’q_, X³”V, ™]˜a–Ī, –k“‡ŒMDŠ“õĒ‹N‰Š‹Ūv‘¬“Æ’č–@(Tm mapping–@)‚ĢŠw“ąŽŽŒ±‰^—p‚ɂ؂Ƃ鐳Šm«‚Ģ•]‰æD‘ę54‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ;2014 Sep 5;“Œ‹žD
  26. ŽR‰ŗ•ō*, –k“‡ŒMDLC-MS/MS‚š—p‚¢‚½ŒŒ“25-ƒqƒhƒƒLƒVƒrƒ^ƒ~ƒ“‚Ģ‘Ŗ’čD‘ę54‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ;2014 Sep 5;“Œ‹žD
  27. “ąŽRŒ«Žq, ’‡‰Ŗ‰pK, ˆÉŒ\ˆź˜Y, ¬ąVˆ»‰Ą, œA–ģŒbˆź, Žs“c•™Žq, –k“‡ŒMDS‘ŸÄ“ÆŠś—Ć–@‚Ģ‘OŒć‚Ģ•]‰æ‚ɐSƒGƒR[‚Ŗ—L—p‚Å‚ ‚Į‚½¬Ž™‚Ģ1—įD‘ę22‰ń–k—¤—Տ°•a—W’c‰ļƒZƒ~ƒi[;2014 Sep 20;•xŽRD
  28. ŽR‰ŗ•ō*, ‘å’ĪW–ē, ‘½‰ź—R‹IŽq, ģ“‡–ŅŽu, –ģŽč—Ē„, –k“‡ŒMDCK-MB ’`”’—Ź‘Ŗ’莎–ņuL ƒ^ƒCƒvƒƒR[CK-MB massv‚Ģ‹@”\•]‰æ‚Ø‚ę‚Ń“d‹C‰j“®–@‚É‚ę‚鉚ĶD‘ę22‰ń–k—¤—Տ°•a—W’c‰ļƒZƒ~ƒi[;2014 Sep 20;•xŽRD
  29. ć–ģ’q_, mˆäŒ©‰pŽ÷, āV“”Ž , –k“‡ŒMDTm mapping –@iŠ“õĒ‹N‰Š‹Ūv‘¬“Æ’č–@j‚Ģ‰@“ąŽŽŒ±‰^—pŒ‹‰Ź‚Ę‚»‚Ģ•]‰æD‘ę22‰ń–k—¤—Տ°•a—W’c‰ļƒZƒ~ƒi[;2014 Sep 20;•xŽRD
  30. ŠÖŒūŒh•¶, X“c–¢, ā–{ƒŽq, –ģŽč—Ē„, –k“‡ŒMDˆÓŽÆįŠQ‚šŒ_‹@‚É”­Œ©‚³‚ź‚½”dŽķ«ƒmƒJƒ‹ƒWƒAĒ‚Ģ1—įD‘ę53‰ń“ś—Õ‹Z’†•”Œ—Žx•”ˆćŠwŒŸøŠw‰ļ;2014 Sep 27;•xŽRD
  31. ‘å’ĪW–ē*, ŽR‰ŗ•ō, –ģŽč—Ē„, –k“‡ŒM. ”Ä—pŽ©“®•ŖĶ‘•’u‚š—p‚¢‚½ƒCƒ“ƒXƒŠƒ“‘Ŗ’莎–ņuƒmƒ‹ƒfƒCƒAƒCƒ“ƒXƒŠƒ“v‚ĢŠī‘b“IŒŸ“¢. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę46‰ń‘å‰ļ;2014 Oct 11;_ŒĖ.
  32. ŽR‰ŗ•ō*, ‘å’ĪW–ē, –ģŽč—Ē„, –k“‡ŒMDV‹KCK-MB ’`”’—Ź‘Ŗ’莎–ņuL ƒ^ƒCƒvƒƒR[CK-MBmass ‚ĢŠī‘b“IŒŸ“¢v“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę46‰ń‘å‰ļ;2014 Oct 11;_ŒĖ.
  33. ‰”“cˆ», –k“‡ŒM. ’¼Śƒgƒƒ“ƒrƒ“‘jŠQ–ņƒ_ƒrƒKƒgƒ‰ƒ“‚Ģƒ‚ƒjƒ^ƒŠƒ“ƒOŒŸø‚ÉŠÖ‚·‚錟“¢. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę46 ‰ń‘å‰ļ;2014 Oct 11;_ŒĖ.
  34. ™XOŽq, ‘匓–ƒˆßŽq, •ś±GŽq, ‹Ÿ“c•¶G, ¬’r‹Ī, ˆäć”Ž, Œ““cŒ’‰E, –k“‡ŒMDŒ’ķ‚Č‹Ī˜JŽŅ‚É‚Ø‚Æ‚é—LŽ_‘f‰^“®‚Ģ“]ŽŹˆöŽqNF-κB Šˆ«‰»‚É‹y‚Ś‚·‰e‹æD‘ę37 ‰ń“ś–{‚ŒŒˆ³Šw‰ļ‘‰ļ;2014 Oct 17;‰”•lD
  35. mˆäŒ©‰pŽ÷Dv‘¬ŠČ•Ö‚ČŠ“õĒ‹N‰Š‹Ū“Æ’č‹Zp‚ĢŠJ”­D“ś—§’†‰›Œ¤‹†Šu‰‰;2014 Nov 13D
  36. mˆäŒ©‰pŽ÷, ć–ģ’q_, X³”V, ‘½—t“c—_, “ģ—m, ™]˜a–Ī, āV“”Ž , –k“‡ŒMDTm mapping –@iŠ“õĒ‹N‰Š‹Ūv‘¬“Æ’č–@j‚Ģ‰@“ąŽŽŒ±‰^—p‚Ę‚»‚Ģ•]‰æD‘ę61 ‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2014 Nov 23;•Ÿ‰ŖD

‚»‚Ģ‘¼

  1. “Į‹–Žę“¾:–k“‡ŒMD“Į‹–‘ę5504477†D”­–¾–¼ĢuŽwė–¬”g‰šĶ‘•’u‹y‚Ń‚±‚ź‚š—p‚¢‚½ŒŒŠĒ“ą”ē‹@”\•]‰æƒVƒXƒeƒ€voŠč”Ō†;“ĮŠč2010-059907DoŠč“ś:•½¬22 ”N3 ŒŽ16 “ś, “o˜^“ś:•½¬26”N3ŒŽ28“ś
  2. “Į‹–Žę“¾: ‘½—t“c—_, “ģ—m, mˆäŒ©‰pŽ÷, –k“‡ŒM, ć–ģ’q_, —ŃŽj˜Y, X³”VD“Į‹–‘ę5583602†D”­–¾–¼Ģu‘Ļ«DNAƒ|ƒŠƒƒ‰[ƒ[‚šŠÜ‚Žy‘f’²®•Ø‚Ø‚ę‚Ń‚»‚Ģ»‘¢•ū–@, •Ą‚Ń‚ÉŒŸo‘ĪŪ¶•Ø‚ĢŒŸo•ū–@vDoŠč”Ō†:“ĮŠč2010|546663DoŠč“ś:•½¬22”N1ŒŽ15“ś, “o˜^“ś:•½¬26”N7ŒŽ25“ś, ŒöŠJ“ś:•½¬26”N9ŒŽ3“ś
  3. –k“‡ŒM:•xŽRŒ§—Տ°ŒŸøŠĒ—‹¦‹c‰ļ‚Ģ‰Ź‚½‚·–šŠ„D•½¬16”N“x—Տ°ŒŸøø“xŠĒ—’²ø•ń‘2014;26:1D
  4. ‚‘qˆźŒb, ¼ˆäĖŽq, –ģŒūŽõ”ü, “‡–Ų‹M‹vŽq, ²–ģ—²Žq, ŽšˆäĀ, –k“‡ŒM.•—]R‘Ģ‰æ‚Ģ“®Œü. Šw‰€‚Ģ—Տ°Œ¤‹† 2014;13:11-5.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2013”N

’˜‘

  1. –k“‡ŒM. •W€—Տ°ŒŸøˆćŠw. ‘ę4”Å. ‚–ŲN, ŽR“crK•Ņ. “Œ‹ž:ˆćŠw‘‰@;2013. d‹ą‘®‚Č‚ē‚Ń‚ÉŠÖ˜A’`”’;p.232-40.
  2. –k“‡ŒM. V‹KR‹ĆŒÅ–ņ‚Ģ‘I‚Ń•ūEŽg‚¢•ū. –L“cˆź‘„•Ņ. ‘åć:ƒtƒWƒƒfƒBƒJƒ‹o”Å;2013. V‹KR‹ĆŒÅ–ņ‚Ģƒ‚ƒjƒ^ƒŠƒ“ƒO;p. 88-99.
  3. –k“‡ŒM. —Տ°ŒŸøƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ģ“, t“ś³‰ė, –k‘ŗ¹•Ņ. “Œ‹ž:ˆćŠw‘‰@;2013. ƒvƒƒgƒƒ“ƒrƒ“ŽžŠŌiPTj, ƒgƒƒ“ƒ{ƒeƒXƒgiTTj, ƒwƒpƒvƒ‰ƒXƒ`ƒ“ƒeƒXƒgiHPTj, Šˆ«‰»•”•Ŗƒgƒƒ“ƒ{ƒvƒ‰ƒXƒ`ƒ“ŽžŠŌiAPTTj;p.375-9.
  4. –k“‡ŒM. —Տ°ŒŸøƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ģ“, t“ś³‰ė, –k‘ŗ¹•Ņ. “Œ‹ž:ˆćŠw‘‰@;2013. ƒtƒBƒuƒŠƒmƒQƒ“, ‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘ĢiFMCj, ƒtƒBƒuƒŠƒ“^ƒtƒBƒuƒŠƒmƒQƒ“•Ŗ‰šŽY•Ø[FDP], Dƒ_ƒCƒ}[;p.375-87, 388-93, 394-9, 401-4, 404-12.
  5. –k“‡ŒM. —Տ°ŒŸøƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ģ“, t“ś³‰ė, –k‘ŗ¹•Ņ. “Œ‹ž:ˆćŠw‘‰@;2013. ƒvƒƒgƒƒ“ƒrƒ“, ƒvƒƒgƒƒ“ƒrƒ“ƒtƒ‰ƒOƒƒ“ƒgiPF1+2j, ‘ęVˆöŽq, ‘ęVIIˆöŽq, ‘ęVIIIˆöŽq, von Willebrand ˆöŽq, von WillenrandˆöŽqƒ}ƒ‹ƒ`ƒ}[‰šĶ, vWFŲ’fy‘fiADAMTS13j, ‘ęIXˆöŽq, ‘ęXˆöŽq, ‘ęXIˆöŽq, ‘ęXIIˆöŽq, ‘ęXIIIˆöŽq;p.387-98.
  6. –k“‡ŒM. —Տ°ŒŸøƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ģ“, t“ś³‰ė, –k‘ŗ¹•Ņ. “Œ‹ž:ˆćŠw‘‰@;2013. ‹ĆŒÅˆöŽqƒCƒ“ƒqƒrƒ^[’萫iƒNƒƒXƒ~ƒLƒVƒ“ƒOŽŽŒ±j, ‘ę‡[ˆöŽqƒCƒ“ƒqƒrƒ^[, ‘ęIXˆöŽqƒCƒ“ƒqƒrƒ^[, ‘gDˆöŽqi‘gDƒgƒƒ“ƒ{ƒvƒ‰ƒXƒ`ƒ“j, ‘‘gDˆöŽqŒo˜HƒCƒ“ƒqƒrƒ^[i‘TFPIj. ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“iATj, ƒgƒƒ“ƒrƒ“EƒAƒ“ƒ` ƒgƒƒ“ƒrƒ“•”‡‘ĢiTATj;p.396-404.
  7. –k“‡ŒM. —Տ°ŒŸøƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ģ“, t“ś³‰ė, –k‘ŗ¹•Ņ. “Œ‹ž:ˆćŠw‘‰@;2013. ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“, ƒvƒƒeƒCƒ“C, ƒvƒƒeƒCƒ“S, ‘gDƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^it-PAj, ƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^ƒCƒ“ƒqƒrƒ^[1iPAI-1j, t-PAEPAI-1 •”‡‘Ģ, ƒvƒ‰ƒXƒ~ƒmƒQƒ“, α2-ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[, ƒvƒ‰ƒXƒ~ƒ“Eα2-ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[•”‡‘ĢiPICƒeƒXƒgj;p.2013-4.

Œ“’˜

  1. Harada K, Mikuni S, Beppu H, Niimi H, Abe S, Hano N, Yamagata K, Kinjo M, Kitajima I. A rapid and high-throughput quantitation assay of the neclear factor κB activity using fluorescence correlation spectroscopy in the setting of clinical laboratories. PLoS One.2013 Oct;8:e75579. PMID:24124497
  2. Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, Kuroda T, Sakata Y. Impact of recombinant sokuble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation.Throm Res. 2013 May;131(5):436-43. PMID:23566534
  3. Madoiwa S, Kitajima I, Ohmori T, Sakata Y, Mimuro J. Distinct reactivity of the commercially available monoclonal antibodies of D-dimer and plasma FDP testing to the molecular variants of fibrin degradation products. Thromb Res. 2013 Oct;132(4):457-64. PMID:24011388

‘ą

  1. –k“‡ŒM. yƒƒ“ƒ‰ƒ“ƒNć‚Ģ¬Ž™‚Ģ—Տ°ŒŸø|¶—‚ÉŠī‚Ć‚­‘I‚Ń•ūEl‚¦•ū|z¬Ž™‚Ģ—Տ°ŒŸø‚ĢŠī‘b’mŽÆ —Տ°ŒŸø‘˜_. ¬Ž™‰ČŠwƒŒƒNƒ`ƒƒ[. 2013;3(2):281-8.
  2. –k“‡ŒM. Ć–¬ŒŒšĒšĒiVTEj. ŒŸø‚Ę‹Zp. 2013;41(9):752-8.
  3. –k“‡ŒM. V‹KŒoŒūƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚É‚Ø‚Æ‚é‹ĆŒÅŒŸø‚Ģd—v«‚Ę–ā‘č“_. •ŗŒÉŒ§ˆćŽt‰ļˆćŠwŽGŽ. 2013;56(1):2-3.
  4. ŽR‰ŗ•ō, –k“‡ŒM. ƒrƒ^ƒ~ƒ“D‚ĢRŽīį‡Œų‰Ź‚É‘Ī‚·‚éƒGƒrƒfƒ“ƒX. —Տ°‰»Šw. 2013;42(2):356-8.
  5. mˆäŒ©‰pŽ÷. ƒƒ^ƒQƒmƒ€‰šĶ‚Ŗ‘ń‚­ƒ}ƒCƒNƒƒoƒCƒI[ƒ€ŒŸø‚Ģ‰Ā”\«. —Տ°‰»Šw. 2013;42(1):83-4.
  6. mˆäŒ©‰pŽ÷. Tm mapping –@:ŒŸ‘ĢĢŽęŒć3ŽžŠŌˆČ“ą‚Å‚Ģ‹Nˆö‹Ū“Æ’č‚š‰Ā”\‚Ę‚·‚éV‚½‚ČŒŸø–@. —Տ°‰»Šw. 2013;42(2):124-30.
  7. mˆäŒ©‰pŽ÷. Š“õĒv‘¬ŒŸø‹Zp‚ĢUp To Date|ŠjŽ_ŒŸø–@‚Ģ‹tP|. —Տ°‰»Šw. 2013;42(2):104.

Šw‰ļ•ń

  1. Niimi H, Ueno T, Hayashi S, Mori M, Tabata H, Minami H, Saito S, Kitajima I. A New rapid, easyand cost-effective method that identifies unknown pathogenic microorganisms within 3 hours from sample collection. 20th European Congress of Clinical Chemistry and Laboratory Medicine; 2013 May 19-23; Milano. (Invited lecture)
  2. Kitajima I, Hirano K, Tani M, Tanaka K. Novel haemostatic biomarkers in acute cardioembolic stroke. 20th European Congress of Clinical Chemistry and Laboratory Medicine; 2013 May 19-23; Milano.
  3. Kitajima I, Hirano K, Tani M, Tanaka K. Novel haemostatic biomarkers in acute cardioembolic stroke. 2013 American Association for Clinical Chemistry Annaul Meetin; 2013 Jul 28-Augst 1; Houston.
  4. Matsushita T, Watanabe J, Goichi Honda, Mimuro J, Takahashi H, Tsuji H, Eguchi Y, Kitajima I, Sakata Y. Thrombomodulin Alfa Treatment For Disseminated Intravascular Coagulation In Acute Promyelocytic Leukemia: A Retrospective Analysis Of The Open-Label, Multicenter Study Cohort. 55th American Society of Hematology Annual Meeting and Exposition; 2013 Dec 10-14; New Orleans.
  5. –k“‡ŒM. V‹KŒoŒūƒgƒƒ“ƒrƒ“‘jŠQ–ņÜ‚É‚Ø‚Æ‚é‹ĆŒÅŒŸø‚Ģd—v«‚Ę–ā‘č“_. “ś–{ˆćŽt‰ļ¶ŠU‹³ˆē‹¦—ĶuĄ;2013 Jan 26;‹ž“s. iµ‘Ņu‰‰j
  6. –k“‡ŒM. V‹KŒoŒū‹ĆŒÅ–ņ‚Ę‹ĆŒÅEü—nŒŸø. “ś–{ˆćŽt‰ļ•ŸˆäŒ§Žx•”¶ŠU‹³ˆē‹¦—ĶuĄ;2013 Feb 17;•Ÿˆä. iµ‘Ņu‰‰j
  7. –k“‡ŒM. Šī‘b‚ĢŠĻ“_‚©‚ēƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ—L—p«‚šl‚¦‚é. ‘ę38‰ń“ś–{”]‘²’†Šw‰ļ‘‰ļSTROKE2013;2013 Mar 23;“Œ‹ž. iµ‘Ņu‰‰j
  8. –k“‡ŒM. Novel clinical laboratory markers of blood coagulation and fibrinolysis. ‘ę38‰ń”]‘²’†Šw‰ļ‘‰ļŒŒšŽ~ŒŒŠw‰ļ‡“ƃVƒ“ƒ|ƒWƒEƒ€;2013 Mar 23;“Œ‹ž. iµ‘Ņu‰‰j
  9. –k“‡ŒM. ŒŒšŽ~ŒŒŠw‚©‚ē‚Ż‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ—L—p«. S‘ŸŒŒŠĒƒtƒH[ƒ‰ƒ€2013;2013 Apr 18;‘åć. iµ‘Ņu‰‰j
  10. –k“‡ŒM. S–[×“®‚Ę”][Ē. “ś–{ˆćŽt‰ļ¶ŠU‹³ˆē‹¦—ĶuĄ;2013 May 11;_ŒĖ. iµ‘Ņu‰‰j
  11. –k“‡ŒM. V‹KŒoŒūR‹ĆŒÅ–ņˆĄ‘S«ƒ`ƒFƒbƒN‚Ģ‚½‚ß‚Ģ‹ĆŒÅŒŸø–ņ’Tõ. ‘ę35‰ń“ś–{ŒŒšŽ~ŒŒŠw‰ļŠwpW‰ļ‰ļ’·—væ‹¤ĆƒVƒ“ƒ|ƒWƒEƒ€;2013 May31;ŽRŒ`. iµ‘Ņu‰‰j
  12. –k“‡ŒM. ‹ĆŒÅŠw‚ĢŽ‹“_‚©‚ēƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ—L—p«‚šl‚¦‚é. ‘ę35‰ń“ś–{ŒŒšŽ~ŒŒŠw‰ļŠwpW‰ļ‰ļ’·ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[;2013 May31;ŽRŒ`. iµ‘Ņu‰‰j
  13. –k“‡ŒM. ƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ“Į’„‚š—‰š‚·‚é. ‘ę4‰ńNational Stroke Summit;2013 Jun 29;“Œ‹ž. iµ‘Ņu‰‰j
  14. –k“‡ŒM. S–[×“®‚É‚Ø‚Æ‚é‹ĆŒÅ˜“i‚Ęƒgƒƒ“ƒrƒ“‘jŠQ–ņ‚Ģ—L—p«. ‘ę28‰ńŒ¢ŽR•s®–¬ƒJƒ“ƒtƒ@ƒŒƒ“ƒX;2013 Aug 24;–¼ŒĆ‰®. iµ‘Ņu‰‰j
  15. –k“‡ŒM. zŠĀŠķŽ¾Š³‚ĢƒoƒCƒIƒ}[ƒJ[ŒŸø‚Ģi•ą ‹ĆŒÅEü—nƒ}[ƒJ[. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę45 ‰ń‘å‰ļ;2013 Oct 11;‰”•l. iµ‘Ņu‰‰j
  16. –k“‡ŒM. ŒŒšEŽ~ŒŒ•ŖŽqƒ}[ƒJ[‚ĢÅ‘O. ‘ę60‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2013 Oct 31;_ŒĖ. iµ‘Ņu‰‰j
  17. –k“‡ŒM. SŒ“«”]ĒšĒ‚Ģ—\–h‚ĘÅVŽ”—ƁE’·–ģ“ś–{ˆćŽt‰ļ¶ŠU‹³ˆē‹¦—ĶuĄ;2013 Oct 13;’·–ģ. iµ‘Ņu‰‰j
  18. mˆäŒ©‰pŽ÷. eukaryote-made Taq DNA polymerase ‚Ø‚ę‚ŃTm mapping –@‚É‚ę‚銓õĒv‘¬ŒŸøƒVƒXƒeƒ€‚Ģ\’z. ‘ę22‰ńM‘å—Տ°ŒŸøƒZƒ~ƒi[;2013 Sep 15;¼–{. iµ‘Ņu‰‰j
  19. mˆäŒ©‰pŽ÷. ˆź”Ź×‹Ū‚É‚Ø‚Æ‚éˆā“`ŽqŒŸø. ŽR—œŒ§—Տ°‰q¶ŒŸø‹ZŽt‰ļ”÷¶•ØEˆā“`ŽqŒŸøŒ¤‹†”Ē‡“ÆŒ¤C‰ļ;2013 Feb 15;’†‰›. iµ‘Ņu‰‰j
  20. –ģŽč—Ē„, —Ń—““ń, ŽO‘ŗ‘וF, –kģ—mŽq, Ā–Ų‰ėŽq, ŽR–{‘P—T, “c‘ć«l. “–‰@‚É‚Ø‚Æ‚éƒAƒ“ƒ`ƒoƒCƒIƒOƒ‰ƒ€‚Ę–ņÜ‘Ļ«‹Ū‚Ģ•Ŗ—£ó‹µ. ‘ę28‰ń“ś–{ŠĀ‹«Š“õŠw‰ļ‘‰ļ;2013 Mar 2;‰”•l.
  21. ‘ź˜e³‹M, ŽR‰ŗ•ō, ‰FŽ”‹`‘„, ‹Ÿ“c•¶G, ¬’r‹Ī, ˆäć”Ž, –k“‡ŒM. –{‘Ō«‚ŒŒˆ³Ē‚ɂ؂Ƃ錌’†Ž‰Žæ‚ĘŒŒ‰t”S«‚ĢŠÖŒW. ‘ę52‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę326‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ;2013 Mar 10;’Ć.
  22. ŽR‰ŗ•ō, ‘ź˜e³‹M, ‰FŽ”‹`‘„, ‹Ÿ“c•¶G, ˆäć”Ž, –k“‡ŒM. –{‘Ō«‚ŒŒˆ³Š³ŽŅ‚ɂ؂Ƃ錌“25-ƒqƒhƒƒLƒVƒrƒ^ƒ~ƒ“D3”Z“x‚ĘCa, P ‘ćŽÓŽw•W‚ĢŠÖŒW. ‘ę52‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę326‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ;2013 Mar 10;’Ć.
  23. ŽR‰ŗ•ō, ‘ź˜e³‹M, ‰FŽ”‹`‘„, –k“‡ŒM, ‹Ÿ“c•¶G, ˆäć”Ž. –{‘Ō«‚ŒŒˆ³ĒŠ³ŽŅ‚ɂ؂Ƃ錌“25-OHƒrƒ^ƒ~ƒ“D3”Z“x‘Ŗ’č‚Ģ•]‰æ. ‘ę24‰ń¶•ØŽŽ—æ•ŖĶ‰ČŠw‰ļ”NŽŸŠwpW‰ļ;2013 Mar 13;”Ž‘½.
  24. ‘ź˜e³‹M, ŽR‰ŗ•ō, ‰FŽ”‹`‘„, ‹Ÿ“c•¶G, ˆäć ”Ž, –k“‡ŒM. –{‘Ō«‚ŒŒˆ³Ē‚ɂ؂Ƃ錌’†Ž‰Žæ‚ĘŒŒ‰t”S«. ‘ę24‰ń¶•ØŽŽ—æ•ŖĶ‰ČŠw‰ļ”NŽŸŠwpW‰ļ;2013 Mar 13:”Ž‘½.
  25. ŠÖŒūŒh•¶, ‘ź˜e³‹M, ‰FŽ”‹`‘„, “c•”ˆä—m‰ī, ó–ģ‘׋v, –k“‡ŒM. y‘f–@‚É‚ę‚錌Ÿ÷Threonine’č—Ź–@‚ĢŠm—§. ‘ę24‰ń¶•ØŽŽ—æ•ŖĶ‰ČŠw‰ļ”NŽŸŠwpW‰ļ;2013 Mar 13:”Ž‘½.
  26. ‰–č^‹|, ŽRŠŻ“ŽX, ¬£—¢Œb, ‹g“cē», ‰FŽ”‹`‘„, •½ˆä’‰˜a, Žs“c•™Žq, ˆäć”Ž, –F‘ŗ’¼Ž÷, –k“‡ŒM. zŠĀŠķ“ą‰ČŠO—ˆ‚Ģ¬lę“V«SŽ¾Š³‚É‚Ø‚Æ‚éSƒGƒR[}ŠŒ©‚Ģ“Į’„. ‘ę77‰ń“ś–{zŠĀŠķŠw‰ļŠwpW‰ļ;2013 Mar 16;‰”•l.
  27. ģ“Y—F‹I, ‹g“c‘, •Ź•{GK, –k“‡ŒM. ŠĢ‚Ŗ‚ń×–E‚É‚Ø‚Æ‚éƒgƒƒ“ƒrƒ“‚É‚ę‚éTF‚ĘPAI-1”­Œ»‚ĘŒĆ“T“INF-κBƒVƒOƒiƒ‹’į”½‰ž«‚Ę‚ĢŠÖ˜A. ‘ę35‰ń“ś–{ŒŒšŽ~ŒŒŠw‰ļŠwpW‰ļ;2013 Jun 1;ŽRŒ`.
  28. “cģŠ°Žq, mˆäŒ©‰pŽ÷, ć–ģ’q_, –k“‡ŒM. ‰t‘ŠCell Counting–@, v‘¬‚ÅŠČ•Ö‚Č–ņÜŠ“Žó«ŽŽŒ±–@‚ĢŠJ”­‚ĢŽŽ‚Ż. ‘ę24‰ń“ś–{—Տ°‰»Šw“ŒŠCE–k—¤Žx•”‘‰ļ^‘ę32‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”—į‰ļ;2013 Jul 20;•l¼.
  29. ć–ģ’q—T, mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ģ—m, āV“”Ž , –k“‡ŒM. eukaryote-made Taq polymerase‚š—p‚¢‚½v‘¬‚ČŽq‹{“ąŠ“õĒE‘Š‘Ī“I’č—ŹŒŸo–@‚Ģ\’z. ‘ę24 ‰ń“ś–{—Տ°‰»Šw“ŒŠCE–k—¤Žx•”‘‰ļ^‘ę32 ‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”—į‰ļ;2013 Jul 20;•l¼.
  30. ŽRŠŻ“ŽX, –k“‡ŒM. œŒ`¬ˆöŽqiBMPjŽó—e‘Ģ•ĻˆŁ‚ĘƒVƒOƒiƒ‹ˆŁķ‚Ķć”ē×–EŽīį‡‰»‚ɉe‹æ‚š—^‚¦‚é. ‘ę53‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ;2013 Aug 30;“擇.
  31. mˆäŒ©‰pŽ÷, ć–ģ’q_, X³”V, ‘½—t“c—_, “ģ—m, –k“‡ŒM. Tm mappng–@:ŒŸ‘ĢĢŽę3ŽžŠŌˆČ“ą‚Å•s“Į’č‚Ģ‹Nˆö‹Ū‚š“Æ’č‚·‚év‘¬ŒŸø–@. ‘ę53‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ;2013 Aug 31;“擇.
  32. ŽRŠŻ“ŽX, ‰–č^‹|, ¬£—Œb, ˆäć”Ž, –k“‡ŒM. S‘Ÿ“ąŽīįŽ‚ĢŒŸo‚É‚Ø‚Æ‚éŒo‹¹SƒGƒR[‚Ģ—L—p«. ‘ę38‰ń–k—¤—Տ°•a—W’k‰ļ;2013 Sep14;‹ą‘ņ.
  33. ć–ģ’q_, mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ģ—m, āV“”Ž , –k“‡ŒM. eukatyote-made Taq polymerase‚š—p‚¢‚½v‘¬‚ČŽq‹{“ąŠ“õĒE‹ŪŒŸo–@‚Ģ\’z. ‘ę38‰ń–k—¤—Տ°•a—W’k‰ļ;2013 Sep 14;‹ą‘ņ.
  34. ŽR‰ŗ•ō, ‘ź˜e³‹M, –ģŽč—Ē„, ‰FŽ”‹`‘„, –k“‡ŒM. AQT90FLEX–ʉu‘Ŗ’č‘•’u‚É‚ę‚éCK-MB’`”’—Ź‘Ŗ’č‚ĢŠī‘b“IŒŸ“¢. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę45‰ń‘å‰ļ;2013 Oct 11;‰”•l.
  35. ŠÖŒūŒh•¶, ‘ź˜e³‹M, ć–ģ’q_, ‰FŽ”‹`‘„, –k“‡ŒM. ‘SŽ©“®¶‰»Šw•ŖĶ‘•’u‚É‚ę‚錌Ÿ÷Threonin, Tryptophan, Glycine•ŖĶ–@\’z‚Ę—Õ°‚Ö‚Ģ‰ž—p. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę45‰ń‘å‰ļ;2013 Oct 11;‰”•l.
  36. ‹g“c‘, ‹g“ciŽq, ŒĆŽsŒb’ĆŽq, ‹g“c‰Į“Ž”ü, ‰Ŗ•”‘f“T, –k“‡ŒM. Image J ‚š—p‰ę‘œ‰šĶ‚Ģ“K‰ž«. “ś–{‰š–UŠw‰ļ’†•”’n‹ę’n•ū‰ļ;2013 Oct 5;ŽR—œ.
  37. mˆäŒ©‰pŽ÷, ć–ģ’q_, X³”V, ‘½—t“c—_, “ģ—m, āV“”Ž , –k“‡ŒM. Tm mapping–@:Š³ŽŅŒŸ‘ĢĢŽęŒć3ŽžŠŌˆČ“ą‚Å‚Ģv‘¬‹Nˆö‹Ū“Æ’č–@. ‘ę60‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2013 Oct 31;_ŒĖ.
  38. ć–ģ’q_, mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ģ—m, āV“”Ž , –k“‡ŒM. eukaryote-made Taq polymerase‚š—p‚¢‚½Žq‹{“ąŠ“õĒ‚Ģ‘Š‘Ī“I’č—ŹŒŸo–@. ‘ę60‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2013 Oct 31;_ŒĖ.
  39. “cģŠ°Žq, mˆäŒ©‰pŽ÷, –k“‡ŒM. ‰t‘ŠCell Counting–@:v‘¬‚©‚ĀŠČ•Ö‚Č–ņÜŠ“Žó«ŽŽŒ±–@ŠJ”­‚ĢŽŽ‚Ż. ‘ę60‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2013 Oct 31;_ŒĖ.
  40. ‘ź˜e³‹M, ŠÖŒūŒh•¶, ‰FŽ”‹`‘„, “c•”ˆä—z‰ī, ó–ģ‘׋v, –k“‡ŒM. y‘f–@‚É‚ę‚錌Ÿ÷Threinine’č—Ź–@‚ĢŠm—§. ‘ę60‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2013 Oct 31;_ŒĖ.
  41. ŽR‰ŗ•ō, ‘ź˜e³‹M, –k“‡ŒM, ‹Ÿ“c•¶G, ¬’r‹Ī, ˆäć”Ž, ‰FŽ”‹`‘„. –{‘Ō«‚ŒŒˆ³Ē‚ɂ؂Ƃ錚Š“_ŒoE•›t‘ŽæŒn‚ĘŒŒ’†FGF-23‚Ę‚ĢŠÖŒW. ‘ę60‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ;2013 Oct 31;_ŒĖ.

‚»‚Ģ‘¼

  1. ‰¢B“Į‹–š–ń‹–‰Ā:Miimi H, Kitajima I. Method for identifying pathogenic microorganisms responsible for infection by extracting the DNA of a microorganism. oŠč”Ō†i07714581. 1jiPTC-TU4-33j
  2. –{“cFs, ¼”öŽū“ń, ³–Ų[, Œ““cŒ’‰E, ‚č‹§, ’†‘ŗ•¶•F. —Տ°‚Å—˜—p‚µ‚ā‚·‚¢ŒŸøŒ‹‰Ź‚š’ń‹Ÿ‚µ‚ꂤ. ‘ę59‰ńŠwpW‰ļReversed Clinicopathological ConferenceiR-CPCj. —Տ°•a—. 2013;6(3):271-82.
  3. ¼ˆäĖŽq, ‚‘qˆźŒb, “‡–Ų‹M‹vŽq, –ģŒūŽõ”ü, ²–ģ—²Žq, ŽšˆäĀ, –k“‡ŒM. –ƒ]ƒAƒEƒgƒuƒŒ[ƒN‚»‚ĢŒć. Šw‰€‚Ģ—Տ°Œ¤‹†i•xŽR‘åŠw•ŪŒ’ŠĒ—ƒZƒ“ƒ^[‹I—vj. 2013;12:1-4.
  4. ŽšˆäĀ, ¼ˆäĖŽq, ‚‘qˆźŒb, “‡–Ų‹M‹vŽq, —§£„Žu, ‹g‰i’Žj, …–ģ ŒO, Œ“ąV‚³‚ä‚Ż, £”ö—F“æ, “ś‰ŗ•”‚Žj, “‡–Ų‹M‹vŽq, ²–ģ—²Žq, ŽlŠŌ’šēŽ}, “‡“c®‰Ą, ‹{‘ŗŒ’‘s, M“c‹v, œAģTˆź˜Y, ‹{˜e—˜’j, –k“‡ŒM. ˆć–ņƒLƒƒƒ“ƒpƒX‚É‚Ø‚Æ‚éŠw¶Žx‰‡‚ĢŒ»ó‚ʉŪ‘č|ˆĄ‘S”z—¶‹`–±‚Ę‚ĢŠÖ˜A‚©‚ē|. Šw‰€‚Ģ—Տ°Œ¤‹†i•xŽR‘åŠw•ŪŒ’ŠĒ—ƒZƒ“ƒ^[‹I—vj. 2013;12:77-82.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2012”N

’˜‘

  1. –k“‡ŒM, N“Œ“V, ŒKŽ•F, ˆĄ“Œ—RŠģ—Y:u—Õą¬‰»Šw Š©–@‘W•Ņ2012”N“x”Łv“ś–{—Տ°‰»Šw‰ļ•Ņ, “ś–{—Տ°‰»Šw‰ļ, “Œ‹ž, 2012.

Œ“’˜

  1. Uji Y., Motomiya Y., and Ando Y.:Effect of heparin on conformation of the β2-microglobulin molecule. Ther Apher Dial. Apr;16(2):159-62.2012. PMID:22458395
  2. Motomiya Y., Uji Y., and Ando Y. :Capillary electrophoretic profile of β2-microglobulin intermediate associated with hemodialysis. Ther Apher Dial. Aug;16(4):350-4.2012. PMID:22817123
  3. Hirano K., Takashima S., Dougu N., Taguchi Y., Nukui T., Konishi H., Toyoda S., Kitajima I., and Tanaka K. :Study of hemostatic biomarkers in acute ischemic stroke by clinical subtype. J Stroke Cerebrovasc Dis. Jul;21(5):404-10.2012. PMID:22516429
  4. ‘ź˜e³‹M–, ‰FŽ”‹`‘„, –k“‡ŒM:‰»Šw”­Œõy‘f–ʉu–@‚š—p‚¢‚½HBsRŒ“‘Ŗ’č‚ĢBŒ^–«ŠĢ‰ŠŠ³ŽŅ‚Å‚Ģ•]‰æ. ¶•ØŽŽ—æ•ŖĶ, 35:127-132, 2012.
  5. ‹v•Ū“c’q”ü–, —ŃŽj˜N, mˆäŒ©‰pŽ÷, –k“‡ŒM:“–‰@6”NŠŌ‚Ģ‚Ø‚Æ‚é×‹Ū«ŠįŠ“õĒ‚ĢŒŸo‹Ū“®Œü’²ø|ŒŸøŽŗ‚ĢŽ‹“_‚©‚ē|. —Տ°•a—, 60(7):605-11.2012. PMID:22973718

‘ą

  1. –k“‡ŒM, mˆäŒ©‰pŽ÷:‹ŪŒŒĒ^‘Sg‰ŠĒ”½‰žĒŒóŒQ‚É‘Ī‚·‚év‘¬E‚Š““xŒŸøƒVƒXƒeƒ€‚Ģ\’z. —Տ°•a—, 60:46-51, 2012.
  2. –k“‡ŒM, ‰”“c_[:ƒ`[ƒ€ˆć—Ć‚šŽx‚¦‚é—Տ°ŒŸø. —Տ°‰»Šw, 41(suppl. 1): 149, 2012.
  3. ‰FŽ”‹`‘„, ‘ź˜e³‹M–, –k“‡ŒM:V‚µ‚¢CK-MB Šˆ«‘Ŗ’č–@. —Տ°‰»Šw, 41: 86-87, 2012.
  4. ‰FŽ”‹`‘„: ‘Ū•W€‰»‹@\iISOj.u“ģŽR“°ˆćŠw‘厫“T 2012v,“ģŽR“°, “Œ‹ž, 2012.
  5. ‰FŽ”‹`‘„: ŒŒ“ƒAƒ‹ƒuƒ~ƒ“, ‚»‚Ģ‘¼‚Ģ’`”’Žæ.uƒƒfƒBƒJƒ‹ƒTƒCƒGƒ“ƒX•a‘Ō¶‰»Šw^—Տ°‰»ŠwŒŸøŠwv, ‹ß‘ćo”Å, “Œ‹ž, 2012

Šw‰ļ•ń

  1. Niimi H., Ueno T.*, Hayashi S., Mori M., Tabata H., Minami H., and Kitajima I. :A novel rapid method enables identification of pathogenic micro-organisms within 3 hours after samples are collected. 22nd European Congress of Clinical Microbiology and Infectious Diseases, 2012, 4, 2, London.
  2. Uji Y., Yamashita M. *, Takiwaki M. *, and Kitajima I. :Evaluation of Sysmex new automated hematology analyzer XN-9000 in routine clinical laboratory. AACC Annual Meeting 2012 & Clinical Lab Expo, 2012, 7, 15-19, Los Angeles.
  3. Yamashita M. *, Takiwaki M. *, Uji Y., Kitajima I., Honda T., and Hidaka H. :Quantitative measurement of serum phosphatidylcholine and lysophosphatidylcholine using matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. AACC Annual Meeting 2012 & Clinical Lab Expo, 2012, 7, 15-19, Los Angeles.
  4. Harada K. *, Mikuni S., Tomoda F., S. Kagitani., Koike T., Kinjo M., Inoue H., and Kitajima I. :Nuclear factor-kappa B activity in the peripheral blood lymphocytes measured with the novel quantitative system using the fluorescent correlation spectroscopy correlates with intra-abdominal fat area in patients with essential hypertension. AACC Annual Meeting 2012 & Clinical Lab Expo, 2012, 7, 15-19, Los Angeles.
  5. Niimi H., Ueno T. *, Hayashi S., Mori M., Tabata H., Minami H., Saito S., and Kitajima I. :A novel TM-mapping methodthat enables identification of pathogenic microorganisms within 3 hours after samples are collected. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2012, 9, 11, San Francisco.
  6. Taki T., Tomoda F., Koike T., Ohara M., Hirose M., Kagitani S., Inoue H., Takiwaki M. *, Uji Y., and Kitajima I. :Relation of small dense low-density lipoprotein cholesterol to carotid atherosclerosis in essential hypertensives with normal renal function. The 24th Scientific Meeting of the International Society of Hypertension, 2012, 9, 30 -10, 3, Sydney.
  7. Miyamoto M., Yamazaki H., Tomoda F., Koike T., Kagitani S., Nakagawa T., Inoue H., Takiwaki M. *, Uji Y., and Kitajima I. :Small dense low-density lipoprotein cholesterol, and its clinical features in patients with nephrotic syndrome. The 45th Annual Meeting of American Society of Nephrology, 2012, 10, 30 -11, 4, San Diego.
  8. ģ“Y—F‹I–, ‰FŽ”‹`‘„, –k“‡ŒM, ˆäć ”Ž:’¼Śƒgƒƒ“ƒrƒ“‘jŠQ–ņƒ_ƒrƒKƒgƒ‰ƒ“ƒGƒeƒLƒVƒ‰[ƒg“Š—^‚É‚Ø‚Æ‚éPT, APTT ƒ‚ƒjƒ^[‚Ģ•K—v«. ‘ę51‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę32‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ ˜A‡‘å‰ļ, 2012, 3, 11, ¬“cŒ“.
  9. ‹v•Ū“c’q”ü–, —Ń Žj˜N, –ģŽč—Ē„, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:“–‰@‚É‚Ø‚Æ‚éŠį‰ČŠ“õĒ‚Ģ‹ŪŒŸo‚ÉŠÖ‚·‚é•ŖĶ. ‘ę51‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę32 ‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ ˜A‡‘å‰ļ, 2012, 3, 11, ¬“cŒ“.
  10. ‘ź˜e³‹M–, ‰FŽ”‹`‘„, ‹g“cē», mˆäŒ©‰pŽ÷, ‹Ÿ“c•¶G, –{‹{‘P‰ų:“§Ķ‚É‚ę‚éβ2-ƒ~ƒNƒƒOƒƒuƒŠƒ“’†ŠŌ‘Ģœ‹Ž”\‚Ģ•]‰æ. ‘ę22‰ń¶•ØŽŽ—æ•ŖĶ‰ČŠw‰ļŠwpW‰ļ, 2012, 3, 10-11, •Ÿ‰Ŗ.
  11. Œ““cŒ’‰E–, •Ź•{GK, mˆäŒ©‰pŽ÷, ˆ¢•”Ž Ž÷, ‰H–ģ—zŽq, ŽRŒ`_ˆź, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ŖŒõ–@(FCS)‚É‚ę‚é“]ŽŹˆöŽqNF-κB Šˆ«‚ĢƒnƒCƒXƒ‹[ƒvƒbƒg’č—Ź–@ŠJ”­. ‘ę51‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę32‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ ˜A‡‘å‰ļ, 2012, 3, 11, ¬“cŒ“.
  12. Œ““cŒ’‰E–, •Ź•{GK, mˆäŒ©‰pŽ÷, ‹Ÿ“c•¶G, Œ®’J‘, ¬’r‹Ī, ˆäć”Ž, –k“‡ŒM:“]ŽŹˆöŽqNF-κB Šˆ«‚Ŗ‚ŒŒˆ³‚É‹y‚Ś‚·‰e‹æ‚Ę‚»‚Ģ‹K’čˆöŽq‚Ģ—Տ°“IˆÓ‹`. ‘ę51‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę32‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ, 2012, 3, 11, ¬“cŒ“.
  13. ŽR‰ŗ•ō–, ‘ź˜e³‹M–, ‰FŽ”‹`‘„, –k“‡ŒM:MtCKŠˆ«‘jŠQR‘Ģ‚š—p‚¢‚½V‹KCK-MB ‘Ŗ’č–@‚Ģ—Տ°•]‰æ. ‘ę52‰ń“ś–{—Տ°‰»Šw‰ļ”N‰ļ, 2012, 9, 6-7, ·‰Ŗ.
  14. ŽR‰ŗ•ō–, ‘ź˜e³‹M–, “ś‚GĘ, ‰FŽ”‹`‘„, –k“‡ŒM:MALSI-TOF MS‚š—p‚¢‚½ƒzƒXƒtƒ@ƒ`ƒWƒ‹ƒRƒŠƒ“‚Ø‚ę‚ŃƒŠƒ]ƒzƒXƒtƒ@ƒ`ƒWƒ‹ƒRƒŠƒ“‚Ģ’č—Ź•ŖĶ. ‘ę23‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę31‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ, 2012, 8, 4, •xŽR.
  15. ć–ģ’q_–, mˆäŒ©‰pŽ÷, —Ń Žj˜N, –ģŽč—Ē„, –k“‡ŒM:Tm mapping –@‚š—p‚¢‚½Š“õĒ‹N‰Š‹Ūv‘¬“Æ’čƒVƒXƒeƒ€‚ĢŠJ”­. ‘ę23‰ń“ś–{—Տ°‰»Šw“ŒŠC–k—¤Žx•”‘‰ļE‘ę31‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ ˜A‡‘å‰ļ, 2012, 8, 4, •xŽR.
  16. ‹v•Ū“c’q”ü–, —ŃŽj˜N, ć–ģ’q_, –ģŽč—Ē„, mˆäŒ©‰pŽ÷, –k“‡ŒM:“–‰@6”NŠŌ‚É‚Ø‚Æ‚é×‹Ū«ŠįŠ“õĒ‚ĢŒŸo‹Ū“®Œü’²ø|ŒŸøŽŗ‚ĢŽ‹“_‚©‚ē|. ‘ę23‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę31‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ, 2012, 8, 4, •xŽR.
  17. ‘ź˜e³‹M–, ŽR‰ŗ•ō–, ‰FŽ”‹`‘„, –k“‡ŒM:MtCKŠˆ«‚Ģ‰e‹æ‚š‰ń”š‚µ‚½V‹KCK-MB‘Ŗ’č–@‚Ģ—Տ°•]‰æ. ‘ę23‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę31‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ ˜A‡‘å‰ļ, 2012, 8, 4, •xŽR.
  18. ‘ź’m•F, ‹Ÿ“c•¶G, ¬’r‹Ī, ‘匓–ƒˆßŽq, œA£‰ė‘ć, ˆäć”Ž, ‘ź˜e³‹M–, ‰FŽ”‹`‘„, –k“‡ŒM:–{‘Ō«‚ŒŒˆ³Ē‚ɂ؂Ƃ鎉ŽæˆŁķĒ‚Ę‘åŒŒŠĒ‚Ģ\‘¢ˆŁķ‚Ę‚ĢŠÖŒW:¬Œ^‚–§“xLDL ‚Ģd—v«. ‘ę35‰ń“ś–{‚ŒŒˆ³Šw‰ļ‘‰ļ, 2012, 9, 20-22, –¼ŒĆ‰®.
  19. ‘ź˜e³‹M–, ŽR‰ŗ•ō–, ‰FŽ”‹`‘„, ‹Ÿ“c•¶G, ¬’r‹Ī, ˆäć”Ž, –k“‡ŒM:–{‘Ō«‚ŒŒˆ³‚É‚Ø‚Æ‚ésmall dense LDL‚ĘŒŒ‰t”S«‚Ę‚ĢŠÖŒW. ‘ę59‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2012, 11, 29-12, 2, ‹ž“s.
  20. mˆäŒ©‰pŽ÷, ć–ģ’q_–, —ŃŽj˜N, X³”V, ‘½—t“c—_, “ģ—m, –ģŽč—Ē„, Ö“”Ž , –k“‡ŒM:Tm mapping–@‚š—p‚¢‚½Š“õĒ‹N‰Š‹Ūv‘¬“Æ’čƒVƒXƒeƒ€‚ĢŠJ”­. ‘ę59‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2012, 11, 29 -12, 2, ‹ž“s.
  21. ć–ģ’q_– , mˆäŒ©‰pŽ÷, —ŃŽj˜N, X³”V, ‘½—t“c—_, “ģ—m, –ģŽč—Ē„, Ö“”Ž , –k“‡ŒM :eukaryote-made Taq polymerase ‚š—p‚¢‚½v‘¬‚ČŽq‹{“ąŠ“õĒŒŸø–@‚Ģ\’z. ‘ę59‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2012, 11, 29 -12, 2, ‹ž“s.
  22. ŽR‰ŗ•ō–, ‘ź˜e³‹M–, ‰FŽ”‹`‘„, ‹Ÿ“c•¶G, ˆäć”Ž, –k“‡ŒM:–{‘Ō«‚ŒŒˆ³Ē‚ɂ؂Ƃ錌’†25-ƒqƒhƒƒLƒVƒrƒ^ƒ~ƒ“D3‚Ģ•]‰æ. ‘ę59‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2012, 11, 29 -12, 2, ‹ž“s.
  23. ‹v•Ū“c’q”ü–, —ŃŽj˜N, ć–ģ’q_–, –ģŽč—Ē„, mˆäŒ©‰pŽ÷, –k“‡ŒM:“–‰@6”NŠŌ‚É‚Ø‚Æ‚é×‹Ū«ŠįŠ“õĒ‚ĢŒŸo‹Ū“®Œü’²ø|ŒŸøŽŗ‚ĢŽ‹“_‚©‚ē|. ‘ę59‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2012, 11, 29 -12, 2, ‹ž“s.
  24. Œ““cŒ’‰E–, ć–ģ’q_–, mˆäŒ©‰pŽ÷, ŽRé““ń, –k“‡ŒM:V‹KHMBSˆā“`Žq•ĻˆŁ‚š”F‚ß‚½‹}«ŠŌŒ‡«ƒ|ƒ‹ƒtƒBƒŠƒ“Ē‚Ģˆź—į. ‘ę59‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2012, 11, 29 -12, 2, ‹ž“s.
  25. ‘ź˜e³‹M–, ŽR‰ŗ•ō–, ŒKŒ“‘ģ”ü, ‰FŽ”‹`‘„, –k“‡ŒM:‘½€–ŚŽ©“®ŒŒ‹…•ŖĶ‘•’uXN-9000 ‚ĢŠī–{«”\‚Ę‹Ę–±Œų—¦‚Ģ•]‰æ. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę44‰ń‘å‰ļ, 2012, 10, 11-13, ‰”•l.
  26. ģ“Y—F‹I–, ‹g“c‘, ć–ģ‹œ•q, •Ź•{GK, –k“‡ŒM:ƒgƒƒ“ƒrƒ“‚É‚ę‚é‘gDˆöŽq‚Ø‚ę‚Ńƒvƒ‰ƒXƒ~ƒm[ƒQƒ“ƒAƒNƒ`ƒx[ƒ^ƒCƒ“ƒqƒrƒ^[1 ‚Ģ”­Œ»‹@\‚Ģ‰šĶ|NF-κB ‚ĘTGF-βƒVƒOƒiƒ‹‚Ģ–šŠ„. ‘ę85‰ń“ś–{¶‰»Šw‰ļ‘å‰ļ, 2012, 12, 15-16, •Ÿ‰Ŗ.
  27. ŽRŠŻ“ŽX–, Īˆä², •Ź•{GK, –k“‡ŒM:BMPR2 •ĻˆŁŠŌŽæ×–E‚É‚Ø‚Æ‚éNF-κB Šˆ«‰»˜“i‚ĘCD34”­Œ»—U“±. ‘ę85‰ń“ś–{¶‰»Šw‰ļ‘å‰ļ, 2012, 12, 15-16, •Ÿ‰Ŗ.

‚»‚Ģ‘¼

  1. –k“‡ŒM, •½–ģPŽ”, ’J‚Ż‚ĖŽq, “c’†k‘¾˜Y:”][Ē‹}«Šś‚É‚Ø‚Æ‚é‹ĆŒÅ•ŖŽqƒ}[ƒJ[‚Ģ•aŒ^•Ź‰šĶ. ‘ę11‰ńTTMƒtƒH[ƒ‰ƒ€‹L˜^, 103-110, 2012.
  2. –k“‡ŒM, –īā³O, ¼–{’¼Ž÷:ƒvƒ‰ƒUƒLƒT‚š“K³‚ÉŽg—p‚·‚邽‚ß‚É•K—v‚Č‚±‚Ę‚šl‚¦‚é. Medical Tribune, 2012”N7ŒŽ26“ś†.
  3. ‰FŽ”‹`‘„:‘Ŗ’č‚Ģ•sŠm‚©‚³‚ĘƒgƒŒ[ƒTƒrƒŠƒeƒB. (ą)VŠƒŒ§—\–hˆćŠw‹¦‰ļƒZƒ~ƒi[, 2012, 1, 6, VŠƒ. iµćŁu‰‰j
  4. ‰FŽ”‹`‘„:ISO15189 ”F’čŽę“¾‚ĢŽĄŪ. “Œ‹žŽœŒb‰ļˆć‰Č‘åŠwE—Տ°ŒŸøˆćŠwƒZƒ~ƒi[, 2012, 9, 25, “Œ‹ž. iµćŁu‰‰j
  5. Niimi H., and Kitajima I. :Method for identifying pathogenic microorganisms responsible for infection by extracting the DNA of a microorganism. United States Patent, Patent NO. US8, 323, 898 B2, Date of patent:12, 4, 2012.
  6. ‰FŽ”‹`‘„, –k“‡ŒMi•Ņj:‘ę23‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”E‘ę31‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ “˜^W, •xŽR, 2012.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2011”N

Œ“’˜

  1. Niimi H., Mori M., Tabata H., Minami H., Ueno T*., Hayashi S.and Kitajima I.: A novel geukaryote-madeh thermo stable DNA polymerase which is free from bacterial DNA contamination. Journal of Clinical Microbiology,49(9): 3316-3320, 2011. PMID:21775543
  2. ‘ź˜e³‹M*, ‰FŽ”‹`‘„, –k“‡ŒM:¬Ž™S•s‘SŠ³ŽŅ‚ɂ؂Ƃ錌“BNP, ŒŒŸ÷NT-ProBNP ‚Ģ•]‰æ. ¶•ØŽŽ—æ•ŖĶ, 34i4j:287-292, 2011.

Ē—į•ń

  1. Takano A., Niimi H., Atarashi Y., Sawasaki T., Terasaki T., Nakabayashi T., Kitajima I., Tobe K., and Takahara T. :A novel Y231del mutation of HFE in hereditary hemochromatosis provides in vivo evidence that the Huh-7 is a human haemochromatotic cell line. Liver International, 31(10): 1593-1594, 2011.

Šw‰ļ•ń

  1. Kitajima I., Yoshioka K., Kabata T., Tani M., Tomita K., and Uji Y. :Rapid change of the finbrin monomer complex level during the perioperative period for early diagnosis of venous thrombolism. 21st Internatinal Congress of Clinical Chemistry and Laboratory Medicine. 2011, 5, 15-19, Berlin, Germany.
  2. Kitajima I., Harada K. *, Tomoda F., Kagitani S., Koike T., and Inoue H. :NF-κB activity in the peripheral blood lymphocytes correlates with metabolic syndrome-related biomarkers in patients with essential hypertension. 2011 American Society for Clinical Pathology Annual Meeting/WASPaLM XXVI Wordld Cobgress, 2011, 10, 19-23, Las Vegas, USA.
  3. Kitajima I., Beppu H., Nogami T., Shoda N., and Fukunaga K. :Reduced expression of the ATRX gene, A chromatin-remodeling factor, causes abnormal behaviors and learning impairment. XXth World Congress of Neurology, 2011, 11, 12-17, Marrakesh, Morocco.
  4. Uji Y., Takiwaki M. *, Yoshida C. *, Niimi H., Motomiya Y., Ando Y., and Kitajima I. :Beta-2 microglobulin intermediate in serum by capillary electrophoresis. 21st International Congress of Clinical Chemistry and Laboratory Medicine. 2011, 5, 15-19, Berlin, Germany.
  5. Takiwaki M*., Uji Y., Yoshida C*., Niimi H., and Kitajima I. :Plasma B-trype natriuremic peptide (BNP) and serum N-terminal pro-BNP (NTP-BNP) and LVEF levels with heart failure children. 21st International Congress of Clinical Chemistry and Laboratory Medicine. 2011, 5, 15-19, Berlin, Germany.
  6. Niimi H., Mori M., Minami H., Ueno T. *, Hayashi S., and Kitajima I. :Highly sensitive detection of bacteria using novel geukaryote-madeh Taq polymerase. 21st International Congress of Clinical Chemistry and Laboratory Medicine. 2011, 5, 15-19, Berlin, Germany.
  7. Sakata Y., Mimuro J., Takahashi H., Tshuji H., Eguchi Y., Kitajima I., Matsushita T., and Kuroda T. :Post-marketing surveillance of the safety and effectiveness of thrombomodulin alfa in Japanease patients with DIC. XXIII Congress of the International Society of Thrombosis and Haemostasis. 2011, 7, 26, Kyoto, Japan.
  8. Takiwaki M*., Uji Y., Ueno T. *, Niimi H., and Kitajima I. :Evaluation of HBs antigen enzyme immunoassay for chronic hepatitis B patients, 2011 Annual meeting of American Association for Clinical Chemistry, 2011, 7, 24-28, Atlanta, USA.
  9. Œ““cŒ’‰E*, •Ź•{GK, mˆäŒ©‰pŽ÷, ˆ¢•”Ž Ž÷, ‰H–ģ—zŽq, ŽRŒ`_ˆź, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ŖŒõ–@‚š—p‚¢‚½¶‘ĢŽŽ—æ’†‚Ģ“]ŽŹˆöŽqNF-κB ‘Ŗ’č–@‚ĢŠJ”­. ‘ę21‰ń¶•ØŽŽ—æ•ŖĶ‰»Šw”NŽŸŠwpW‰ļ, 2011, 2, 19, ¼ŽR.
  10. ‘ź˜e³‹M*, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:BNP, NT-proBNP, ¬Ž™S•s‘SŠ³ŽŅ‚É‚Ā‚¢‚Ä‚Ģ•]‰æ. ‘ę21‰ń¶•ØŽŽ—æ•ŖĶ‰»Šw”NŽŸŠwpW‰ļ, 2011, 2, 19, ¼ŽR.
  11. –k“‡ŒM, ’J‚Ż‚ĖŽq, •½–ģPŽ”, “c’†k‘¾˜Y:”][Ē‹}«Šś‚É‚Ø‚Æ‚é•aŒ^•Ź‰šĶ. ‘ę11‰ńTTM ƒtƒH[ƒ‰ƒ€, 2011, 3, 5, “Œ‹ž.
  12. ‘ź˜e³‹M*, ć–ģ’q_*, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:‰»Šw”­Œõ–ʉu‘Ŗ’č–@‚É‚ę‚éHBsRŒ“‘Ŗ’č‚ĢŠī‘b“IŒŸ“¢. ‘ę50‰ń“ś–{—Տ°ŒŸøŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļ ‘ę322‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠCE–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ, 2011, 3, 13, ‹ą‘ņ.
  13. mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ģ—m, ć–ģ’q_*, —ŃŽj˜N, –k“‡ŒM:eukaryote-made Taq polymerase ‚ĢŠJ”­‚É‚ę‚鍂Š““x‚ČƒoƒNƒeƒŠƒAŒŸo–@. ‘ę322‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠCE–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ, 2011, 3, 13, ‹ą‘ņ.
  14. Žsģ‹v”ü, ‹Ÿ“c•¶G, œA£‰ė‘ć, —«˜aK, ‘匓–ƒˆßŽq, ŽRčGŒ›, ’†ģ‘׎O, ¬’r‹Ī, Œ®’J‘Žu, ˆäć”Ž, –k“‡ŒM, ‰FŽ”‹`‘„, ›Œ“G•ä, ‰”“c—Ķ:β2-ƒ~ƒNƒƒOƒƒuƒŠƒ“•Ŗ‰ę‚Ģ“§Ķœ‹Ž”\:ƒ|ƒŠƒXƒ‹ƒtƒHƒ“iPSj–Œ‚Ęƒ|ƒŠƒG[ƒeƒ‹–Œ(PES)–Œ‚Ę‚Ģ·ˆŁ. ‘ę56‰ń“ś–{“§ĶˆćŠw‰ļŠwpW‰ļ, 2011, 6, 18, ‰”•l.
  15. ‹g“cē»*, Œ““cŒ’‰E*, •ŠĄ»Žq, ģ“‡–ŅŽu, œA£‰ė‘ć, ‹Ÿ“c•¶G, ‰FŽ”‹`‘„, –k“‡ŒM:Endo-PAT2000 ‚Ø‚ę‚щü—ĒŒ^ŒŒŠĒ‰šĶƒVƒXƒeƒ€PRAS‚Ģ•]‰æ. ‘ę22‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, ‘ę30‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ, 2011, 8, 6, –¼ŒĆ‰®.
  16. ‘ź˜e³‹M*, ć–ģ’q_*, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:HBsRŒ“’č—Ź‘Ŗ’č‚ĢŠī‘b“IŒŸ“¢‚Ę—Õ°•]‰æ, ‘ę51‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ, 2011, 8, 26, ŽD–y.
  17. mˆäŒ©‰pŽ÷, ć–ģ’q_*, —ŃŽj˜N, X³”V, ‘½—t“c—_, “ģ—m, ‰FŽ”‹`‘„, –k“‡ŒM:"eukaryote-made" Taq polymerase ‚š—p‚¢‚½‚Š““xEv‘¬‚ČŠ“õĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€‚Ģ\’z. ‘ę51‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ, 2011, 8, 26, ŽD–y.
  18. ˆĄ–{—R‰Ą, X‰ŗ‰p—Žq, ŠÖ’J‹ÅŽq, ŠŪŽRŒbŽq, ’‡—ёבć, mˆäŒ©‰pŽ÷, –k“‡ŒM, ’©‘q‰pō, ‘å’|–ĪŽ÷, ’†”öįĮ“ń:[•”Ć–¬ŒŒšĒ‚š”­Ē‚µ‚½ę“V«‘ę‡XˆöŽqiFVjŒ‡–RĒ‚Ģˆź—į. ‘ę36‰ń–k—¤—Տ°•a—W’k‰ļ, 2011, 9, 10, ‹ą‘ņ.
  19. ‘ź˜e³‹M*, ‰FŽ”‹`‘„, ‹g“cē», ‹Ÿ“c•¶G, –{‹{‘P‰ų, mˆäŒ©‰pŽ÷, –k“‡ŒM:β2-ƒ~ƒNƒƒOƒƒuƒŠƒ“’†ŠŌ‘Ģ‚Ģ“§Ķ‚É‚ę‚鏜‹Ž”\‚É‚Ā‚¢‚Ä. ‘ę36‰ń–k—¤—Տ°•a—W’k‰ļ, 2011, 9, 10, ‹ą‘ņ.
  20. ć–ģ’q_*, mˆäŒ©‰pŽ÷, —ŃŽj˜N, –ģŽč—Ē„, ‰FŽ”‹`‘„, –k“‡ŒM:v‘¬‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€‚Ģ\’z‚ʐ³Šm«‚Ģ•]‰æ. ‘ę36‰ń–k—¤—Տ°•a—W’k‰ļ, 2011, 9, 10, ‹ą‘ņ.
  21. ‘ź˜e³‹M*, ć–ģ’q_*, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:–«BŒ^ŠĢ‰ŠŠ³ŽŅ‚É‚Ø‚Æ‚éHBsRŒ“’č—Ź‚Ģ•]‰æ. “ś–{—Õą¬ŒŸøŽ©“®‰»Šw‰ļ‘ę43‰ń‘å‰ļ, 2011, 10, 8, ‰”•l.
  22. ‰FŽ”‹`‘„:ˆć—ĆŒ»ź‚Ģƒj[ƒY‚ɉž‚¦‚錤‹†‚Ę’mŽÆ‚šŠˆ—p‚Å‚«‚鋳ˆēhV‚µ‚¢—Տ°ŒŸø–@‚ĢŠJ”­‚Ęˆć—Ć‚Ö‚ĢvŒ£h. ‹ćB‘åŠw •ŪŒ’ŠwŒ¤‹†‰@ƒZƒ~ƒi[ 2011, 10, 24, •Ÿ‰Ŗ.
  23. mˆäŒ©‰pŽ÷, ć–ģ’q_*, —ŃŽj˜N, –ģŽč—Ē„, ‰FŽ”‹`‘„, –k“‡ŒM:eukaryote-made Taq polymerase ‚š—p‚¢‚½³Šm‚Őv‘¬‚ČŠ“õĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€‚Ģ\’z. ‘ę58‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2011,11,18, ‰ŖŽR.
  24. ć–ģ’q_*, mˆäŒ©‰pŽ÷, —ŃŽj˜N, –ģŽč—Ē„, ‰FŽ”‹`‘„, –k“‡ŒM:v‘¬‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€‚Ģ\’z‚ʐ³Šm«‚Ģ•]‰æ. ‘ę58‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2011, 11, 18, ‰ŖŽR.
  25. ‘ź˜e³‹M*, ‰FŽ”‹`‘„, ‹g“cē», ‹Ÿ“c•¶G, –{‹{‘P‰ų, mˆäŒ©‰pŽ÷, –k“‡ŒM:β2-ƒ~ƒNƒƒuƒƒOƒŠƒ“•Ŗ‰ę‚Ģ“§Ķ‚É‚ę‚鏜‹Ž”\‚É‚Ā‚¢‚Ä‚ĢŒŸ“¢. ‘ę58‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2011,11,18, ‰ŖŽR.
  26. ‹ß“” , mˆäŒ©‰pŽ÷, –k“‡ŒM:Huh-7‚š—p‚¢‚½ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX•a‘ŌƒƒJƒjƒYƒ€‚Ģ‰šĶ\Hepcidin ”­Œ»ˆŁķ‚ÉŠÖ‚·‚ékey mediator ‚Ģ’Tõ\. ‘ę58‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2011,11,18, ‰ŖŽR.
  27. ŒKŒ“‘ģ”ü, ŽÄ‘„Žq, ×’JFŽq, ‰FŽ”‹`‘„, –k“‡ŒM:XN-9000Šī‘bŒŸ“¢, ‰^—p—į. •xŽRŒ§—Տ°ŒŸø‹ZŽt‰ļŒŒ‰tŒŸøŒ¤‹†”ĒƒZƒ~ƒi[, 2011, 12, 12, •xŽR.

‚»‚Ģ‘¼

  1. ‰FŽ”‹`‘„:ÅVˆć—Ć’T–K\¢ŠEÅ‚…€‚ĢŒŸø‚š–ŚŽw‚·\. •xŽR‘åŠw•‘®•a‰@‚¾‚ę‚č ‚©‚ķ‚ē”Å, 116:8-9, 2011.
  2. –ģŽč—Ē„, ‹v•Ū“c’q”ü*, ŠÖŒūŒh•¶*:ƒCƒ“ƒXƒgƒ‰ƒNƒ^[, ‘ę2‰ń“h–•‹¾ŒŸƒXƒLƒ‹ƒgƒ‰ƒ“ƒXƒtƒ@[ in •xŽR, 2011, 12, 11, •xŽR.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2010”N

’˜‘

  1. Œ““cŒ’‰E, –k“‡ŒM:ƒoƒCƒ^ƒ‹ˆŁķE‹}•ĻEME‹@Šķ‚Å‚ĢƒAƒ‰[ƒ€ƒTƒCƒ“‚ĢƒAƒvƒ[ƒ`. ‹Ł‹}Ž”—Ć‚š—v‚·‚鎾Š³‚Ģ•a‘Ō¶—‚Ę–ņ•ØŽ”—Ć. i¬–ģŽ›Œ›Ž”•Ņj, –ņŽ–“ś•ńŽŠi“Œ‹žjp1-186, 2010.

Œ“’˜

  1. Nogami T., Beppu H., Tokoro T., Moriguchi S., Shioda N., Fukunaga K., Ohtsuka T., Ishii Y., Sasahara M., Shimada Y., Nishijo H., Li E., Kitajima I.:Reduced expression of the ATRX gene, a chromatin-remodeling factor, causes hippocampal dysfunction in mice. Hippocampus; 21(6):678-87, 2011.PMID:20865721
  2. Yoshioka K., Kitajima I., Kabata T., Tani M., Kawahara N., Murakami H., Demura S., Tsubokawa T., Tomita K.:Venous thromboembolism after spinal surgery: Changes of the fibrin monomer complex and D-dimer level during the perioperative period. Journal of Neurosurgery. Spine, 13(5):594-599, 2010.PMID:21039150
  3. Shioda N., Beppu H., Fukuda T., Li E., Kitajima I., Fukunaga K.:Aberrant Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Activity Is Associated with Abnormal Dendritic Spine Morphology in the ATRX Mutant Mouse Brain. J Neurosci., 31(1): 346-58, 2011.PMID:21209221
  4. mˆäŒ©‰pŽ÷, ”öģ’q”ü, –ģŽč—Ē„, —ŃŽj˜N, ć–ģ’q_, Œ““cŒ’‰E, ‰FŽ”‹`‘„, –k“‡ŒM:ˆā“`ŽqŒŸøŽŗ‚É‚Ø‚Æ‚éƒXƒvƒ‰ƒCƒVƒ“ƒOˆŁķ‚Ģˆā“`Žqf’f|ƒsƒbƒgƒtƒH[ƒ‹‚ĘƒAƒvƒ[ƒ`•ū–@|. —Տ°•a—58:1162-1168, 2010.PMID:21348235

‘ą

  1. –k“‡ŒM:DICf’f‚Ģ‚½‚ß‚ĢV‹Kƒ}[ƒJ[‚Ę‚»‚Ģ•]‰æ. ŒŒš‚ʏzŠĀ17 (4):30-35, 2009.
  2. –k“‡ŒM:IŒ^ƒvƒƒRƒ‰[ƒQƒ“C––’[ƒvƒƒyƒvƒ`ƒhiPICPj, IŒ^ƒRƒ‰[ƒQƒ“C––’[ƒeƒƒyƒvƒ`ƒhiICTPj. “ś–{—Õą¬. L”ĶˆĶŒŒ‰tE”A‰»ŠwŒŸø–ʉuŠw“IŒŸø2: 252-255, 2010.
  3. –k“‡ŒM:“®‚«Žn‚ß‚½‚ķ‚Ŗ‘‚Ģƒtƒ@[ƒ}ƒRƒQƒmƒ~ƒNƒX. —Տ°ŒŸø54i10j: 1105-1106, 2010.
  4. •Ź•{GK:BMPƒVƒOƒiƒ‹“`’BˆŁķ‚ĘŽ¾Š³. ŽĄŒ±ˆćŠw28i4j:888-893, 2010.

Šw‰ļ•ń

  1. Kitajima I.:Anti-inflammatory effect of pitavastatin on NF-κB activated by TNF-alfa through Rho kinase pathway in breast cancer cells. Keystone Symposia 2010 NF-kappa B in inflammation and Disease, 2010, 1, 5-10, Santa Fe, USA.
  2. Kitajima I., Tani M., Uji Y., Yoshioka K., Kabara T.:Elevated levels of the fibrin monomer compex and D-dimer indicate high risk of venous thromboembolism after spinal surgery. 2010 AACC (American Association for Clinical Chemistry) Annual Meetin, 2010, 7, 25-29, Anaheim, CA, USA.
  3. Uji Y., Takiwaki M., Ueno T., Taga Y., Shiba N., Yoshida C., Kuwabara T., Niimi H., Kitajima I.:Plasma B-type natiuremic peptide (BNP) and serum N-terminal-proBNP (NTpBNP) levels with heart faifure children. 2010 AACC (American Association for Clinical Chemistry) Annual Meetin, 2010, 7, 25-29, Anaheim, CA, USA.
  4. Harada K., Kitajima I.:Nuclear factor-kappa B activity correlates with metabolic syndrome-related biomerkers in patients with essential hypertension. 2010 AACC (American Association for Clinical Chemistry) Annual Meetin, 2010, 7, 25-29, Anaheim, CA, USA.
  5. Niimi H., Takano A., Takahara T., Kitajima I.:A HEF-mutated hemochoromatotic cell line, which suggests the mechanism hepcidine expression rehulated by HEF-BMP-6-Samd pathway. Annual TGF-β meeting, 2010, 9, 3 Leiden, The Netherland.
  6. Beppu H., Leyton P., Liu R., and Bloch K. D.:BMP7 induces enhanced Smad1/5/8 phosphorylationin BMPR2 tail domain-deficient cells. TGF-β meeting, 2010, 9, 1-3, Leiden.
  7. Beppu H.:BMPR2-deficiency causes abnormal cell proliferation in cardiovascular and intestinal tracts. The 59th Fujihara Seminar, Molecular Mechanisms of TGF-beta signaling and disease, 2010, 7, 14-17, Hokkaido.(Invited lecture)
  8. –k“‡ŒM:V‚µ‚¢“®–¬d‰»ŒŸø–@‚ĢŠJ”­. •½¬21”N“x‘—§‘åŠw–@l•‘®•a‰@‹ZŽt‰ļŒ¤C‰ļ, 2010, 2, 5, •xŽR
  9. –k“‡ŒM:“®–¬d‰»ŒŸø‚Ģup to date. ‘ę23‰ń’†•”’n‹ę¶—ŒŸøŒ¤C‰ļ, 2010, 2, 27, •xŽR
  10. –k“‡ŒM, •Ź•{GK, –ģć’B–ē, Īˆä—zŽq, łŒ“³“, XŒū–ĪŽ÷, ‰–“c—ĻŽj, •Ÿ‰i_Ži, ¼šŽõ•v:ƒNƒƒ}ƒ`ƒ“ƒŠƒ‚ƒfƒŠƒ“ƒOˆöŽqATRX’`”’”­Œ»’į‰ŗƒ}ƒEƒX‚ĢŠC”nEG“‘Ģ‹@”\ˆŁķ‚Ę‚»‚Ģ•ŖŽq‹@\. ķ—Ŗ“I‘n‘¢Œ¤‹†Ž–‹Ę„iŽ–‹ĘiCRESTju”]‚Ģ‹@”\”­’B‚ĘŠwKƒƒJƒjƒYƒ€‚Ģ‰š–¾v‘ę7‰ń—Ģˆę“ąŒ¤‹†‰ļ, 2010, 3, 1, ‘åć.
  11. –k“‡ŒM:V‹KŒŒŠĒ‹@”\ŒŸø–@ŠJ”­‚É‚ę‚錌ŠĒƒGƒCƒWƒ“ƒO‚Ģ‰ČŠw“I•]‰æ‚Ę—Õ°‰ž—p. ‘ę4‰ń–¢•a—\–hƒVƒXƒeƒ€Œ¤‹†‰ļ, •½¬21”N“x’m“IƒNƒ‰ƒXƒ^[’nˆęƒvƒƒWƒFƒNƒgŽ–‹Ę, 2010, 3, 4, •xŽR.
  12. Œ““cŒ’‰E, ‹Ÿ“c•¶G, Œ®’J‘Žu, ¬’r‹Ī, ˆäć”Ž, –k“‡ŒM:“]ŽŹˆöŽqNF-κBŠˆ«‰»‚Ŗ‚ŒŒˆ³‚É‹y‚Ō‚·‰e‹æ‚Ę‚»‚Ģ‹K’čˆöŽq‚Ģ—Տ°“IˆÓ‹`. ‘ę49‰ń“ś–{—Տ°ŒŸøŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę320‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ, 2010, 3, 14, –¼ŒĆ‰®.
  13. ć–ģ’q_, –ģŽč—Ē„, mˆäŒ©‰pŽ÷, ‰FŽ”‹`‘„, –k“‡ŒM:Staphylococcus aureus‚Ģ‹Ū‘ĢŠO“Å‘f‚ÉŠÖ‚·‚錟“¢. ‘ę49‰ń“ś–{—Տ°ŒŸøŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę320‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ, 2010, 3, 14, –¼ŒĆ‰®.
  14. Œ““cŒ’‰E, ‹Ÿ“c•¶G, Œ®’J‘Žu, ¬’r ‹Ī, ˆäć”Ž, –k“‡ŒM:–¢Ž”—Ć–{‘Ō«‚ŒŒˆ³Š³ŽŅ‚É‚Ø‚Æ‚é“]ŽŹˆöŽqNF-κB‚ĢŠˆ«‰»‚Ę‚»‚Ģ‹@˜. ‘ę107‰ń“ą‰ČŠw‰ļ‘‰ļ, 2010, 4, 10, “Œ‹ž.
  15. Œ““cŒ’‰E, mˆäŒ©‰pŽ÷, ī’J»Žq, ‰FŽ”‹`‘„, –k“‡ŒM:ę“V«‘ęVˆöŽqŒ‡‘¹ĒiPhe160Serj‚É‚Ø‚Æ‚é•ŖŽq•a‘Ō‰šĶ. ‘ę33‰ń“ś–{ŒŒšŽ~ŒŒŠw‰ļŠwpW‰ļ, 2010, 4, 22, Ž­Ž™“‡.
  16. mˆäŒ©‰pŽ÷, –k“‡ŒM:ę“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RĒ‚Ģˆā“`Žq‰šĶ. ‘ę33‰ń“ś–{ŒŒšŽ~ŒŒŠw‰ļŠwpW‰ļ, 2010, 4, 22, Ž­Ž™“‡.
  17. –k“‡ŒM:αƒTƒ‰ƒZƒ~ƒAEø_’x‘ŲĒŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚Ķ, •¶–¬‹L‰Æ”\—Ķ‚Ģ’į‰ŗ‚šŽ¦‚·. ‘ę51‰ń“ś–{_ŒoŠw‰ļ‘‰ļ, 2010, 5, 20, “Œ‹ž.
  18. mˆäŒ©‰pŽ÷, –ģŽč—Ē„, ć–ģ’q_, ‰FŽ”‹`‘„, –k“‡ŒM:Staphylococcus aureus‚Ģ‹Ū‘ĢŠO“Å‘fŽY¶‚ÉŠÖ‚·‚錟“¢. ‘ę17‰ń“ś–{ˆā“`Žqf—ĆŠw‰ļ‘å‰ļ, 2010, 8, 7, ŽOd.
  19. ‘ź˜e³‹M, “ś‚GĘ, ‰FŽ”‹`‘„, –k“‡ŒM:Žæ—Ź•ŖĶ‚š—p‚¢‚½ƒRƒŒƒXƒeƒ[ƒ‹ƒGƒXƒeƒ‰[ƒ[‚ĢƒŠƒ“Ž‰Žæ•Ŗ‰ę‚ÉŠÖ‚·‚锽‰ž«‚ĢŒŸ“¢. ‘ę21‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę29‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ, 2010, 8, 28, •Ÿˆä.
  20. ‹g“cē», Œ““cŒ’‰E, ī’J»Žq, ģ“‡–ŅŽu, œA£‰ė‘ć, ‹Ÿ“c•¶G, ‰FŽ”‹`‘„, –k“‡ŒM:¶‘ĢŒŒŠĒ‹@”\‚š”½‰f‚·‚éEndo-PAT2000‚Ģ«”\•]‰æ‚ĘŒŸøø“xŒüć‚ÉŒü‚Æ‚½ŒŸ“¢. ‘ę21‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”‘‰ļE‘ę29‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”—į‰ļ˜A‡‘å‰ļ, 2010, 8, 28, •Ÿˆä.
  21. –k“‡ŒM:POCT‚Ģl‚¦•ū‚Ę‚»‚ĢŠˆ—p–@‚š“±“ü‚µ‚½ŒŸø•”ŽĄK‚ĢŽę‚č‘g‚Ż. ‘ę57‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2010, 9, 10, “Œ‹ž.
  22. –k“‡ŒM:X˜A½αƒTƒ‰ƒZƒ~ƒAEø_’x‘ŲĒŒóŒQ‚š—‰š‚·‚邽‚߂ɃlƒYƒ~‚šŽg‚Į‚½Œ¤‹†. ‘ę2‰ńX˜A½αƒTƒ‰ƒZƒ~ƒAEø_’x‘ŲĒŒóŒQiATR-XĒŒóŒQjŠ³ŽŅ•×‹­‰ļ, 2010, 9, 18, ‰”•l.
  23. –k“‡ŒM:NF-κB‚©‚ēŽa‚銹E‰ŠĒ«Ž¾Š³E¶ŠˆKŠµ•a‚Ģ•ŖŽq•a‘Ō‰šĶ. ‘ę50‰ń“ś–{—Տ°‰»Šw”NŽŸŠwpW‰ļ, 2010, 9, 25, ŽR—œ.
  24. –k“‡ŒM:ŒŒšĒ‘Šś”­Œ©‚ÖŒü‚Æ‚½ƒ‚ƒjƒ^ƒŠƒ“ƒO. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę42‰ń‘å‰ļ, 2010, 10, 9, _ŒĖ.
  25. –k“‡ŒM:DIC‚Ģ•a‘ŌEf’fEŽ”—Ɓ\•ŖŽqƒ}[ƒJ[‚©‚ē‚Ģ’ńŒ¾\. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę42‰ń‘å‰ļ, 2010, 10, 9, _ŒĖ.
  26. mˆäŒ©‰pŽ÷, ‰FŽ”‹`‘„, –k“‡ŒM:ŠÖßƒŠƒEƒ}ƒ`‚Ģ•a‘ŌƒƒJƒjƒYƒ€‚É‚Ø‚Æ‚éE1AF‚Ģ‹@”\‰šĶ. ‘ę57‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2010, 9, 11, “Œ‹ž.
  27. mˆäŒ©‰pŽ÷, –ģŽč—Ē„, ‰FŽ”‹`‘„:HFEˆā“`Žq‚É•ĻˆŁ‚š”F‚ß‚½ˆā“`«ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒXĒ—į‚É‚Ø‚Æ‚é•a‘ŌƒƒJƒjƒYƒ€‚Ģ‰šĶ. ‘ę57‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2010, 9, 11, “Œ‹ž.
  28. Œ““cŒ’‰E, ‹Ÿ“c•¶G, Œ®’J‘Žu, ¬’r‹Ī, ˆäć”Ž, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ŖŒõ–@‚š—p‚¢‚½“]ŽŹˆöŽqNF-κB‚ĢV‚½‚Č‘Ŗ’č–@‚ĢŠm—§‚Ę‚»‚Ģ—Տ°‰ž—p. ‘ę57‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2010, 9, 10, “Œ‹ž.
  29. ‘ź˜e³‹M, ć–ģ’q_, ‘½‰ź—R‹IŽq, ŽÄ‘„Žq, ‹g“cē», ŒKŒ“‘ģ”ü, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:¬Ž™S•s‘SŠ³ŽŅ‚ɂ؂Ƃ錌Ÿ÷BNP’l, ŒŒ“NT-ProBNP’l‚Ģ•]‰æ. ‘ę57‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2010, 9, 12, “Œ‹ž.
  30. —ŃŽj˜N, mˆäŒ©‰pŽ÷, ć–ģ’q_, ā–{ƒŽq, ‹g“cˆčŽq, X“c–¢, ‰FŽ”‹`‘„, –k“‡ŒM:Žq‹{“ąŠ“õĒ‚É‚Ø‚Æ‚év‘¬‚ČŒŸø. f—ĆƒVƒXƒeƒ€‚Ģ\’z. ‘ę57‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2010, 9, 12, “Œ‹ž.
  31. ć–ģ’q_, mˆäŒ©‰pŽ÷, —ŃŽj˜N, ‰FŽ”‹`‘„, –k“‡ŒM:masked primer dimer–@‚ĘŠ“õĒŠČˆÕ’č—ŹƒVƒXƒeƒ€‚ĢŠJ”­. ‘ę57‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2010, 9, 12, “Œ‹ž.
  32. —ŃŽj˜N, mˆäŒ©‰pŽ÷, ć–ģ’q_, ā–{ƒŽq, ‹g“cˆčŽq, X“c–¢, ‰FŽ”‹`‘„, –k“‡ŒM:v‘¬‚ȍR¶ÜŠ“Žó«ŒŸø–@‚ĢŠJ”­. ‘ę57‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2010, 9, 12, “Œ‹ž.
  33. ‘ź˜e³‹M, ‰FŽ”‹`‘„, –k“‡ŒM, ŽR‰ŗ•ō, ģčŒ’Ž”, ›–ģŒõr, “ś‚ŒbˆČŽq, –{“cFs, “ś‚GĘ:ƒRƒŒƒXƒeƒ[ƒXƒGƒXƒeƒ‰[ƒ[ˆ—‚ɂ؂Ƃ錌“HDLŽ‰Žæ‚Ģ•ŖĶ. ‘ę50‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ, 2010, 9, 24, ŽR—œ.
  34. ‘ź˜e³‹M, ć–ģ’q_, ‘½‰ź—R‹IŽq, ŽÄ‘„Žq, ‹g“cē», ŒKŒ“‘ģ”ü, ‰FŽ”‹`‘„, –k“‡ŒM:‘SŒŒ’†, ŒŒŸ÷’†BNP‚Ø‚ę‚ŃŒŒ“’†NT-ProBNP‚Ģ•]‰æ. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę42‰ń‘å‰ļ, 2010, 10, 9, _ŒĖ.
  35. ‹g“cē», Œ““cŒ’‰E, ī’J»Žq, ģ“‡–ŅŽu, œA£‰ė‘ć, ‹Ÿ“c•¶G, ‰FŽ”‹`‘„, –k“‡ŒM:¶‘ĢŒŒŠĒ‹@”\‚š”½‰f‚·‚éEndo-PAT2000‚Ģ•]‰æ‚ʐø“xŒüć‚š–ŚŽw‚µ‚½Ž©“®‰»‚Ö‚ĢŽę‚č‘g‚Ż. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę42‰ń‘å‰ļ, 2010, 10, 9, _ŒĖ.
  36. Œ““cŒ’‰E, •Ź•{GK, mˆäŒ©‰pŽ÷, ˆ¢•”Ž Ž÷, ‰H–ģ—zŽq, ŽRŒ`_ˆź, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ŖŒõ–@‚š—p‚¢‚½¶‘ĢŽŽ—æ’†‚Ģ“]ŽŹˆöŽqNF-κB‘Ŗ’č–@‚ĢŠJ”­. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę42‰ń‘å‰ļ, 2010, 10, 9, _ŒĖ.
  37. ć–ģ’q_, mˆäŒ©‰pŽ÷, —ŃŽj˜N, ‰FŽ”‹`‘„, –k“‡ŒM:masked primer dimer–@ & one step nested PCR–@‚É‚ę‚鍂Š““xE‚“ĮˆŁ“x‚ČŠ“õ‹ŪŠČˆÕ’č—ŹƒVƒXƒeƒ€‚ĢŠJ”­. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę42‰ń‘å‰ļ, 2010, 10, 9, _ŒĖ.
  38. —ŃŽj˜N, mˆäŒ©‰pŽ÷, ć–ģ’q_, ‰FŽ”‹`‘„, –k“‡ŒM:v‘¬‚ȍR¶ÜŠ“Žó«ŽŽŒ±–@‚ĢŠJ”­‚ĘŽq‹{“ąŠ“õĒ‚É‚Ø‚Æ‚év‘¬ŒŸøƒVƒXƒeƒ€‚Ö‚Ģ‰ž—p. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę42‰ń‘å‰ļ, 2010, 10, 9, _ŒĖ.
  39. mˆäŒ©‰pŽ÷, —ŃŽj˜N, ć–ģ’q_, Œ““cŒ’‰E, ‰FŽ”‹`‘„, –k“‡ŒM:ˆā“`ŽqŒŸøŽŗ‚É‚Ø‚Æ‚éƒXƒvƒ‰ƒCƒVƒ“ƒOˆŁķ‚Ģˆā“`Žqf’f\ƒsƒbƒgƒtƒH[ƒ‹‚ĘƒAƒvƒ[ƒ`–@\. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę42‰ń‘å‰ļ, 2010, 10, 9, _ŒĖ.
  40. ¼–ģŽåįĮ, “¹–ģ~Žq, ’†oĖ‘ć, ²’|ˆÉ’ĆŽq, “‡‹žŽq, ˆĄ‘ŗ•q, –k“‡ŒM:“–‰@‚ɂ؂Ƃ鎞ŠŌŠO—AŒŒŒŸø‹Ę–±‚ĢŒ»ó‚É‚Ā‚¢‚Ä. “ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ‘ę28‰ń–k—¤Žx•”—į‰ļ, 2010, 10, 9, •Ÿˆä.
  41. ’†oĖ‘ć, ²’|ˆÉ’ĆŽq, “¹–ģ~Žq, ¼–ģŽåįĮ, “‡‹žŽq, ˆĄ‘ŗ•q, –k“‡ŒM:PBSCT‚É‚ę‚é‰@“ą‚ĢCD34+×–E”‚Ģ‘Ŗ’č‚Ģ•K—v«. “ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ‘ę28‰ń–k—¤Žx•”—į‰ļ, 2010, 10, 9, •Ÿˆä.
  42. ‘ź˜e³‹M, ć–ģ’q_, ‘½‰ź—R‹IŽq, ŽÄ‘„Žq, ‹g“cē», ŒKŒ“‘ģ”ü, ‰FŽ”‹`‘„, –k“‡ŒM:¬Ž™‚É‚Ø‚Æ‚éBNP, NT-ProBNP‚Ģ•]‰æ. ‘ę35‰ń–k—¤—Տ°•a—W’k‰ļ, 2010, 10, 16, •xŽR.
  43. mˆäŒ©‰pŽ÷, –ģŽč—Ē„, ‰FŽ”‹`‘„, –k“‡ŒM:HFE•ĻˆŁ‚š”F‚ß‚½ˆā“`«ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒXĒ—į‚É‚Ø‚Æ‚é•a‘ŌƒƒJƒjƒYƒ€‚Ģ‰šĶ. ‘ę35‰ń–k—¤—Տ°•a—W’k‰ļ, 2010, 10, 16, •xŽR.
  44. ”ņ“c–ė”nl, [’J¹O, •U“c^‹I, ‹g‰ŖŽõ—Ļ, –k“‡ŒM, ˆäć‰p“ń, “n•Ó‰ė•F, ‘å’Ė–«‹v:•½–Ź“ą×–E‹É«§Œä•ŖŽqPrickle‚ĶŒćƒVƒiƒvƒX”ģŒś•”‚É‹ĒŻ‚µPSD-95‚Ø‚ę‚ŃNMDAŽó—e‘Ģ‚Ę•”‡‘Ģ‚šŒ`¬‚·‚é. ‘ę33‰ń“ś–{•ŖŽq¶•ØŠw‰ļ”N‰ļ, 2010, 12, 9, _ŒĖ.

‚»‚Ģ‘¼

  1. ‘Ū“Į‹–oŠč:k”­–¾ŽŅl‘½—t“c—_, “ģ—m, mˆäŒ©‰pŽ÷, –k“‡ŒM, ć–ģ’q_, —ŃŽj˜N, X³”V k”­–¾–¼Ģl‘Ļ”M«DNAƒ|ƒŠƒƒ‰[ƒ[‚šŠÜ‚Žy‘f’²®•Ø‚Ø‚ę‚Ń‚»‚Ģ»‘¢•ū–@, •Ą‚Ń‚ÉŒŸo‘ĪŪ•Ø‚ĢŒŸo•ū–@ k‘Ū“Į‹–oŠč”Ō†lPTC/JP2010/050443 k‘ŪoŠč“śl2010”N1ŒŽ15“ś.
  2. ‘“ą“Į‹–oŠč:k”­–¾ŽŅl–k“‡ŒMk”­–¾–¼ĢlŽwė–¬”g‰šĶ‘•’u‹y‚Ń‚±‚ź‚š—p‚¢‚½ŒŒŠĒ“ą”ē‹@”\•]‰æƒVƒXƒeƒ€ koŠč”Ō†l“ĮŠč2010-59907† koŠč“śl2010”N3ŒŽ16“ś.
  3. ‘“ą“Į‹–Žę“¾:k”­–¾ŽŅlmˆäŒ©‰pŽ÷, –k“‡ŒM k“Į‹–Œ ŽŅl‘—§‘åŠw–@l•xŽR‘åŠw k”­–¾–¼ĢlŠ“õĒ‹Nˆö‹Ū‚Ģv‘¬“Æ’č•ū–@ k“Į‹–”Ō†l“Į‹–4590573†.
  4. ‘Ū“Į‹–oŠč:k”­–¾ŽŅlmˆäŒ©‰pŽ÷, –k“‡ŒM k“Į‹–oŠčll•xŽR‘åŠw k”­–¾–¼ĢlŠ“õĒ‹Nˆö‹Ū‚Ģv‘¬“Æ’č•ū–@ k”Ō†l“ĮŠč2008-501721 k”F’č“śl•½¬22”N8ŒŽ10“ś.
  5. ’J‚Ż‚ĖŽq, ‹g‰ŖŽl, ‰Į”Ø‘½•¶, ‰FŽ”‹`‘„, –k“‡ŒM:Ņ’ÅŽčp‚É‚Ø‚Æ‚éVTE”­Ē‚ʏp’†, pŒć‚Ģ‹ĆŒÅEü—nŒn•ŖŽqƒ}[ƒJ[‚Ģ•Ļ“®‚ĢˆÓ‹`. ‘ę9‰ńTTMƒtƒH[ƒ‰ƒ€‹L˜^:69-76, 2010.
  6. –k“‡ŒM:ƒvƒƒtƒFƒVƒ‡ƒiƒ‹ƒŠƒYƒ€‚Ģ‹³ˆē‚š–ŚŽw‚µ‚Ä. •xŽR‘åŠwˆćŠw•”Œć‰‡‰ļ‰ļ•ń37:3, 2010.
  7. –k“‡ŒM:•½¬22”N“xˆćŠw‹³ˆēƒtƒ@ƒJƒ‹ƒeƒCEƒfƒxƒƒvƒƒ“ƒg‚Ģ‚²•ń. •xŽR‘åŠwˆćŠw•”Œć‰‡‰ļ‰ļ•ń38:3-4, 2010.
  8. –k“‡ŒM:•½¬22”N“x•xŽR‘åŠwˆćŠw•”ˆćŠw‰ČFD‚Ģ‘Š‡. •½¬22”N“x•xŽR‘ęŠzˆćŠw•”ˆćŠw‰ČFD•ń‘:1-2, 2010.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2009”N

’˜‘

  1. –k“‡ŒM:EDTA•‰‰×ŽŽŒ±. ˆćŠw‘厫“Ti‘ę2”Łj, 258, ˆćŠw‘‰@, “Œ‹ž, 2009.
  2. –k“‡ŒM:ƒJƒ‹ƒVƒEƒ€‹zŽūŽŽŒ±. ˆćŠw‘厫“Ti‘ę2”Łj, 471, ˆćŠw‘‰@, “Œ‹ž, 2009.
  3. –k“‡ŒM:tŒ“«ƒTƒCƒNƒŠƒbƒNAMP. ˆćŠw‘厫“Ti‘ę2”Łj, 1406-7, ˆćŠw‘‰@, “Œ‹ž, 2009.
  4. –k“‡ŒM:ƒrƒ^ƒ~ƒ“D ‘Ŗ’č–@. ˆćŠw‘厫“Ti‘ę2”Łj, 2335, ˆćŠw‘‰@, “Œ‹ž, 2009.
  5. –k“‡ŒM:•›bó‘B‹@”\ŒŸø. ˆćŠw‘厫“Ti‘ę2”Łj, 2429, ˆćŠw‘‰@, “Œ‹ž, 2009.
  6. –k“‡ŒM:•›bó‘Bƒzƒ‹ƒ‚ƒ“ŠÖ˜A’`”’Žæ. ˆćŠw‘厫“Ti‘ę2”Łj, 2430, ˆćŠw‘‰@, “Œ‹ž, 2009.
  7. –k“‡ŒM:•›bó‘Bƒzƒ‹ƒ‚ƒ“•‰‰×ŽŽŒ±. ˆćŠw‘厫“Ti‘ę2”Łj, 2340-1, ˆćŠw‘‰@, “Œ‹ž, 2009.
  8. –k“‡ŒM:ƒCƒ“ƒ^ƒNƒg•›bó‘Bƒzƒ‹ƒ‚ƒ“. ˆćŠw‘厫“Ti‘ę2”Łj, 180, ˆćŠw‘‰@, “Œ‹ž, 2009.
  9. –k“‡ŒM:IŒ^ƒRƒ‰[ƒQƒ“‰Ė‹“N-ƒeƒƒyƒvƒ`ƒh. ˆćŠw‘厫“Ti‘ę2”Łj, 133, ˆćŠw‘‰@, “Œ‹ž, 2009.
  10. –k“‡ŒM:β-ƒNƒƒXƒ‰ƒvƒX. ˆćŠw‘厫“Ti‘ę2”Łj, 2535, ˆćŠw‘‰@, “Œ‹ž, 2009.
  11. –k“‡ŒM:—Տ°ŒŸø‚ĢŒ““_‚ĶfŽ@Žŗ‚É‚ ‚č. ˆć—Ć‚š•Ļ‚¦‚éŠ÷‚Ģć‚ĢŒŸøŽŗ, 14-29, •ūˆćŠw‰»ŠwŒ¤‹†Š, “Œ‹ž, 2009.

Œ“’˜

  1. Tsuboi Y, Kurimoto M, Nagai S, Hayakawa Y, Kamiyama H, Hayashi N, Kitajima I, Endo S. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B actication in human glioma cell lines. J Neurosurg. 2009;110(3):594-604.
  2. Tamura N, Kitajima I, Kawamura Y, Toda E, Eguchi Y, Ishida H, Goto S. Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions. Circ J. 2009;73(3):540-8.
  3. Yamamoto M, Beppu H, Takaoka K, Meno C, Li E, Miyazono K, Hamada H. Antagonism between Smad1 and Smad2 signaling determines the site of distal visceral endoderm formation in the mouse embryo. J Cell Biol. 2009;184(2):323-34.
  4. Beppu H, Malhotra R, Beppu Y, Lepore JJ, Parmacek MS, Bloch KD. BMP type II receptor regulates positioning of outflow tract and remodeling of atrioventricular cushion during cardiogenesis. Dev Biol. 2009;331(2):167-178.

Ē—į•ń

  1. Katayama Y, Kitajima I, Niimi H, Kitahara H, Kawai H. Diagnosis of cerebral cortical vein thrombosis with T2*-weighted magnetic resonance imaging. BMJ Case Reports published online 6 Sep 2009, doi:10.1136/bcr.03.2009.1651.

‘ą

  1. –k“‡ŒM, Œ““cŒ’‰E:‹³ˆē‚ĘŒ[–ÖŠˆ“®‚Ŗ•a‰@ŒŸø•”‚šŠˆ‚©‚·. Laboratory and Clinical Practice, 2008;26(29):78-89.
  2. –k“‡ŒM:ALP‚Ŗ‚‚¢I —Տ°Œ¤Cƒvƒ‰ƒNƒeƒBƒX. 2009;6(3):60-5.
  3. –k“‡ŒM:—Տ°ŒŸøˆćŠw‹³ˆē‚Ģ‚ ‚é‚ׂ«Žp, ˆćŠw•”1”N¶‚Ģ‰ČŠw“I‹»–”‚ʐi˜HŠó–]i—Տ°ŒŸø‚š’S‚¤ˆćŽtˆē¬‚ÉŒü‚Ƃāj. Laboratory and Clinical Practice. 2009;27(1):8-12.
  4. –k“‡ŒM:ƒ`[ƒ€ˆć—Ć‘˜_:ˆć—Ə]Ž–EŽķ‚š’m‚é. –ņÜŽt. ƒ`[ƒ€ˆć—Ć‚Ę—Õ°ŒŸø. ƒ`[ƒ€ˆć—Ćƒlƒbƒgƒ[ƒNE—Տ°ŒŸøŠÖ˜AŠé‹Ę‚ĢŽx‰‡. —Տ°•a—ƒŒƒrƒ…[. 2009;144:15-7.
  5. –k“‡ŒM:ŒŒ¬”ĀE’P‹…EŒŒŠĒ“ą”ē×–E—R—ˆ‚Ģƒ}ƒCƒNƒƒp[ƒeƒBƒNƒ‹. —Տ°ŒŸø. 2009;53(10):1133-8.
  6. –k“‡ŒM:ƒŠƒsƒbƒhƒp[ƒIƒLƒVƒh(LPO). “ś–{—Õą¬ L”ĶˆĶŒŒ‰tE”A‰»ŠwŒŸø–ʉuŠw“IŒŸø. 2009;1:581-4.
  7. Œ““cŒ’‰E, –k“‡ŒM:Š³ŽŅŒü‚ÆŒŸø‘Š’k. —Տ°ŒŸø. 2009;53(3):275-9.
  8. Œ““cŒ’‰E, –k“‡ŒM:ŒŸø‘Š’k‚ĢŽĄŪ, •xŽR‘åŠw. —Տ°ŒŸø. 2009;53(3):333-4.
  9. ‰FŽ”‹`‘„, ģ“‡–ŅŽu, ŒKŒ“‘ģ”ü, ‹g“cē», mˆäŒ©‰pŽ÷, –k“‡ŒM:•xŽR‘åŠw•‘®•a‰@ŒŸø•”‚É‚Ø‚Æ‚éISO15189”F’č‚ĢŒų‰Ź. —Տ°•a—. 2009;57:752-60.

Šw‰ļ•ń

  1. Niimi H, Kitajima I. Fastest ID system for detecting septic bacteris. 2009 Bio International Convention. The Global event for Biotechnology., 2009, 5, 18-21, Atlanta, USA.
  2. Uji Y, Miura M, Motomiyta Y, Ando Y, Yoshida C, Kitajima I. Meagerment of beta-2 microblobulin intermediate in serum by capillary electrophoresis. 2009 AACC Annual Meeting, 2009, 7, 21, Chicago, USA.
  3. –k“‡ŒM:‘Sg«‰ŠĒ”½‰žĒŒóŒQŠ³ŽŅ‹~–½—¦Œüć‚š–ŚŽw‚µ‚½“Š‡“IŒŸøƒVƒXƒeƒ€‚Ģ\’z. 2009 ”NƒVƒXƒƒbƒNƒX’†‰›Œ¤‹†ŠƒZƒ~ƒi[, 2009, 4, 21, _ŒĖ.
  4. –k“‡ŒM:“ą‰Čˆć‚Ŗ’m‚Į‚Ä‚Ø‚­‚ׂ«—Տ°ŒŸø‚Ģi•ą. “ą‰ČŠw‰ļ–k—¤Žx•”‘ę47‰ń¶ŠU‹³ˆēu‰‰‰ļ, 2009, 6, 7, •xŽR
  5. mˆäŒ©‰pŽ÷, –k“‡ŒM:cDNAƒ}ƒCƒNƒƒAƒŒƒC”­Œ»ƒvƒƒtƒ@ƒCƒ‹‚Ģ•]‰æ. ‘ę49‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ, 2009, 9, 19, ’·č.
  6. –ģŽč—Ē„, mˆäŒ©‰pŽ÷, ‰FŽ”‹`‘„, –k“‡ŒM:Š“õĒˆā“`ŽqŒŸø‚ɂ؂Ƃ銓“x‘Ŗ’č‚Ę’č—Ź–@, ‚Ø‚ę‚ŃDNA ’Šo–@‚É‚ę‚é•Ļ“®‚É‚Ā‚¢‚Ä‚ĢŒŸ“¢. ‘ę19‰ń¶•ØŽŽ—æ•ŖĶ‰ČŠw‰ļ‘å‰ļ, 2009, 2, 21, –¼ŒĆ‰®.
  7. ‘½‰ź—R‹IŽq, ć–ģ—R”ü, Šp“c”ü—é, ŽÄ‘„Žq, ŒKŒ“‘ģ”ü, ‰FŽ”‹`‘„, –k“‡ŒM:¬Ž™‚É‚Ø‚Æ‚éNT-proBNP‚ĘBNP‚Ę‚ĢŠÖŒW. ‘ę48‰ń“ś–{—Տ°ŒŸø“ŒŠCE–k—¤Žx•”‘‰ļ, 2009, 3, 8, Šņ•Œ.
  8. ’J‚Ż‚ĖŽq, ‹g‰ŖŽl, ‰Į”Ø‘½•¶, ‰FŽ”‹`‘„, –k“‡ŒM:Ņ’ÅŽčp‚É‚Ø‚Æ‚ép’†, pŒć‚Ģ‹ĆŒÅEü—nƒ}[ƒJ[‚Ģ•Ļ“®‚ĢˆÓ‹`. ‘ę48‰ń“ś–{—Տ°ŒŸø“ŒŠCE–k—¤Žx•”‘‰ļ, 2009, 3, 8, Šņ•Œ.
  9. ć–ģ’q_, mˆäŒ©‰pŽ÷, —ŃŽj˜N, –ģŽč—Ē„, ‰FŽ”‹`‘„, –k“‡ŒM:v‘¬EŠČ•ÖEˆĄ‰æ‚Č”sŒŒĒ“Æ’čITƒVƒXƒeƒ€‚Ģ\’z. ‘ę48‰ń“ś–{—Տ°ŒŸø“ŒŠCE–k—¤Žx•”‘‰ļ, 2009, 3, 8, Šņ•Œ.
  10. ’J‚Ż‚ĖŽq, ‹g‰ŖŽl, ‰Į”Ø‘½•¶, ‰FŽ”‹`‘„, –k“‡ŒM:Ņ’ÅŽčp‚É‚Ø‚Æ‚éVTE ”­Ē‚ʏp’†, pŒć‚Ģ‹ĆŒŒEü—n•ŖŽqƒ}[ƒJ[‚Ģ•Ļ“®‚ĢˆÓ‹`. ‘ę9‰ńTTMƒtƒH[ƒ‰ƒ€, 2009, 3, 7, “Œ‹ž.
  11. –ģć’B–ē, Š’, mˆäŒ©‰pŽ÷, ‰–“c—ĻŽj, •Ź•{GK, •Ÿ‰i_Ži, –k“‡ŒM:’jŽ™ø_’x‘ŲATRX ĒŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚Ø‚Æ‚éŠC”n‘Ģ‚ʝG“‘Ģ‚Ģˆā“`Žq”­Œ»ƒvƒƒtƒ@ƒCƒ‹‰šĶ. ķ—Ŗ“I‘n‘¢Œ¤‹†Ž–‹Ę„iŽ–‹Ę(CREST)u”]‚Ģ‹@”\”­’B‚ĘŠwKƒƒJƒjƒYƒ€‚Ģ‰š–¾v‘ę6‰ń—Ģˆę“ąŒ¤‹†‰ļ, 2009, 3, 11, ‘åć.
  12. ’J‚Ż‚ĖŽq, –k“‡ŒM:Ņ’ÅŽčp‚É‚Ø‚Æ‚ép’†, pŒć‚Ģ‹ĆŒÅEü—n•ŖŽqƒ}[ƒJ[•Ļ“®‚ʐƖ¬ŒŒšĒšĒ”­Ē‚Ę‚ĢŠÖ˜A. ‘ę32‰ń“ś–{ŒŒšŽ~ŒŒŠw‰ļŠwpW‰ļ, 2009, 6, 6, ¬‘q.
  13. –k“‡ŒM:V‹KŒŒŠĒ‹@”\ŒŸø–@ŠJ”­‚É‚ę‚錌ŠĒƒGƒCƒWƒ“ƒO‚Ģ‰ČŠw“I•]‰æ‚Ę—Õ°‰ž—p. ’m“IƒNƒ‰ƒXƒ^[’nˆęƒvƒƒWƒFƒNƒgu‘ę1‰ń–¢•a—\–hƒVƒXƒeƒ€Œ¤‹†‰ļv, 2009, 6, 16, •xŽR.
  14. ¼ˆä“Ä, ‘åˆä“cŒ›‘×, –k“‡ŒM, mˆäŒ©‰pŽ÷:v‘¬EŠČ•Ö‚Čˆā“`ŽqˆŁķƒXƒNƒŠ[ƒjƒ“ƒO–@‚ĢŠJ”­‚ĘƒLƒbƒg‚ĢŠJ”­. ‘ę2‰ń‚Ę‚ā‚܃rƒWƒlƒXƒvƒ‰ƒ“ƒRƒ“ƒeƒXƒg, 2009, 6, 24, •xŽR.
  15. ’J‚Ż‚ĖŽq, ‹g‰ŖŽl, ‰Į”Ø‘½•¶, ‰FŽ”‹`‘„, –k“‡ŒM:3 Žķ—Ž‚Ģ‰Ā—n«ƒtƒBƒuƒŠƒ“^ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘ĢŒoŽž‘Ŗ’č‚É‚ę‚éŅ’ÅŽčp‚É‚Ø‚Æ‚éVTE”­Ē‚Ģ•]‰æ. ‘ę10‰ń“ś–{ŒŸøŒŒ‰tŠw‰ļŠwpW‰ļ, 2009, 7, 4, b•{.
  16. mˆäŒ©‰pŽ÷, –k“‡ŒM:ęiˆć—Ć‚Ę‚µ‚Ä‚Ģę“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RĒ‚Ģˆā“`Žqf’f]‹ß”N‚Ģ‹@”\‰šĶĒ—į‚š’†S‚Ɂ]. ‘ę10‰ń“ś–{ŒŸøŒŒ‰tŠw‰ļŠwpW‰ļ, 2009, 7, 4, b•{.
  17. Œ““cŒ’‰E, mˆäŒ©‰pŽ÷, ī’J»Žq, ‰FŽ”‹`‘„, –k“‡ŒM:ę“V«‘ęVˆöŽqŒ‡‘¹ĒiPhe190Serj‚É‚Ø‚Æ‚é”­ĒƒƒJƒjƒYƒ€‚Ģ‰š–¾. ‘ę56‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2009, 8, 27, ŽD–y.
  18. ’J‚Ż‚ĖŽq, ‰FŽ”‹`‘„, –k“‡ŒM:Ņ’ÅŽčp‚É‚Ø‚Æ‚éVTE”­Ē‚ʏp’†, pŒć‚Ģ‹ĆŒÅEü—nŒn•ŖŽqƒ}[ƒJ[‚Ģ•Ļ“®‚ĢˆÓ‹`. ‘ę56‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2009, 8, 27, ŽD–y.
  19. mˆäŒ©‰pŽ÷, ¼ˆä“Ä, ‘åˆä“cŒ›‘×, ‰FŽ”‹`‘„, –k“‡ŒM:’č—ŹPCR–@‚š—p‚¢‚½V‹Kˆā“`Žq•ĻˆŁƒXƒNƒŠ[ƒjƒ“ƒO–@‚ĢlˆÄ‚ĘŽĄ—p‰»‚Ö‚ĢŽŽ‚Ż. ‘ę56‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2009, 8, 27, ŽD–y.
  20. mˆäŒ©‰pŽ÷, ‰FŽ”‹`‘„, –k“‡ŒM:’č—Ź“IPCR –@‚š—p‚¢‚½v‘¬‚ÅŠČ•Ö‚ČV‹Kˆā“`Žq•ĻˆŁƒXƒNƒŠ[ƒjƒ“ƒO–@‚ĢlˆÄ‚ĘŽĄ—p‰»‚Ö‚ĢŽŽ‚Ż. ‘ę41‰ń“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘å‰ļ, 2009, 10, 9, ‰”•l.
  21. –k“‡ŒM:1•ŖŽqŒuŒõ‘ŠŠÖ–@‚š—p‚¢‚½“]ŽŹˆöŽqNF-κBŒv‘Ŗ–@ŠJ”­‚ʐv‘¬‚ȉŠĒ•a‘Ō‰šĶ. 2009, 10, 9, ‰”•l.
  22. ’J‚Ż‚ĖŽq, ‰FŽ”‹`‘„, –k“‡ŒM:3Žķ—Ž‚Ģ‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ“ÆŽž‘Ŗ’č‚É‚ę‚éŽüpŠś‹ĆŒÅ”\‚Ģ•]‰æ. 2009,10,9, ‰”•l.
  23. ć–ģ’q_, ‹g“cē», ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM, ˆĄ“Œ—RŠģ—Y:ƒLƒƒƒsƒ‰ƒŠ[“d‹C‰j“®(CE)‘•’u‚š—p‚¢‚½β2mƒAƒ~ƒƒCƒh‘O‹ģ’`”’‘Ŗ’č–@‚ĢŠJ”­. 2009,10,9, ‰”•l.
  24. mˆäŒ©‰pŽ÷, ć–ģ’q_, —ŃŽj˜N, ‰FŽ”‹`‘„, –k“‡ŒM:ę“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RĒIIŒ^‚Ģˆā“`Žq‰šĶ. ‘ę34‰ń–k—¤—Տ°•a—W’k‰ļ, 2009,9,26, ‹ą‘ņ.

‚»‚Ģ‘¼

  1. “ĮŠč2009-23707. ”­–¾ŽŅ:mˆäŒ©‰pŽ÷, ć–ģ’q_, –k“‡ŒM, —ŃŽj˜N. ”­–¾–¼Ģuƒvƒ‰ƒCƒ}[ƒ_ƒCƒ}[”ń•\Ž¦•ū–@v. oŠč“ś:•½¬21”N2ŒŽ4“ś.
  2. “ĮŠč2009-40052. ”­–¾ŽŅ:‘½—t“c—_, “ģ—m, mˆäŒ©‰pŽ÷, –k“‡ŒM, ć–ģ’q_, —ŃŽj˜N. ”­–¾–¼ĢuŒŸo‘ĪŪ¶•Ø‚Ģ‚Š““x’č—Ź•ū–@v. oŠč“ś:•½¬21”N2ŒŽ23“ś.
  3. “ĮŠč2009-181755. ”­–¾ŽŅ:mˆäŒ©‰pŽ÷, ć–ģ’q_, –k“‡ŒM, —ŃŽj˜N. ”­–¾–¼Ģu‚Š““xE‚“ĮˆŁ“x‚ČPCR•Ļ–@voŠč“ś:•½¬21”N8ŒŽ4“ś.
  4. ‘Ū“Į‹–oŠč:mˆäŒ©‰pŽ÷, –k“‡ŒM, ¼ˆä“Ä, ‘åˆä“cŒ›‘×. ”­–¾–¼Ģu’č—Ź–@‚š—˜—p‚µ‚½ˆā“`Žq•ĻˆŁƒXƒNƒŠ[ƒjƒ“ƒO–@v. oŠč“ś:•½¬21”N7ŒŽ17“ś.
  5. –k“‡ŒM:‘ę31‰ń“ś–{ŒŒšŽ~ŒŒŠw‰ļ•ń, ŒŒšĒ‚Ģ•]‰æ‚Ŗ‰Ā”\‚É. Medical Tribune, 42(9): 31, 2009.
  6. –k“‡ŒM:‘ę19‰ń“ś–{—Տ°ŒŸøź–åˆć‰ļt‹G‘å‰ļ‘Š‡. JACLap News, 105: 4, 2009.
  7. mˆäŒ©‰pŽ÷, –k“‡ŒM:real-time PCR –@‚š—p‚¢‚½v‘¬‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€‚Ģ\’z‚ÉŠÖ‚·‚錤‹†. ’†’J“dŽqŒv‘Ŗ‹ZpU‹»ą’cAnnual Report 2009, 42-56, 2009.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2008”N

’˜‘

  1. –k“‡ŒM:DIC ‚ɂ؂Ƃ錌Ÿ÷•Ŗ‰ę»Ü‚ĢŽg‚¢•ū. ŒŒ‰t»Ü‚Ģl‚¦•ū, Žg‚¢•ū. i‘å‹v•ŪŒõ•v•Ņj, 229-232, ’†ŠOˆćŠwŽŠ, “Œ‹ž, 2008.
  2. –k“‡ŒM:‹ĆŒÅEü—nEŒŒ¬”Ā‹@”\ŒŸø. ŒŒ‰tE‘¢ŒŒŠķŽ¾Š³Šwi¬ąVŒh–ē, ’¼]’mŽ÷, ā“c—mˆź•Ņj, 94-99, Medical viewŽŠ, “Œ‹ž, 2008.
  3. Ohtsuka T and Takai Y. Roles of the ELKS/CAST family and SAD kinase in neurotransmitter release: Chapter 9, 157-170, molecular mechanisms of neurotransmitter release. 2008.

Œ“’˜

  1. Kwan E, Xie L, Sheu L, Ohtsuka T, Gaisano HY. Interaction between Munc13-1 and RIM is Critical for Glucagon-like Peptide-1-mediated Rescue of Exocytotic Defects in Munc13-1-deficient pancreatic β-cells. Diabetes. 2007;56:2579-88.
  2. Wang J, Xu Z, Kitajima I, Wang Z. Effects of different statins on endothelial nitric oxide synthase and AKT phosphorylation in endothelial cells. International Journal of Cardiology. 2008;127:33-9.
  3. Misaki T, Kitajima I, Kabata T, Tani M, Kabata C, Tsubokawa T, Asakura H, Tomita K. Changes of the soluble fibrin monomer complex level in the perioperative period of hip replacement surgery. J Orthop Sci. 2008;13:419-24.
  4. Œ““cŒ’‰E, Žs–Ń—RŠóŽq, Šp“c”ü—é, ‘½‰ź—R‹IŽq, ŽÄ‘„Žq, –k“‡ŒM:ˆćŠw¶‚É‘Ī‚·‚鑲‘O¶‰»ŠwŒŸøŽĄK‚Ģ‰Ū‘č‚ʉšŒˆ, ŒŸø‘Ŗ’čŒ“—‚šŒų‰Ź“I‚ÉŽĄK‚Å‚«‚éƒc[ƒ‹‚Ö‚ĢPOCT ‘Ī‰žŒ^¬Œ^Ž©“®•ŖĶŠķ‚Ģ‰ü‘¢‚Ę‚»‚ĢŠwKŒų‰Ź. —Տ°•a—. 2008;56(9):753-760.

Ē—į•ń

  1. ģl_”V, ’†Œ“Ė•¶, Æ–ģ‰·, ‰|–{¹Žq, ‘q“c”Ž”V, ’†‘ŗ—²Žu, –k“‡ŒM, mˆäŒ©‰pŽ÷. Catheter-directed Intrathrombus Thrombolysis ‚Ŗ’˜Œų‚µ‚½[•”Ć–¬ŒŒšĒ‡•¹ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡‘¹”D•w‚Ģ1—į. ŒÄ‹z‚ʏzŠĀ. 2008;56:219-23.

‘ą

  1. –k“‡ŒM:ƒNƒŠƒjƒbƒN‚É‚Ø‚Æ‚é—Տ°ŒŸø‚ĢŒ»ó‚ʐV‚½‚ȉĀ”\«. ’nˆęˆć—Ć, ‚Ö‚«’nˆć—Ć, ‚»‚µ‚Ä“Į’čŒ’fE“Į’č•ŪŒ’Žw“±‚Ö‚Ģ‘Ī‰ž. •ŹūASAHI Medical. 2008;37(4):1-6.
  2. –k“‡ŒM:‹ĆŒÅEü—n‚Ę—Õ°ŒŸø. “ś–{ŒŒšŽ~ŒŒŠw‰ļŽGŽ. 2008;19(4):462-6.
  3. –k“‡ŒM:•xŽR‘åŠw•‘®•a‰@ŒŸøŽŗ‚Ŗ‘Ū‹KŠiISO18159 ”F’č‚šŽę“¾. •xŽRŽsˆćŽt‰ļ•ń. 2008;450:5-6.

Šw‰ļ•ń

  1. Kitajima I: Role of Nuclear factor-kappa B (NF-κB) in tumor progresion. The 1st International traditional chinese medicine (TCM) and Interative Medicine Oncology Formum. 2008, 10, 18-19, Shanghai, China. (invited lecture)
  2. Kitajima I, Note R, Ogawa T, Abe S, Kadowaki M, Yamagata K: A new assay for NF-κB activity in biological samples using fluorescence correlation spectroscopy and its application to perioperative cardiac monitoring. 2008 Keystone symposia NF-κB. 2008, 2, 12-17, Banff, Canada.
  3. Kitajima I, Motomura H, Niimi H.:mRNA and micro RNA expression profile in chondrogenic differentiation regulated by BMP. Annual TGF-β meeting Leiden, 2008, 9, 4-6, Leiden, The Netherland.
  4. Ohtsuka T.:Phosphorylation network at the presynaptic active zone. US-Japan Brain Research Collaborative Program - "Workshop on Receptor Trafficking and Cell Biology of Neurons: Physiology and Disease. 2008, 2, 24-27. Asilomer, CS, USA.
  5. Niimi H, Motomura H, Kitajima I.:Gas 6, a new regulator of chodrogenic diffetentiation promoted by BMP. Annual TGF-β meeting Leiden, 2008, 9, 4-6, Leiden, The Netherland.
  6. –k“‡ŒM:ƒNƒƒ}ƒ`ƒ“ƒŠƒ‚ƒfƒŠƒ“ƒO’`”’ATRX •ĻˆŁƒ}ƒEƒX‚Ģs“®EŠwKįŠQ‚Ęƒqƒgø_’x‘Ų•a‚Ę‚ĢŠÖ˜A. ‘ę81‰ń“ś–{–ņ—Šw‰ļ”N‰ļ, 2008, 3, 19, ‰”•l. iµ‘Ņu‰‰j
  7. •Ÿ‰i_Ži, ‰–“c—ĻŽj, Š’, •Ź•{GK, Œ“‰p², –k“‡ŒM:ø_Ž¾Š³ƒ‚ƒfƒ‹ƒ}ƒEƒX‚ĢƒXƒpƒCƒ“Œ`¬ˆŁķ‚ĢƒƒJƒjƒYƒ€. ‘ę81‰ń“ś–{–ņ—Šw‰ļ”N‰ļ, 2008, 3, 19-21, ‰”•l.
  8. ŒKŒ“‘ģ”ü, ģ“‡–ŅŽu, ‰FŽ”‹`‘„, –k“‡ŒM:ISO15189 ”F’č\æ’¼‘OŽ{Ż]\æ‚Ü‚Å‚ĢŒ»ó]. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  9. –k“‡ŒM:‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ‘Ŗ’č‚Ģ—Տ°“IˆÓ‹`. ‘ę57‰ń“ś–{ˆćŠwŒŸøŠw‰ļ, 2008, 5, 29-31, ŽD–y. (µ‘Ņu‰‰)
  10. –k“‡ŒM:ŒŒšĒ‘Šśf’f–@ŠJ”­‚Ę‚»‚Ģ•‹y‚É‚ę‚é—Տ°‚Ö‚ĢvŒ£. ‘ę2‰ń–k—¤ŒŒšŽ~ŒŒŒŸø§˜b‰ļ, 2008, 7, 5, ‹ą‘ņ. (µ‘Ņu‰‰)
  11. –k“‡ŒM:–Ō—…“Iˆā“`Žq”­Œ»‰šĶŽč–@‚š—p‚¢‚½ŠÖßƒŠƒEƒ}ƒ`‚ĢŠæ•ū•ūÜ–ņŒų‰šĶ. ‘ę11‰ń“V‘R–ņ•ØŒ¤‹†•ū–@˜_ƒAƒJƒfƒ~[Œą‰HŽRƒVƒ“ƒ|ƒWƒEƒ€, 2008, 8, 1, •xŽR. (µ‘Ņu‰‰)
  12. –k“‡ŒM:ƒtƒ@[ƒ}ƒRƒQƒmƒ~ƒNƒXiPGxjŽĄ—p‰»‚ĢŒ»ó. ‘ę2‰ńJMCoE ƒlƒbƒgƒ[ƒNŠwpƒtƒH[ƒ‰ƒ€, 2008, 8, 9, “Œ‹ž. iµ‘Ņu‰‰j
  13. mˆäŒ©‰pŽ÷, –ģŽč—Ē„, ć–ģ’q_, —ŃŽj˜N, ‰FŽ”‹`‘„, –k“‡ŒM:v‘¬, ŠČ•Ö, ˆĄ‰æ‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čIT ƒVƒXƒeƒ€‚ĢŠJ”­. ‘ę48‰ń“ś–{—Տ°‰»Šw”NŽŸŠwpW‰ļ, 2008, 8, 30, •l¼. iµ‘Ņu‰‰j
  14. ‘å’Ė–«‹v:ƒvƒŒƒVƒiƒvƒX‹@”\§Œä‚Ģ•ŖŽq¶—Šw. ‘ę31‰ń“ś–{_Œo‰ČŠwŠw‰ļ‘å‰ļ, ‰”•l, 2008, 7, 9. iµ‘Ņu‰‰j
  15. –ģŽč—Ē„, ”öģ’q”ü, ī’J»Žq, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:ę“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RĒ‚Ģˆā“`Žq‰šĶ‚ÉŠÖ‚·‚錟“¢. ‘ę18‰ń¶•ØŽŽ—æ•ŖĶ‰ČŠw‰ļŠwpW‰ļ, 2008, 2, 10, ‘åć.
  16. Š’, ‰–“c—ĻŽj, •Ź•{GK, •Ÿ‰i_Ži, –k“‡ŒM:ATRX •ĻˆŁƒ}ƒEƒX‚ĢŠwK‹L‰ÆįŠQ‚ĘƒXƒpƒCƒ“Œ`‘ŌˆŁķ. ķ—Ŗ“I‘n‘¢Œ¤‹†Ž–‹Ę„iŽ–‹ĘiCRESTju”]‚Ģ‹@”\”­’B‚ĘŠwKƒƒJƒjƒYƒ€‚Ģ‰š–¾v‘ę5‰ń—Ģˆę“ąŒ¤‹†‰ļ, 2008, 3, 5, ‘åć.
  17. —ŃŽj˜N, ²’|ˆÉ’ĆŽq, ×’JFŽq, ‰„–ģ^‹|, ¬£—¢Œb, ‰FŽ”‹`‘„, Žs“c•™Žq, –k“‡ŒM:ƒzƒ‹ƒ^[S“d}ŒŸø‚ɂ؂Ƃ鏬Ž™‚š‘ĪŪ‚Ę‚µ‚½QT ‰„’·Šī€ŽQl”ĶˆĶ‚ĢŒŸ“¢. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  18. ¬£—¢Œb, ²’|ˆÉ’ĆŽq, —ŃŽj˜N, ‰FŽ”‹`‘„, •Ÿ“cM”V, –k“‡ŒM:’ˆÓ[‚­•]‰æ‚µ‚½‚¢S‘Ÿ’“‰¹”gŒŸø‚Ģ1—įiSŽG‰¹øøj. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  19. ‰„–ģ^‹|, —ŃŽj˜N, ¬£—¢Œb, ×’JFŽq, ²’|ˆÉ’ĆŽq, ‰FŽ”‹`‘„, –k“‡ŒM:Heart rate turbulence (HRT)‚Ģ“ś“ą•Ļ“®‚Ę—Õ°“IˆÓ‹`. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  20. ī’J»Žq, ‹“–{–ƒˆßŽq, ‹g“cŒd, ģ“‡–ŅŽu, ’J‚Ż‚ĖŽq, ŒKŒ“‘ģ”ü, ŽRŒū—R–¾, ]”¦˜a”ü, ‹{‰€‘ģé, ‘ŗćƒ, ™ŽR•q˜Y, ĪąVL, ‚–ģN—Y, ‰FŽ”‹`‘„, –k“‡ŒM:Œ`Žæ×–E‚Ģ’˜–¾‚Č‘‰Į‚š”F‚ß‚½Angioimmunoblastic T-cell lymphoma(AILT)‚Ģ1—į. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  21. X“c–¢, ā–{ƒŽq, ‹g“cˆčŽq, ‰FŽ”‹`‘„, ¼“c—I, “”āŽĄē˜Y, –k“‡ŒM:Mycobacterium fortuitum ‚Ŗ•Ŗ—£‚³‚ź‚½’†ŽØ‰Š‚ĢˆźĒ—į. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  22. Œ““cŒ’‰E, ”öģ’q”ü, –ģŽč—Ē„, mˆäŒ©‰pŽ÷, –k“‡ŒM, ™–{^–ē, ķ“cFK, ‹TŽR’qŽ÷, ˆäć”Ž:Žį”N”­Ē‚Ģ”xŒŒšĒšĒ‚Å“ü‰@‚Ę‚Č‚Į‚½ƒvƒƒeƒCƒ“S Œ‡–R—į‚Ģˆā“`‰šĶ. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  23. ”öģ’q”ü, –ģŽč—Ē„, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:ę“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RĒ‚Ģˆā“`Žq‰šĶ‚Ę‹@”\ˆŁķŒ¤‹†. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  24. –ģŽč—Ē„, ”öģ’q”ü, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:ˆā“`«ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX‚Ģˆā“`Žq‰šĶ. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  25. Š’, mˆäŒ©‰pŽ÷, ˆų–ŌG², –k“‡ŒM:ŠÖßƒŠƒEƒ}ƒ`Š³ŽŅ‚š‘ĪŪ‚Ę‚µ‚½ŒjŽ}‰ĮžQ•“’•ž—pŒų‰Ź‚Ģƒ}ƒCƒNƒƒAƒŒƒC‚š—p‚¢‚½‰šĶ. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  26. ć–ģ’q_, ‰FŽ”‹`‘„, ŒKŒ“‘ģ”ü, ģ“‡–ŅŽu, ŽÄ‘„Žq, Šp“c”ü—é, ‘½‰ź—R‹IŽq, –k“‡ŒM, ˆĄ“Œ—RŠģ—Y, ‹g“cē», ŽO‰Y‰ėˆź, –{‹{‘S‰ų:ŒŒ“’†β2m ƒAƒ~ƒƒCƒh‘O‹ģ‘Ģ’`”’Žæ•ŖĶ–@‚Ģ•]‰æ. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠC–k—¤Žx•”‘‰ļ, 2008, 3, 9, •xŽR.
  27. –k“‡ŒM:’jŽ™ø_‰^“®’x‘Ų‚š’ę‚·‚éATR-X ĒŒóŒQ‚Ģƒ‚ƒfƒ‹ƒ}ƒEƒXģ»‚Ę‚»‚Ģ‚ŽŸ”]‹@”\‰šĶ. ‘ę49‰ń“ś–{_ŒoŠw‰ļ‘‰ļ, 2008, 5, 17, ‰”•l.
  28. mˆäŒ©‰pŽ÷, ”öģ’q”ü, –ģŽč—Ē„, ć–ģ’q_, ‰FŽ”‹`‘„, –k“‡ŒM:ę“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RĒ‚Ģˆā“`Žq‰šĶ‚Ę‹@”\ˆŁķŒ¤‹†. ‘ę15‰ń“ś–{ˆā“`Žqf—ĆŠw‰ļ‘å‰ļ, 2008, 8, 1, å‘ä.
  29. –k“‡ŒM, Š’, –ģć‘ń–ē, mˆäŒ©‰pŽ÷:cDNA ƒ}ƒCƒNƒƒAƒŒƒC‚š—p‚¢‚½ŠÖßƒŠƒEƒ}ƒ`‚É‚Ø‚Æ‚éŠæ•ū–ņ–ņŒų‚ĢŒŸŲ. ‘ę48‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ, 2008, 8, 29-30, •l¼.
  30. ‘åˆä“cŒ›‘×, ¼ˆä“Ä, mˆäŒ©‰pŽ÷, –k“‡ŒM:real-time PCR ‚š—p‚¢‚½v‘¬EŠČ•Ö‚Čˆā“`Žq•ĻˆŁƒXƒNƒŠ[ƒjƒ“ƒO–@. ‘ę48‰ń“ś–{—Տ°‰»Šw‰ļ”NŽŸŠwpW‰ļ, 2008, 8, 29-30, •l¼.
  31. —ŃŽj˜N, ć–ģ’q_, mˆäŒ©‰pŽ÷, –k“‡ŒM:ę“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RĒ‚Ģˆā“`Žqf’f‚Ę‹@”\‰šĶ. ‘ę6‰ń–k—¤ŒŒšŒ¤‹†‰ļ, 2008, 10, 25, ‹ą‘ņ.
  32. ‘ŗćƒ, ‹{‰€‘ģ‹X, •ÄąV˜a”ü, ²’|ˆÉ’ĆŽq, ’†oĖ‘ć, “¹–ģ~Žq, ¼–ģŽåįĮ, “‡‹žŽq, ˆĄ‘ŗ•q, –k“‡ŒM:•p‰ń‚ÉHLA“K‡ŒŒ¬”Ā—AŒŒ‚š—v‚µ‚½œ‘ˆŁŒ`¬ĒŒóŒQ‚Ģ1—į. ‘ę26‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ–k—¤’n•ū‰ļ, 2008, 11, 15, •xŽR.
  33. “‡‹žŽq, ‹{—ѐē’ߎq, ˆĄ‘ŗ•q, ²’|ˆÉ’ĆŽq, ’†oĖ‘ć, “¹–ģ~Žq, ¼–ģŽåįĮ, •ÄąV˜a”ü, –k“‡ŒM:ƒnƒCƒŠƒXƒN”DŽY•w‚Ģ’™ŒŒŽ®Ž©ŒČŒŒ—AŒŒ‚ĢŒ»ó‚ʉŪ‘č. ‘ę26‰ń“ś–{—AŒŒE×–EŽ”—ĆŠw‰ļ–k—¤’n•ū‰ļ, 2008, 11, 15, •xŽR.
  34. mˆäŒ©‰pŽ÷, ‰FŽ”‹`‘„, –k“‡ŒM:’č—ŹPCR –@‚š—p‚¢‚½v‘¬‚ÅŠČ•Ö‚ČV‹Kˆā“`Žq•ĻˆŁƒXƒNƒŠ[ƒjƒ“ƒO•ū–@‚ĢlˆÄ. ‘ę55‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2008, 11, 27-30, –¼ŒĆ‰®.
  35. mˆäŒ©‰pŽ÷, ”öģ’q”ü, –ģŽč—Ē„, ‰FŽ”‹`‘„, –k“‡ŒM:ęiˆć—Ć‚Ę‚µ‚Ä‚Ģę“V«ƒAƒ“ƒ`ƒƒ“ƒrƒ“Œ‡–RĒ‚Ģˆā“`Žqf’f|‹ß”N‚Ģ‹@”\‰šĶĒ—į‚š’†S‚Ɂ|‘ę55‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2008, 11, 27-30, –¼ŒĆ‰®.
  36. mˆäŒ©‰pŽ÷, –ģŽč—Ē„, ć–ģ’q_, —ŃŽj˜N, ‰FŽ”‹`‘„, –k“‡ŒM:v‘¬, ŠČ•Ö, ˆĄ‰æ‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čIT ƒVƒXƒeƒ€‚Ģ\’z. ‘ę55‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2008, 11, 27-30, –¼ŒĆ‰®.
  37. –k“‡ŒM, Œ³‘ŗ‘ń:“īœ•Ŗ‰»‚š’²ß‚·‚é•ŖŽqGas6 ‚Ģ”­Œ©‚Ę‚»‚Ģ‹@”\‰šĶ. ‘ę55‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2008, 11, 27-30, –¼ŒĆ‰®.
  38. –ģŽč—Ē„, ”öģ’q”ü, ‹g“cē», ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:HFE ˆā“`Žq‚ĢV‹K•ĻˆŁ‚š”F‚ß‚½ˆā“`«ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX‚Ģ1—į. ‘ę55‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2008, 11, 27-30, –¼ŒĆ‰®.
  39. ī’J»Žq, ģ“‡–ŅŽu, ’J‚Ż‚ĖŽq, ŒKŒ“‘ģ”ü, ‰FŽ”‹`‘„, ‹{‰€‘ģ‹X, ‘ŗćƒ, ĪąVL, –k“‡ŒM:––½ŒŒ‚Ø‚ę‚Ń‹¹…’†‚ÉŒ`Žæ×–E‚Ŗ‘½”oŒ»‚µ‚½ŒŒŠĒ–ʉu‰č‹…«T×–EƒŠƒ“ƒpŽīiAILTj‚Ģ1Ē—į. ‘ę55‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2008, 11, 27-30, –¼ŒĆ‰®.

‚»‚Ģ‘¼

  1. –k“‡ŒM:cDNA ƒ}ƒNƒƒAƒŒƒC‚š—p‚¢‚½ŠÖßƒŠƒEƒ}ƒ`‚É‚Ø‚Æ‚éuŲv‚ĢŒŸŲ. •xŽR‘åŠw21 ¢‹ICOE ƒvƒƒOƒ‰ƒ€u“Œ—m‚Ģ’m‚É—§‹r‚µ‚½ŒĀ‚Ģˆć—Ć‚Ģ‘n¶vŠˆ“®•ń‘:43-46, 2008.
  2. –k“‡ŒM:•ŅWŒć‹L, —Տ°ŒŸø‚ĢŽæ. —Տ°•a—56(9): 833, 2008.
  3. Œ““cŒ’‰E, –k“‡ŒM:ŒŒ‰tŒŸøŒ‹‰Ź‚Ģ‚Ę‚ē‚¦‚©‚½`ƒƒ^ƒ{ŒŸf€–Ś‚š’†S‚Ɂ`. •xŽR‘åŠw•t‘®•a‰@‚¾‚ę‚č‚©‚ķ‚ē”Å103†2008, 8, 1 ”­s.
  4. ‘Ū“Į‹–Šč:Hideki N, Kitajima I: Rapid method for identifying causative microorganism for infectious disease. Priority JP/21. 02. 06/JPA20006043469, JP/12. 1006/JPA2006278371, Date 15. 10. 08 Date of filing 20. 02. 07.
  5. ‘“ą“Į‹–Šč:mˆäŒ©‰pŽ÷, –k“‡ŒM, ¼ˆä“Ä, ‘åˆä“cŒ›‘×2008-18678 PS08HOIJP ‘Ū“Į‹–•Ŗ—ŽC12Q1/68 ”­–¾–¼Ģ:ˆā“`Žq•ĻˆŁ‚ĢƒXƒN[ƒŠƒ“ƒO–@oŠč“ś:2008, 7, 18.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2007”N

’˜‘

  1. –k“‡ŒM, –Ų‘ŗ—TŽO, œAģTˆź˜Y–ó:uƒƒ‹ƒ{ƒ‹ƒ“‘åŠwŽ®“‡Œ^PBL, ƒRƒA—Տ°Ē—į‚©‚ēŠī‘b•a‘Ō¶—‚ցv. Core Clinical Cases in Basic Biomedical Science. A problem-based learning approach. Samy A. Azer’˜, ƒGƒ‹ƒZƒrƒAEƒWƒƒƒpƒ“, “Œ‹ž, 1-412, 2007
  2. –k“‡ŒM:_ŒoE‹ŲŽ¾Š³. u’m‚Į‚Ä‚Ø‚«‚½‚¢—Տ°ŒŸø’lv“ś–{–ņŠw‰ļ•Ņ, “Œ‹ž‰»Šw“Ɛl, “Œ‹ž, 132-135, 2007

Œ“’˜

  1. Yao I, Takagi H, Ageta H, Kahyo T, Sato S, Hatanaka K, Fukuda Y, Chiba T, Morone N, Yuasa S, Inokuchi K, Ohtsuka T, MacGregor GR, Tanaka K, and Setou M. SCRAPPER-dependent ubiquitination of active zone protein RIM1 regulates synaptic vesicle release. Cell. 2007;130:943-57.
  2. Grigoriev I, Splinter D, Keijzer N, Wulf P, Demmers J, Ohtsuka T, Modesti M, Maly I, Grosveld F, Hoogenraad CC, Akhmanova A. Rab6A regulates transport and targeting of exocytotic carriers. Dev Cell. 2007;13:305-14.
  3. Niimi H, Pardali K, Vanlandewijck M, Heldin CH, Moustakas A. Notch signaling is necessary for epithelial growth arrest by TGF-β. J Cell Biol. 2007;176:695-707.
  4. Suzuki S, Singhirunnusorn P, Mori A, Yamaoka S, Kitajima I, Saiki I, Sakurai H. Constitutive activation of TAK1 by HTLV-I Tax-dependent overexpression of TAB2 induces activation of JNK-ATF2 but not IKK-NF-κB. J Biol Chem. 2007;282:25177-81.
  5. Siksou L, Rostaing P, Lechaire JP, Boudier T, Ohtsuka T, Fejtov A, Kao HT, Greengard P, Gundelfinger ED, Triller A, Marty S. Three-dimensional architecture of presynaptic terminal cytomatrix. J Neurosci. 2007;27:6868-77.
  6. Matsuda N, Hatakeyama N, Shakunaga K, Sugano M, Kitajima I, Yamazaki M, Hattori Y. Silencing of caspase-8 and caspase-3 by RNA interference prevents vascular endothelial cell injury in septic mice. Cardiovascular Res. 2007;76:132-40.
  7. Motomura H, Niimi H, Sugimori K, Otsuka T, Kimura T, and Kitajima I. Gas6, a new regulator of chondrogenic differentiation in mesenchymal cells. Biochem Biophys Res Commun. 2007;357:997-1003.
  8. Tokoro T, Higa S, Deguchi-Tawarada M, Inoue E, Kitajima I, and Ohtsuka T. Localization of the active zone protein CAST, ELKS, and Piccolo at neuromuscular junctions. Neuroreport. 2007;18:313-6.
  9. Wang J, Kitajima I. Pitavastatin inactivates NF-κB and decreases IL-6 production through Rho kinase pathway in MCF-7 cells. Oncology Report. 200715:1149-54.
  10. Moustakas A, Valcourt U, Kowanetz M, Pardali K, Niimi H, Thuault S. Tumor suppressor and tumor promoting pathways under the control of TGF-β. Eur J Clin Invest. 2007;37:49.
  11. –ģŽč—Ē„, ī’J»Žq, ŽRŠŻ–GŽq, X“c–¢, ‘½‰ź—R‹IŽq, ā–{ƒŽq, ‹g“cˆčŽq, ‘å–å—Ē’j, mˆäŒ©‰pŽ÷, –k“‡ŒM:–ņÜ‘Ļ«ˆā“`Žq‚ĢŒŸo‚Ęˆā“`ŽqŒ^•Ź–@‚Ģ—Տ°‰ž—p. •xŽRŒ§‰q¶ŒŸø‹ZŽt‰ļŽ. 2007;32:35-44.

‘ą

  1. –k“‡ŒM, ”öģ’q”ü, ’J‚Ż‚ĖŽq:‚ķ‚Ŗ‘‚ÅŠJ”­‚³‚ź‚½ŒŒšĒ‹}«Šś‚š‘Ø‚¦‚錌‰t‹ĆŒÅ•ŖŽqƒ}[ƒJ[, ‰Ā—n«ƒtƒBƒuƒŠƒ“(SF)/ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ(FMC). ˆć•ń‚Ę‚ā‚Ü. 2007;1422:8-10.
  2. –k“‡ŒM, ŽRŒūŒjŽi, ”öģ’q”ü, ’J‚Ż‚ĖŽq:‰Ā—n«ƒtƒBƒuƒŠƒ“(SF)‚ĘƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ(FMC)ŽŽ–ņŠŌ‚É‚ę‚é˜Ø—£ŒŸ“¢‚ĘŠeŒŸø‚Ģ—L—p«‚É‚Ā‚¢‚Ä. TTMƒtƒH[ƒ‰ƒ€. 2007;6:53-63.
  3. –k“‡ŒM:ŒŒš‚ʏzŠĀ‚ĢŒŸø–@. ƒgƒƒ“ƒrƒ“¶¬–ŚˆĄ‚Ę‚µ‚Ä‚ĢTAT‚Ęfibrin monomer‘Ŗ’č–@‚Ę‚»‚ĢˆÓ‹`. ŒŒš‚ʏzŠĀ. 2007;15:126-33.
  4. –k“‡ŒM:•a‰@ŒŸøŽŗ‚ÅŽĄ‘H‚Å‚«‚é•ŖŽq•a‘ŌŒŸø–@ŠJ”­, “]ŽŹˆöŽqŠˆ«‰»ŒŸø‚Ģ—Տ°‰ž—p‚ÉŒü‚Æ‚Ä. —Տ°•a—. 2007;55:262-71.
  5. –k“‡ŒM:NF-κBŒ¤‹†‚ĢV“WŠJ. —Տ°‰»Šw. 2007;36:249-50.
  6. –k“‡ŒM:‹³ˆē—Ķ. —Տ°•a—. 2007;55:596.
  7. –k“‡ŒM:—Տ°‰»Šw‚Ģ”Œć‚Ģ•ūŒü‚ʁu—Տ°‰»ŠwvŽ‚Ģ–šŠ„. —Տ°‰»Šw. 2007;36:236-48.
  8. YąV˜a•F, “y“cŒj‘ , –k“‡ŒM:VŠƒŒ§’†‰z’nk”ķŠŽŅzŠĀŠķŠO—ˆŠ³ŽŅ‚ĢDVT‚ĘŒŒ‰t‹ĆŒÅƒ}[ƒJ[‚É‚Ā‚¢‚Ä. TTMƒtƒH[ƒ‰ƒ€. 2007;6:71-3.

Šw‰ļ•ń

  1. Kitajima I.:Molecular role of tumor angiogenesis in hepatoma cells through constitutive interleukin-8 expression. 12th World congress on Advantages in Oncology and 10th Internatinal Symposium on Molecular Medicine, 2007, 10, 11-13, Crete, Greece. (Invited lecture)
  2. Kitajima I., and Tokoro T.:In search of Chinese Medicine showing molecular pharmacology efficacy against rheumatoid arthritis. Innovantive Team Program in Peking University-21st Century COE program in University of Toyama Joint Symposium. 2007, 6, 25, Biejing, China.
  3. Ohtsuka T.:Biochemistry of the presynaptic active zone , Gordon Research Canferencers, 2007, 6, 10-15, New Hampshire, USA(Invited lecture)
  4. Niimi H, and Moustakas A.:Notch signaling is necessary for epithelial growth arrest by TGF-β. The 8th TGF-β meeting, 2007, 5, 21-23, Uppsala, Sweden.
  5. Niimi H., and Moustakas A.:Notch signaling is necessary for epithelial growth arrest by TGF-β. International Conference "Phosphorylation, Signaling and Disease", 2007, 5, 16-20, Cold Spring Harbor Laboratory, USA.
  6. Tokoro T, Beppu H, Moriguchi S, Shioda N, Fukunaga K, Nishijo H, Niimi H, Ohtsuka T, En Li, and Kitajima I.:The analysis of ATRX mutant mice as a model of mild mental retardation. 2007 Keystone Synposia Epigenetics. 2007, 4-15, Cororado, USA
  7. Tokoro T and Kitajima I.:Proof of "SHO" in Rheumatoid Arthritis by cDNA array analysis. Innovantive Team Program in Peking University-21st Century COE program in University of Toyama Joint Symposium. 2007, 6, 25 , Biejing, China
  8. Tokoro T, Beppu H, Moriguchi S, Shioda N, Fukunaga K, Hori E, Nishijo H, Kitajima I and Li E.:The chomatin-remodeling gene ATRX mutant mice related to ADHD. 37th Annual meeting of Neuroscience. 2007, 11, 5, 2007, San Diego, USA
  9. Motomura H, Sugimori K, Kimura T and Kitajima I.:GAS6, New regulator of chondrogenic diffrentiation in mesenchymal cells. 53rd Annual Meeting of the Orthopaedic Research Society, 2007, 2, 11-14, San Diego, USA
  10. Shioda N, Tokoro T, Kitajima I, Beppu H and Fukunaga K.:Actication of CaM kinase II is implicated in generation of abnormal dendritic spines via Tiam1/PAK signaling in ATRX mutant mouse brain. 37th Annual meeting of Neuroscience 2007, 11, 5, 2007, San Diego, USA
  11. –k“‡ŒM:ŒŒšĒ‹}«Šś‚š”½‰f‚·‚é‹ĆŒŒ•ŖŽqƒ}[ƒJ[’Tõ‚Ę‚»‚Ģ—Տ°‰ž—p, ‘ę7‰ń•ŖŽqŒŒŠĒŒ¤‹†‰ļ, 2007, 1, 5, ‘åć(µ‘Ņu‰‰)
  12. –k“‡ŒM:—ā‚¦‚Ę’É‚Ż‚É—R—ˆ‚·‚鍜EŠÖßŽ¾Š³‚É‘Ī‚·‚éŠæ•ū–ņ‚Ģ’Tõ‚Ę‚»‚Ģ–ņ—‹@˜‚Ģ‰š–¾, •xŽRŒ§Šæ•ū–ņu‰‰‰ļ, 2007, 1, 23, •xŽR
  13. –k“‡ŒM, ”öģ’q”ü, ’J‚Ż‚ĖŽq, ŽOč’q”Ķ, ‰Į”Ø‘½•¶:ŒŅŠÖßŽčp‚Ģp’†EpŒć‚É‚Ø‚Æ‚é‹ĆŒŒ•ŖŽqƒ}[ƒJ[•Ļ“®‚ĘDVTEPE”­Ē‚ĢŠÖŒW\‘I‘š“IXa‘jŠQÜ‚Ģ”­Ē—\–hŒų‰Ź‚ĢŒŸ“¢\ ‘ę7‰ńTTMƒtƒH[ƒ‰ƒ€, 2007, 3, 10, “Œ‹ž
  14. –k“‡ŒM:ŒŒšĒ‹}«Šś‚š”½‰f‚·‚é‹ĆŒŒ•ŖŽqƒ}[ƒJ[‚É‚Ā‚¢‚Ä, ‘ę22‰ń’†•”’n‹ęŒŒ‰tŒŸøŒ¤C‰ļ, 2007, 3, 11, •xŽRiµ‘Ņu‰‰j
  15. –k“‡ŒM:“]ŽŹˆöŽqŠˆ«‰»‰šĶ–@‚ĢV‚½‚ČŠm—§‚Ę—Õ°ŒŸø‚Ö‚Ģ‰ž—p, ‘ę26‰ń“ś–{—Տ°‰»Šw‰ļ‰ÄŠśƒZƒ~ƒi[, 2007, 7, 6, ˆÉØŽu–€
  16. –k“‡ŒM:‹ĆŒÅü—n•ŖŽqƒ}[ƒJ[‚Ģ—Տ°‰ž—p\ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ‚ĘŠeŽķŒŒšĒ‚É‚Ā‚¢‚ā|, ‘ę8‰ń“ś–{ŒŸøŒŒ‰tŠw‰ļŠwpW‰ļƒZƒ~ƒi[, 2007, 7, 21, •Ÿˆäiµ‘Ņu‰‰j
  17. –k“‡ŒM:ˆā“`Žq‚Ģ•sŽv‹c, •xŽRŒ§–Æ‚ĢŒ’N‚šl‚¦‚é‰ļŽs–ÆŒöŠJuĄ, 2007, 8, 12, •xŽR
  18. –k“‡ŒM, Š’, mˆäŒ©‰pŽ÷, ˆų–ŌG²:cDNAƒ}ƒCƒNƒƒAƒŒƒC‚š—p‚¢‚½ŠÖßƒŠƒEƒ}ƒ`‚É‚Ø‚Æ‚éŲ‚ĢŒŸŲ‚ĘŠæ•ū–ņ‚Ģ•ŖŽq–ņ—‹@\‰š–¾, •xŽR‘åŠw21¢‹ICOEƒvƒƒOƒ‰ƒ€ƒVƒ“ƒ|ƒWƒEƒ€, 2007, 11, 16, •xŽR
  19. –k“‡ŒM, mˆäŒ©‰pŽ÷, Š’, —ŃŽj˜N:‘ć•\“I–¬f‚ĘŽ¾Š³‚ĢŠÖ˜A. •½¬18”N“x‰ČŠw‹ZpU‹»’²®”ļ. ‰ČŠw‹Zp‚É•K—v‚Č’²øŒ¤‹†, Šæ•ūu–¬fvf’f–@‚ĢƒJƒIƒX‰šĶ‚ʉȊw‰»Œ¤‹†•ń‰ļ, 2007, 3, 16, Ž­Ž™“‡
  20. –k“‡ŒM, Œ““cŒ’‰E, mˆäŒ©‰pŽ÷, Žs–Ń—R‹IŽq:—Տ°ŒŸøŽĄKŒų‰ŹŒüć‚š–ŚŽw‚µ‚½‘ģćŒ^ŒŸø‹@ŠķŠˆ—p‚Ę‚»‚ĢŠwK•]‰æ, ‘ę39‰ń“ś–{ˆćŠw‹³ˆēŠw‰ļ‘å‰ļ, 2007, 7, 27, ·‰Ŗ
  21. –k“‡ŒM:ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚Ę‚Ķ, •½¬19”N“x‘OŠś•xŽR‘åŠwŒöŠJuĄ, 2007, 8, 4, •xŽR
  22. –k“‡ŒM, –ģŽč—Ē„, ”öģ’q”ü, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, ˆ¢•”Ž Ž÷, –å˜e³˜a, ŽRŒ`_ˆź:1•ŖŽqŒuŒõ‘ŠŠÖ–@‚š—p‚¢‚½“]ŽŹˆöŽqNF-κB‘Ŗ’č‚É‚ę‚éS‘ŸŽüpŠśƒ‚ƒjƒ^[‚Ö‚Ģ‰ž—p, ‘ę54‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2007, 11, 23, ‘åć
  23. ‘å’Ė–«‹v:_ŒoƒVƒiƒvƒXƒAƒeƒBƒuEƒ][ƒ“‚Ģ¶‰»Šw, ‘ę30‰ń“ś–{•ŖŽq¶•Ø‰ļ”N‰ļ, 2007, 12, 11-15, ‰”•l
  24. mˆäŒ©‰pŽ÷:ˆā“`ŽqŒŸø‚ĢŒ»ó‚ʏ«—ˆ“W–], ‹³ˆēu‰‰, ‘ę22‰ń’†•”’n‹ęŒŒ‰tŒŸøŒ¤C‰ļ, 2007, 3, 10, •xŽR
  25. mˆäŒ©‰pŽ÷:real-time PCR‚š—p‚¢‚½v‘¬‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€‚Ģ\’z, ‘ę46‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļ, 2007, 3, 4, ŽOd
  26. mˆäŒ©‰pŽ÷, –ģŽč—Ē„, –k“‡ŒM:real-time PCR–@‚š—p‚¢‚½v‘¬‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€‚Ģ\’z‚ÉŠÖ‚·‚錤‹†, ‘ę39‰ń“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘å‰ļ, 2007, 9, 27, ‰”•lŽs
  27. mˆäŒ©‰pŽ÷, –ģŽč—Ē„, –k“‡ŒM, :v‘¬‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€‚Ģ\’z‚ÉŠÖ‚·‚錤‹†, ‚Ę‚ā‚ÜŽYŠwŒš—¬‰ļ2007, 2007, 11, 21, •xŽRŽs
  28. mˆäŒ©‰pŽ÷, ”öģ’q”ü, ī’J»Žq, –ģŽč—Ē„, ‰FŽ”‹`‘„, ¬ąV“N•v, –k“‡ŒM:‚“xęiˆć—Ć‚Ę‚µ‚Ä‚Ģę“V«‘ęVIIˆöŽqŒ‡–RĒˆā“`Žqf’f‚ĢŽę‚č‘g‚Ż, ‘ę54‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2007, 11, 24, ‘åćŽs
  29. Œ““cŒ’‰E, ā–{ƒŽq, Šp“c”ü—é, –k“‡ŒM:NSTŠˆ“®‚Ģ‰h—{ŠĒ—‚É‚Ø‚Æ‚érefeeding syndrome‚Ę’įƒŠƒ“ŒŒĒ‚Ģd—v«. ‘ę46‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļ, 2007, 3, 4, ’Ć
  30. Œ““cŒ’‰E:ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚ÉŠÖ‚·‚錌‰tŒŸø’l‚Ģ“Ē‚Ż•ū. •½¬19”N“x‘OŠś•xŽR‘åŠwŒöŠJuĄ, 2007, 8, 4, •xŽR
  31. Œ““cŒ’‰E:’“‰¹”g‚Å‚Ż‚郁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€. •½¬19”N“x‘OŠś•xŽR‘åŠwŒöŠJuĄ, 2007, 8, 4, •xŽR
  32. Œ““cŒ’‰E, –k“‡ŒM, Žs–Ń—RŠóŽq:ŒŸø‘Ŗ’čŒ“—‚šŒų‰Ź“I‚ÉŽĄK‚Å‚«‚éƒc[ƒ‹‚Ö‚ĢPOCT‘Ī‰žŒ^¬Œ^Ž©“®•ŖĶŠķ‚Ģ‰ü‘¢‚Ę‚»‚ĢŠwKŒų‰Ź. ‘ę54‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ. 2007, 11, 23, ‘åć
  33. ć–ģ’q_, ‰FŽ”‹`‘„, ŒKŒ“‘ģ”ü, ģ“‡–ŅŽu, ī’J»Žq, ’J‚Ż‚ĖŽq, ŽÄ‘„Žq, ‰œ“c’‰s, –k“‡ŒM, –{‹{‘P‰ų, ŽO‰Y‰ėˆź, ‹g“cē», ˆĄ“Œ—RŠģ•v. ‘ę54‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ. 2007, 11 , 24, ‘åć
  34. ˆ¢•”Ž Ž÷, –å˜e³˜a, ŽRŒ`_ˆź, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ŖŒõ–@‚š—p‚¢‚½“]ŽŹˆöŽqŠˆ«v‘¬‘Ŗ’č–@‚ĢŠJ”­. ‘ę22‰ń¶‘Ģ‹@”\ŠÖ˜A‰»ŠwƒVƒ“ƒ|ƒWƒEƒ€, 2007, 9, 28, å‘ä
  35. ŽOč’q”Ķ, ‰Į”Ø‘½•¶, ‘O“c‹œ, ā‰z‘åŒå, “ą“”[Œ[, ˆĄ“”’q¬, •x“cŸ˜Y, ’J‚Ż‚ĖŽq, –k“‡ŒM:ŒŅŠÖßŽčp‚É‚Ø‚Æ‚ép’†, pŒć‚Ģ‹ĆŒÅEü—nŒnƒ}[ƒJ[‚Ģ•Ļ“®. ‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ‚É’…–Ś‚µ‚Ä, ‘ę37‰ń“ś–{lHŠÖßŠw‰ļ, 2007, 2, 3, “Œ‹ž
  36. ŽRŠŻ–GŽq, X“c–¢, ‘½‰ź—R‹IŽq, ā–{ƒŽq, ‹g“cˆčŽq, ‘å–å—Ē’j, mˆäŒ©‰pŽ÷, –k“‡ŒM, L‰H‰Ā“ŽŒÄ, ¬‹“eW, rˆäM‹M, ¬—ѐ³:L. pneumophila‚É‚ę‚é”x‰Š‚š‹N‚±‚µ‚½2Ē—į. ‘ę46‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļ, 2006, 3, 4, ’Ć
  37. ”ä‰Ć i, Š’, –k“‡ŒM, ‘å’Ė–«‹v: SAD kinase directly phosphorylates the active zone protein Bassoon. Œ¤‹†—Ģˆęu”]‚Ģ”­’B‚ĘŠwKƒƒJƒjƒYƒ€‚Ģ‰š–¾v‘ę4‰ń—Ģˆę“ąŒ¤‹†•ń‰ļ. 2007, 3, 6, ‘åć
  38. Š’, •Ź•{GK, ¼šŽõ•v, mˆäŒ©‰pŽ÷, ‘å’Ė–«‹v, En Li, –k“‡ŒM:Œy“xø_’x‘Ųƒ‚ƒfƒ‹ATRX•ĻˆŁƒ}ƒEƒX‰šĶ. Œ¤‹†—Ģˆęu”]‚Ģ”­’B‚ĘŠwKƒƒJƒjƒYƒ€‚Ģ‰š–¾v‘ę4‰ń—Ģˆę“ąŒ¤‹†•ń‰ļ. 2007, 3, 6, ‘åć
  39. Š’, •Ź•{GK, XŒū–ĪŽ÷, ‰–“c—ĻŽj, •Ÿ‰i_Ži, ¼šŽõ•v, mˆäŒ©‰pŽ÷, ‘å’Ė–«‹v, En Li, –k“‡ŒM:Œy“xø_’x‘Ųƒ‚ƒfƒ‹ATRX•ĻˆŁƒ}ƒEƒX‚Ģ‰šĶ. ‘ę127‰ń“ś–{–ņŠw‰ļ. 2007, 3, 28, •xŽR
  40. ć–ģ’q_, ‰FŽ”‹`‘„, ŒKŒ“‘ģ”ü, ģ“‡–ŅŽu, ’J‚Ż‚ĖŽq, ŽÄ‘„Žq, –ģŽč—Ē„, ‰œ“c’‰s, –k“‡ŒM:ƒLƒƒƒsƒ‰ƒŠ[“d‹C‰j“®‘•’u‚š—p‚¢‚½ƒŠƒ|’`”’•ŖĶ–@‚Ģ•]‰æ. ‘ę32‰ń–k—¤—Տ°•a—W’c‰ļE‘ę15‰ń“ƃZƒ~ƒi[, 2007, 9, 8, ‹ą‘ņ
  41. ć–ģ’q_, ‰FŽ”‹`‘„, ŒKŒ“‘ģ”ü, ģ“‡–ŅŽu, ’J‚Ż‚ĖŽq, ŽÄ‘„Žq, –ģŽč—Ē„, ‰œ“c’‰s, –k“‡ŒM:ŒŒ“’†β2mƒAƒ~ƒƒCƒh‘O‹ģ‘Ģ’`”’Žæ‚Ģ•ŖĶ–@. ‘ę32‰ń–k—¤—Տ°•a—W’c‰ļE‘ę15‰ń“ƃZƒ~ƒi[, 2007, 9, 8, ‹ą‘ņ
  42. ”öģ’q”ü, ’J‚Ż‚ĖŽq, ‰FŽ”‹`‘„, –k“‡ŒM:ŒŅŠÖßŽčp‚Ģp’†EpŒć‚É‚Ø‚Æ‚é‹ĆŒŒ•ŖŽqƒ}[ƒJ[‚Ģ•Ļ“®‚Ę‘I‘š«Xa‘jŠQÜ‚É‚ę‚éĆ–¬ŒŒšĒ‚Ģ—\–hŒų‰Ź”»’č. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę39‰ń‘å‰ļ, 2007, 9, 27, ‰”•l
  43. –ģŽč—Ē„, ”öģ’q”ü, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, –k“‡ŒM:ŒŸø•”‚ɂ؂Ƃ鍂“xęiˆć—Ć‚Ę‚µ‚Ä‚Ģę“V«ŒŒ‰t‹ĆŒÅˆŁķĒˆā“`Žq‰šĶ10”N‚ĢŽę‚č‘g‚Ż‚ʍ”Œć‚Ģ“W–]. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘ę39‰ń‘å‰ļ, 2007, 9, 27, ‰”•l
  44. ŽOč’q”Ķ, ‰Į”Ø‘½•¶, ‘O“c‹œ, “ą“”[Œ[, ‘½‰ź³, ˆĄ“”’q¬, •x“cŸ˜Y, –k“‡ŒM, ’J‚Ż‚ĖŽq, ‰Į”ؐēt, ŽR–{ Œ’, ’©‘q‰pō:ŒŅŠÖßŽčp‚É‚Ø‚Æ‚ép’†, pŒć‚Ģ‹ĆŒÅEü—nŒnƒ}[ƒJ[‚Ģ•Ļ“®\‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ‚É’…–Ś‚µ‚ā[. ‘ę5‰ń–k—¤ŒŒšŒ¤‹†‰ļ. 2007, 10, 6, ‹ą‘ņ
  45. Žß‰i“Žu, a’JLŽq, “ģ ‰ė”ü, ’J‚Ż‚ĖŽq, –k“‡ŒM, ŽRčŒõĶ:lH•GŠÖß’uŠ·p‚ɂ؂Ƃ錌šĒEŽ_‰»ƒXƒgƒŒƒXƒ}[ƒJ[‚Ģ‰šĶ]–ƒŒ•ū–@‚É‚ę‚é”äŠr]. ‘ę5‰ń–k—¤ŒŒšŒ¤‹†‰ļ, 2007, 10, 6, ‹ą‘ņ
  46. Š’, –k“‡ŒM:ŠÖßƒŠƒEƒ}ƒ`‚Ģ–ņŒų‚šŽ¦‚·Šæ•ū•ūÜ‚Ģ’Tõ‚Ę“]ŽŹˆöŽqŠˆ«’²ß‹@”\‚Ģ‰š–¾. •xŽR‘åŠw21¢‹ICOEƒvƒƒOƒ‰ƒ€ƒVƒ“ƒ|ƒWƒEƒ€, 2007, 11, 16, •xŽR
  47. ˆ¢•”Ž Ž÷, –å˜e³˜a, ŽRŒ`_ˆź, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ŖŒõ•ū‚š—p‚¢‚½¶‘ĢŽŽ—æ’†‚Ģ“]ŽŹˆöŽqŠˆ«v‘¬‘Ŗ’č–@‚ĢŠJ”­. ‘ę54‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2007, 11, 24, ‘åć
  48. ”öģ’q”ü, –ģŽč—Ē„, ‰FŽ”‹`‘„, mˆäŒ©‰pŽ÷, ‘Oģ^l, –k“‡ŒM:”ńĒŒóŒQ«“ŖŠWœ‘Šś–ü‡Ē‚ĢŒ“ˆöˆā“`Žq’Tõ. ‘ę54‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ, 2007, 11, 24, ‘åć

‚»‚Ģ‘¼

  1. H‹ĘŠ“¾Œ , mˆäŒ©‰pŽ÷, –k“‡ŒM:Š“õĒ‹Nˆö‹Ū‚Ģv‘¬“Æ’č•ū–@, ‘ŪoŠč”Ō†:PCT/JP2007/053078, 2007
  2. H‹ĘŽę“¾Œ , –k“‡ŒM, ŽRŒ`_ˆź, ˆ¢•”Ž Ž÷:ƒXƒeƒƒCƒhŠ“Žó«‚Ģ”»’č•ū–@‹y‚Ń‘Sg«‰ŠĒ”½‰žĒŒóŒQ‚Ģ”­Ē—\‘Ŗ•ū–@, “Į‹–Šč2007-177135, 2007

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2006”N

’˜‘

  1. –k“‡ŒM:d‹ą‘®‚Č‚ē‚Ń‚ÉŠÖ˜A’`”’. •W€—Տ°ŒŸøˆćŠwi’–Žė~, ’†Œ“ˆź•F•ŅW, ˆćŠw‘‰@, “Œ‹ž, 233-238, 2006
  2. –k“‡ŒM:—¬‚ź‚Ŗ‚ķ‚©‚鎥‘HŒŸøƒ}ƒjƒ…ƒAƒ‹ćŠŖiŒŸø‚ĢŠī‘b’mŽÆ, ŒŸøŠT—vji–k“‡ŒMŠÄCj, ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽŠ, “Œ‹ž, 1-235, 2006
  3. –k“‡ŒM:—¬‚ź‚Ŗ‚ķ‚©‚鎥‘HŒŸøƒ}ƒjƒ…ƒAƒ‹‰ŗŠŖi‘ŸŠķ•ŹŽ¾Š³‚É‘Ī‚·‚錟ø‚Ģ—¬‚źji–k“‡ŒMŠÄCj, ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽŠ, “Œ‹ž, 10-495, 2006
  4. ¬ąV“N•v, –k“‡ŒM:Šˆ«‰»ƒvƒƒeƒCƒ“C ƒŒƒWƒXƒ^ƒ“ƒX, ŒŒšĒƒiƒrƒQ[ƒ^[i’r“cN•v, “ąŽRTˆź˜Y, Œć“”MĘ, d¼G, ”¼“c½•Ņj, ƒƒfƒCƒJƒ‹ƒŒƒrƒ…[ŽŠ, “Œ‹ž, 102-103, 2006.

Œ“’˜

  1. Deguchi-Tawarada M, Inoue E, Takao-Rikitsu E, Unoue M, Kitajima I, Ohtsuka, T, Takai Y. The active zone protein CAST is a component of conventional and ribbon synapses in mouse retina. J Comp Neurol. 2006;495:480-96.
  2. Wang J, Tokoro T, Higa S, Kitajima I. Anti-inflammatory Effect of Pitavastatin on NF-„{B Activated by TNF-α in Hepatocellular Carcinoma Cells. Biol Pharm Bull 2006;24:634-9.
  3. Matsui K, Sugimori K, Motomura H, Ejiri N, Tsukada K, Kitajima I. PEA3 cooperates with c-Jun in regulation of HER2/neu transcription. Oncology Reports. 2006;16:153-8.
  4. Inoue E, Mochida S, Takagi H, Higa S, Deguchi-Tawarada M, Unoue M, Yao I, Takeuchi K, Kitajima I, Setou M, Ohtsuka T, Takai Y. SAD: a novel presynaptic kinase associated with synaptic vesicles and the active zone cytomatrix that regulates neurotransmitter release. Neuron. 2006;50:261-75.
  5. Inoue E, Deguchi-Tawarada M, Takao-Rikitsu E, Inoue M, Ohtsuka T, Takai Y. ELKS, a protein structurally related to the active zone protein CAST, is involved in Ca-dependent exocytosis from PC12 cells. Gene Cells. 2006;11:659-72.
  6. Lansbergen G, Grigoriev I, Mimori-Kiyosue Y, Ohtsuka T, Higa S, Kitajima I, Demmers J, Galjart N, Houtsmuller AB, Grosveld F, Akhmanova A. CLASPs attach microtube plus ends to the cell cortex through a complex with LL5β. Dev Cell. 2006;11:21-32.
  7. Fujioka S, Hamazaki K, Itomura M, Huan M, Nishizawa H, Sawazaki S, Kitajima I, Hamazaki T. The effects of eicosapentaenoic acid-fortified food on inflammatory markers in healthy subjects-A randomized, placebo-controlled, double-blind study. J Nurtr Sci Vitaminol. 2006;52:261-5.
  8. Higa S, Tokoro T, Inoue E, Kitajima I, Ohtsuka T. The active zone protein CAST diretly associates with ligand of Numb protein X. Biochem Biophysic Res Commun. 2007;354:686-92.
  9. ”öģ’q”ü, ’J‚Ż‚ĖŽq, ģ“‡–ŅŽu, ‘å–å—Ē’j, –k“‡ŒM:Point of Care Testing(POCT)“±“ü‚š–ŚŽw‚µ‚½‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ(SFMC)‘SŒŒ‘Ŗ’č–@‚ĢŒŸ“¢. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‰ļŽ 2006;30:727-31.
  10. –k“‡ŒM:‰Ā—n«ƒtƒBƒuƒŠƒ“(SF)‚ĘƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ(FMC). “ś–{ŒŸøŒŒ‰tŠw‰ļŽGŽ 2006;7:470-7.

‘ą

  1. –k“‡ŒM:ŒŸ‘ĢŒŸøƒsƒbƒgƒtƒH[ƒ‹. ˆć•ń‚Ę‚ā‚Ü. 2006;1409:10-1.
  2. –k“‡ŒM:‘ģć“dŽqŒ°”÷‹¾. •xŽRŽsˆćŽt‰ļ‰ļ•ń. 2006;424:6-8.
  3. –k“‡ŒM:—Տ°‰»Šw‚ĢŽ‹“_‚É‚ę‚éƒAƒ‹ƒcƒnƒCƒ}[•aÅ‘Oü. —Տ°‰»Šw. 2006;35:320-1.
  4. ‘å’Ė–«‹v:Ž„‚Ŗ–¼•t‚Æ‚½ˆā“`Žq, ƒAƒNƒeƒBƒuƒ][ƒ“‚ĢƒƒCƒ“ƒLƒƒƒXƒgCAST ŽĄŒ±ˆćŠw. 2006;24:875-7.
  5. ‘å’Ė–«‹v, ˆäć‰p“ń:_Œo×–E‚Ģ‹É«Œ`¬‚šŽi‚éSAD ƒLƒi[ƒ[‚Ķ_Œo“`’B•ØŽæ‚Ģ•śo‚š§Œä‚·‚é. ×–EHŠw. 2006;25:776-7.
  6. ‘å’Ė–«‹v:_ŒoƒVƒiƒvƒXƒAƒNƒeƒBƒuƒ][ƒ“‚Ģ\‘¢‚Ę‹@”\ ¶‰»Šw. 2006;78:979-86.
  7. mˆäŒ©‰pŽ÷, –k“‡ŒM:×–E“ąƒVƒOƒiƒ‹“`’B‰šĶ‚Ģ—Տ°ŒŸøŒ»ź‚Ö‚Ģ“WŠJ. Medical Technology. 2006;34:122-3.
  8. ”öģ’q”ü, –k“‡ŒM:‰Ā—n«ƒtƒBƒuƒŠƒ“. V‚µ‚¢—Տ°ŒŸøE–¢—ˆ‚Ģ—Տ°ŒŸø. ŒŸø‚Ę‹Zp. 2006;34:1099-100.

Šw‰ļ•ń

  1. Kitajima I, Sugimori K: Bone morphogenic protein-2 requires phosphorylation of NF-κB p65 and nuclear accumulation of IKK-α in chondrocyte differntiation and survival. 2006 Keystone Synposia Conference. NF-κB: 20 years on road from biochemistry to pathology. 2006, 3, Banff, Canada.
  2. Sugimori K, Motomura H, Kitajima I, Matsui K, Kimura T: The relationship between BMP-2 and PI3K/Akt-NF-κB activation pathway in chondrogenesis. 52nd Annual Meeting of the Orthopaedic Research Society, 2006, 3, Chicago, USA.
  3. Niimi H, Pardali K, Heldin C-H, Moustakas A: Notch signaling is necessary for epithelial growth arrest by TGF-β. 7th TGF-β meeting, 2006, 5, Uppsala, Sweden.
  4. Hanzawa K, Hayashi J-I, Nakajima T, Kitajima I, Tsuchida K: Economy class syndrome (venous thromboembolism) in midle Niigata prefecture earthquake 2004. 8th Asia Conference on Disaster Medicine (APCDM)-Global Collaboration for Disaster response-, 2006, 11, Tokyo, Japan
  5. –k“‡ŒM:ŒŸø•”‚ĢˆÓŽÆ‰üŠv. •xŽRŒ§—Տ°‰q¶ŒŸø‹ZŽt¶ŠU‹³ˆēƒZƒ~ƒi[. 2006, 1, •xŽR.
  6. –k“‡ŒM:ŒŒšĒ‚Ģ‹}«Šś‚š‘Ø‚¦‚é‹ĆŒÅ•ŖŽqƒ}[ƒJ[EƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ. ƒtƒH[ƒ‰ƒ€•xŽRu‘n–ņv‘ę18‰ńŒ¤‹†‰ļ. 2006, 2, •xŽR.
  7. –k“‡ŒM:SF ‚ĘFMC. ‘ę7‰ń“ś–{ŒŸøŒŒ‰tŠw‰ļŠwpW‰ļƒeƒNƒjƒJƒ‹ƒZƒ~ƒi[. 2006, 7, “Œ‹ž.
  8. –k“‡ŒM:ŽŸ¢‘ć—Տ°‰»Šw‚Ģ‚½‚߂ɍ”‚·‚ׂ«‚±‚Ę:lŽˆē¬, ˆćŽt‹³ˆē‚Ģ—§ź‚©‚ē, ‘ę25‰ń“ś–{—Տ°‰»Šw‰ÄŠśƒZƒ~ƒi[, 2006. 8, ŽD–y.
  9. –k“‡ŒM:ˆć—Ć‚ÉŽæ‚ĢŒüć‚ĘŠ³ŽŅ’†S‚Ģˆć—Ć‚š–ŚŽw‚µ‚½ŒŸø•”‚Ģƒ}ƒlƒWƒƒ“ƒg. ‘ę25‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”—į‰ļ. 2006, 9, “ą“å.
  10. –k“‡ŒM:ˆć—Ć‚ĢŽæ‚ĢŒüć‚ĘŒŸø•”‘¶Ż‰æ’l‚š‚‚ß‚éV‚µ‚¢ŒŸøƒVƒXƒeƒ€“±“üƒXƒgƒ‰ƒeƒW[. ‘ę45‰ń’†•”ˆćŠwŒŸøŠw‰ļƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[, 2006, 9, ’Ć.
  11. –k“‡ŒM:“]ŽŹˆöŽqŒ¤‹†‚ĢŽ‹“_‚©‚ēŒ©‚½—Տ°ŒŸøˆćŠw‚Ģ–£—Ķ. ‘ę1‰ń•a‘Ōī•ń‰šĶŠwƒZƒ~ƒi[. 2006, 10, ŒF–{.
  12. –k“‡ŒM:—Տ°ŒŸø‚Ģ–¢—ˆ‚šŲ‚čŠJ‚­V‚µ‚¢ŒŸøƒVƒ“ƒ|ƒEƒ€:•a‰@ŒŸøŽŗ‚ÅŽĄ‘H‚Å‚«‚é•ŖŽq•a‘ŌŒŸø–@ŠJ”­i“]ŽŹˆöŽqŠˆ«‰»ŒŸø‚Ģ•ŖŽq•a‘ŌŒŸø–@ŠJ”­j. ‘ę53‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ. 2006, 11, O‘O.
  13. –k“‡ŒM:äPŒ“•a‚ĢĒó‚ʐf’f. ‘ę1‰ńäPŒ“•aŽx‰‡ƒlƒbƒgƒ[ƒN‘‰ļˆć—ƍu‰‰‰ļ. 2006, 11, ‹ą‘ņ.
  14. –k“‡ŒM. ‹{č—Ēˆź, ”~Œ“‹v”Ķ:Žį”NäPŒ“•a‚Ę”DPoŽY. ‘ę1‰ńäPŒ“•aƒlƒbƒgƒ[ƒN‘‰ļƒ[ƒNƒVƒ‡ƒbƒv, 2006, 11, ‹ą‘ņ.
  15. –k“‡ŒM:“]ŽŹˆöŽqNF-κB‚©‚ēŽa‚é•ŖŽq•a‘Ō. ‘ę3‰ń•xŽR‘åŠw•a‰@•a—•”ƒZƒ~ƒi[. 2006, 2 •xŽR.
  16. ‘å’Ė–«‹v:_Œo×–E‚Ģ‹É«Œ`¬‚šŽi‚éSAD ƒLƒi[ƒ[‚Ģ\‘¢‚Ę‹@”\. “ś–{•ŖŽq¶•ØŠw‰ļ2006 ƒtƒH[ƒ‰ƒ€, •ŖŽq¶•ØŠw‚Ģ–¢—ˆ. 2006, 12, –¼ŒĆ‰®.
  17. ‘å’Ė–«‹v _ŒoI––ƒAƒNƒeƒBƒuEƒ][ƒ“‚ĢŒ`¬‚Ę‹@”\‚É‚Ø‚Æ‚éSAD ƒLƒi[ƒ[‚Ģ–šŠ„. ‘ę29‰ń“ś–{_Œo‰ČŠwŠw‰ļ‘å‰ļ. 2006, 7, ‰”•l.
  18. ‘å’Ė–«‹v:SAD ƒLƒi[ƒ[‚É‚ę‚é_Œo“`’B•ØŽæ•śo‚Ģ•ŖŽq‹@\. ¶—ŠwŒ¤‹†‰ļƒVƒiƒvƒX‰Ā‘Y«‚Ģ•ŖŽqŠī”Õ. 2006, 6, ‰Ŗč.
  19. ŽRŠŻ–GŽq, X“c–¢, ‘½‰ź—R‹IŽq, ā–{ƒŽq, ‹g“cˆčŽq, ‘å–å—Ē’j, –k“‡ŒM:ƒ}ƒCƒNƒƒXƒLƒƒƒ“Rapid plus ƒpƒlƒ‹‚š—p‚¢‚½‹ŪŒŒĒ‚Ģv‘¬f’f•ń‚ĢŽŽ‚Ż. ‘ę45‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļE“ŒŠC–k—¤Žx•”‘‰ļ. 2006, 3, •l¼.
  20. –ģŽč—Ē„, ī’J»Žq, X“c–¢, ‘½‰ź—R‹IŽq, ā–{ƒŽq, ‹g“cˆčŽq, ‘å–å—Ē’j, mˆäŒ©‰pŽ÷, –k“‡ŒM:Real-time PCR–@‚š—p‚¢‚½v‘¬‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€\’z‚ĢŒŸ“¢. ‘ę45‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļE“ŒŠC–k—¤Žx•”‘‰ļ. 2006, 3, •l¼.
  21. ”öģ’q”ü, ’J‚Ż‚ĖŽq, ģ“‡–ŅŽu, ‘å–å—Ē’j, –k“‡ŒM:ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘ĢiFMCj‚ʉĀ—n«ƒtƒBƒuƒŠƒ“iSFj‚Ģ˜Ø—£ó‹µ‚Ę—Õ°“IˆÓ–”. ‘ę45‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļE“ŒŠC–k—¤Žx•”‘‰ļ. 2006, 3, •l¼.
  22. Š’, •Ź•{GK, XŒū–ĪŽ÷, ‰–“c—ĻŽj, •Ÿ‰i_Ži, –x‰x˜Y, ć–ģĘŽq, ¬–ģ•”N, ¼šŽõ•v, ‘å’Ė–«‹v, En Li, –k“‡ŒM:ƒNƒƒ}ƒ`ƒ“ƒŠƒ‚ƒfƒŠƒ“ƒO•ŖŽqATRX ”­Œ»’į‰ŗƒ}ƒEƒX‚Ģ‹L‰ÆEŠwKįŠQ. CREST ‘ę3‰ń”]‚Ģ‹@”\”­’B‚ĘŠwKƒƒJƒjƒYƒ€‚Ģ‰š–¾—Ģˆę“ąŒ¤‹†•ń‰ļ. 2006, 3, ‘åć.
  23. –k“‡ŒM, ŽRŒūŒjŽi, ”öģ’q”ü, ’J‚Ż‚ĖŽq:SFEFMC ŽŽ–ņŠŌ‚É‚Ø‚Æ‚é˜Ø—£ŒŸ“¢‚ĘŠeŒŸø‚Ģ—L—p«‚É‚Ā‚¢‚Ä. ‘ę6‰ńTTM (Thrombosis & Thrombolysis Markers Forum). 2006, 3, “Œ‹ž
  24. Y‘ņ˜a•F, “y“cŒj‘ , –k“‡ŒM:VŠƒŒ§’†‰z’nk”ķŠŽŅŠ³ŽŅzŠĀŠķŠO—ˆŠ³ŽŅ‚ĢDVT ‚ĘŒŒ‰t‹ĆŒÅƒ}[ƒJ[‚É‚Ā‚¢‚Ä. ‘ę6‰ńTTM (Thrombosis & Thrombolysis Markers Forum). 2006. 3, “Œ‹ž.
  25. Œ³‘ŗ‘ń, mˆäŒ©‰pŽ÷, ™Xˆźm, ‘å’Ė–«‹v, –Ų‘ŗ—FŒś, –k“‡ŒM:–¢•Ŗ‰»ŠŌ—tŒn×–E‚ĢGrowth Arrest Specific 6 ‚š‰ī‚·‚é“īœ•Ŗ‰»’²ß‹@\. ‘ę24‰ń“ś–{œ‘ćŽÓŠw‰ļŠwpW‰ļ. 2006, 7, “Œ‹ž.
  26. mˆäŒ©‰pŽ÷, –ģŽč—Ē„, ī’J»Žq, –k“‡ŒM:•xŽR‘åŠw•‘®•a‰@ˆā“`ŽqŒŸøŽŗŠJŻ‚É”ŗ‚¤ę“V«ŒŒ‰t‹ĆŒÅˆŁķĒ‰šĶó‹µ. ‘ę2‰ń–k—¤ŒŒšŽ~ŒŒƒZƒ~ƒi[. 2006, 7, ‹ą‘ņ.
  27. ī’J»Žq, –ģŽč—Ē„, ŠŻ“c‚Ż‚©, ‘å–å—Ē’j, mˆäŒ©‰pŽ÷, –k“‡ŒM:ƒAƒ~ƒmŽ_‘¤½ƒtƒFƒjƒ‹Šī‚Ģ—L–³‚ŖFV ’`”’‹@”\‚ɉe‹æ‚š—^‚¦‚邱‚Ę‚Ŗ‰š–¾‚Å‚«‚½V‹Kę“V«‘ęV ˆöŽqŒ‡–RĒiPhe190Serj. ‘ę7‰ń“ś–{ŒŸøŒŒ‰tŠw‰ļŠwpW‰ļ. 2006, 7, “Œ‹ž.
  28. ‹g“cŒd, ‚‘q—Œb, ”öģ’q”ü, ī’J»Žq, ģ“‡–ŅŽu, ’J‚Ż‚ĖŽq, ŒKŒ“‘ģ”ü, ‘å–å—Ē’j, å‹v”T, –ģ‘ŗŒbŽq, ‹ąŒ“O˜a, –k“‡ŒM:Ō‰č‹…Œn×–E‚Ģ‘‰Į‚š”ŗ‚Į‚½Žį”N«œ‘’P‹…«”’ŒŒ•aiJMMLj‚Ģ1 Ē—į. ‘ę31‰ń–k—¤—Տ°•a—W’k˜b‰ļ. 2006, 8, •xŽR.
  29. ‹g“cˆčŽq, ŽRŠŻ–GŽq, X“c”ü, ā–{ƒŽq, –ģŽč—Ē„, ‘å–å—Ē’j, •½“‡¬•S‡, –k“‡ŒM:“ś—§‘ģć“dŽqŒ°”÷‹¾TM-1000Miniscope ‚ĢŽg—pŒoŒ±. ‘ę31‰ń–k—¤—Տ°•a—W’k˜b‰ļ. 2006, 8, •xŽR.
  30. ×’JFŽq, ²’|ˆÉ’ĆŽq, ¬£—Œb, ‰„–ģ^‹|, —ŃŽj˜Y, Œ““cŒ’‰E, –k“‡ŒM, “¹‹ļL_:Œz“®–¬ƒGƒR[‚Őf’f‚É‹ź—¶‚·‚鋐‘匌š—l\‘¢•Ø‚š”F‚ß‚½ˆźĒ—į. ‘ę31‰ń–k—¤—Տ°•a—W’k˜b‰ļ. 2006, 8, •xŽR.
  31. ²’|ˆÉ’ĆŽq, ×’JFŽq, ¬£—Œb, ‰„–ģ^‹|, —ŃŽj˜Y, Œ““cŒ’‰E, –k“‡ŒM:ˆÓŽÆĮŽø”­ģ‚š”ŗ‚Į‚½”xĒšŒŒšĒ‚ĢŒo‰ß•ń. ‘ę31‰ń–k—¤—Տ°•a—W’k˜b‰ļ. 2006, 8, •xŽR.
  32. ŽÄ‘„Žq, Šp“c”ü—é, ‘½‰ź—R‹IŽq, ć–ģ’q_, ‰”“cˆ», ‘å–å—Ē’j, –k“‡ŒM:PhD ƒVƒXƒeƒ€IFA ƒ‚ƒWƒ…[ƒ‹‚š—p‚¢‚½RŠjR‘ĢŒŸøiHep-2j‘Ŗ’č‚ĢŠī‘b“IŒŸ“¢. ‘ę31‰ń–k—¤—Տ°•a—W’k˜b‰ļ. 2006, 8, •xŽR.
  33. –k“‡ŒM, Œ““cŒ’‰E, Žs–Ń—RŠóŽq, ŽšˆäēŽ÷:‘ģćŽ©“®ŒŸø‹@Šķ‚š—p‚¢‚½—Տ°‰»Šw‚ÉŠÖ‚·‚éˆćŠw•”Šw¶ŽĄK‚Ö‚Ģ‰ž—p. ‘ę46‰ń“ś–{—Տ°‰»Šw”N‰ļ. 2006, 9, “Œ‹ž.
  34. –k“‡ŒM, ‘ü–ģd‘¾˜Y:ƒe[ƒ}‚Ķu—Տ°ŒŸø‚ĢŒ““_‚ĶfŽ@Žŗ‚É—L‚č`‚Ē‚Ģ‚ꂤ‚ČˆćŽt‚šˆē‚Ä‚é‚©`v. “ś—§»ģŠƒp[ƒ\ƒiƒ‹Eƒwƒ‹ƒXƒPƒAƒxƒ“ƒ`ƒƒ[ƒJƒ“ƒpƒj[EƒZƒ~ƒi[. 2006, 9, “Œ‹ž.
  35. ‰œ“c’‰s, –k“‡ŒM, •Ÿ‰išę’£°:Ž©“®ŒŒ‰tƒKƒX•ŖĶ‘•’uRoche ŽŠOMNIS ‚Ø‚ę‚Ńƒ‰ƒWƒIƒ[ƒ^[ŽŠABL800 ‚ɂ؂Ƃ錟“¢. ‘ę38‰ń“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘å‰ļ. 2006, 10, _ŒĖ.
  36. ŽÄ‘„Žq, Šp“c”ü—é, ć–ģ’q_, ‘å–å—Ē’j, –k“‡ŒM:EVOLIS ‚šŽg—p‚µ‚½PIVKA-II ’ZŽžŠŌ‘Ŗ’č‚ĢŠī‘b“IŒŸ“¢. ‘ę38‰ń“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘å‰ļ. 2006, 10, _ŒĖ
  37. ŒKŒ“‘ģ”ü, ’J‚Ż‚ĖŽq, ”öģ’q”ü, ‚‘q—Œb, ī’J»Žq, ć–ģ’q_, ģ“‡–ŅŽu, ‘å–å—Ē’j, –k“‡ŒM:‘½€–ŚŽ©“®ŒŒ‹…•ŖĶ‘•’uXE-2100 ‚š—p‚¢‚½”jÓŌŒŒ‹…‘Ŗ’č‚Ģ—L—p«‚É‚Ā‚¢‚Ä. ‘ę38‰ń“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘å‰ļ. 2006, 10, _ŒĖ.
  38. mˆäŒ©‰pŽ÷, –k“‡ŒM, –ģŽč—Ē„:Real-time PCR ‚š—p‚¢‚½v‘¬‚Č”sŒŒĒ‹Nˆö‹Ū“Æ’čƒVƒXƒeƒ€‚Ģ\’z. ‘ę38‰ń“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‘å‰ļ. 2006, 10, _ŒĖ.
  39. mˆäŒ©‰pŽ÷, —ŃŽj˜Y, ŽšˆäL–ē, “ģąVŒ‰, “ˆ“c–L, –k“‡ŒM:–¬fEŲ‚ĘƒJƒIƒX‰šĶ‚Ģ‘ŠŠÖ‚É‚Ā‚¢‚Ä(‘ę2•ń). •½¬18”N“x‘ęˆź‰ń‰ČŠw‹ZpU‹»’²®”ļuŠæ•ūu–¬fvf’f–@‚ĢƒJƒIƒX‰šĶ‚ʉȊw‰»v¬‰ŹŒŸ“¢‰ļ. 2006, 11, •xŽR.
  40. ‰œ“c’‰s, –k“‡ŒM, •Ÿ‰iŽõ°:•xŽRŒ§‚ɂ؂Ƃ錌‰tƒKƒX•ŖĶƒRƒ“ƒgƒ[ƒ‹ƒT[ƒxƒCŠī€’l‚šŠO‚ź‚½Œ“ˆö‚ĢŒŸ“¢. ‘ę53‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ. 2006, 11, O‘O.
  41. ’J‚Ż‚ĖŽq, •£ć‰fŽq, ŽRŒūŒjŽi, YąV˜a•F, —яƒˆź, “y“cŒj‘ , –k“‡ŒM:VŠƒ’†‰z’nk”ķŠŽŅ‚É‚Ø‚Æ‚éŒoŽž“I‹ĆŒŒ•ŖŽqƒ}[ƒJ[‚Ģ•Ļ‰». ‘ę53‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ. 2006, 11, O‘O.
  42. mˆäŒ©‰pŽ÷, –ģŽč—Ē„, ī’J»Žq, ”öģ’q”ü, –k“‡ŒM:ˆā“`ŽqŒŸøŽŗŠJŻ‚É”ŗ‚¤ˆā“`ŽqŒŸøf’fƒVƒXƒeƒ€\’z‚ĢˆÓ‹`‚Ę‚»‚Ģ‰šŒˆ‚·‚ׂ«–ā‘č“_. ‘ę53‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ. 2006, 11, O‘O.
  43. ŒKŒ“‘ģ”ü, ć–ģ’q_, ģ“‡–ŅŽu, ‹g“cŒd, ”öģ’q”ü, ć–ģ—R”ü, ‚‘q—Œb, ‰”“cˆ», Šp“c”ü—é, ’J‚Ż‚ĖŽq, ŽÄ‘„Žq, ‘å–å—Ē’j, –k“‡ŒM:Œo”ļķŒø‚š–Ś“I‚Ę‚µ‚½¶‰»Šw–ʉu•ŖĶƒVƒXƒeƒ€‚Ģ\’z‚Ę‚»‚Ģ“±“üŒų‰Ź‚É‚Ā‚¢‚Ä. ‘ę53‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ. 2006, 11, O‘O.
  44. ‹g“cˆčŽq, X“c”ü, ŽRŠŻ–GŽq, ā–{ƒŽq, –ģŽč—Ē„, ‘å–å—Ē’j, •½“‡¬•S‡, –k“‡ŒM:“ś—§‘ģćŒ°”÷‹¾TM-100Miniscope ‚š—p‚¢‚½×‹Ū‰ę‘œ‚É‚Ā‚¢‚Ä. ‘ę53‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļŠwpW‰ļ. 2006, 11, O‘O.
  45. ‹{—ѐē’ߎq, ˆĄ‘ŗ•q, ‘½—t“cĖŽq, “¹–ģ~Žq, ]”¦˜a”ü, ¼–ģŽåįĮ, –k“‡ŒM:V”CŠÅŒģŽm‚Ö‚ĢˆĄ‘S‚Č—AŒŒ‚ĢŽę‚čˆµ‚¢‚Ģ‚½‚ß‚Ģ‹³ˆē‚É‚Ā‚¢‚Ä. ‘ę24‰ń“ś–{—AŒŒŠw‰ļ–k—¤Žx•”‘‰ļ. 2006, 11, •Ÿˆä.
  46. “¹–ģ~Žq, ‘½—t“cĖŽq, ¼–ģŽåįĮ, ‹{—ѐē’ߎq, ]”¦˜a”ü, ˆĄ‘ŗ•q, –k“‡ŒM, ŽR’J–¾Žq:RDib ‚š—L‚·‚é•s“K‡”DP‚Ģˆź—į. ‘ę24‰ń“ś–{—AŒŒŠw‰ļ–k—¤Žx•”‘‰ļ. 2006, 11, •Ÿˆä.
  47. Œ““cŒ’‰E, –k“‡ŒM, ‹g‘ŗ’¼Ž÷, ŽOč‘ń˜Y, “nē²ˆ»‰Ą, Žs“c•™Žq, ‹{˜e—˜’j:ƒ[ƒtƒ@ƒŠƒ“ƒRƒ“ƒgƒ[ƒ‹—ĒD‚ąŒŒš•Ł‚šŒJ‚č•Ō‚·’PSŽŗ‚ĢlH•Ł’uŠ·pŒć3ĪŽ™’jŽ™. ‘ę4‰ń–k—¤DICŒ¤‹†‰ļ. 2006, 11, ‹ą‘ņ.
  48. —é–Ųr•ć, Singhirunnunsom Pattama, ŽR‰ŖøŽi, –k“‡ŒM, Ļ–Ųˆē•v, ŸNˆäG–¾:HTLV-I Tax ‚Ģ‚ę‚éPķ“ITAK1Šˆ«‰»‚Ę‚»‚Ģ×–E“ąƒVƒOƒiƒ‹‹@\‚É‚Ø‚Æ‚é–šŠ„. •ŖŽq¶•ØŠw‰ļ2006 ƒtƒH[ƒ‰ƒ€, •ŖŽq¶•ØŠw‚Ģ–¢—ˆ. 2006, 12, –¼ŒĆ‰®.
  49. Š’, ”ä‰Ći, –k“‡ŒM, ‘å’Ė–«‹v:ƒ}ƒEƒX_Œo‹ŲŚ‡•”‚É‚Ø‚Æ‚éƒAƒNƒeƒCƒuƒ][ƒ“’`”’ŽæCAST/ELKS ‚Ģ‹ĒŻ. •ŖŽq¶•ØŠw‰ļ2006 ƒtƒH[ƒ‰ƒ€, •ŖŽq¶•ØŠw‚Ģ–¢—ˆ. 2006, 12, –¼ŒĆ‰®.
  50. Higa S, Inoue E, Tokoro T, Kitajima I, Ohtsuka T: The active zone protein CAST directly associates with the ligand Numb. •ŖŽq¶•ØŠw‰ļ2006ƒtƒH[ƒ‰ƒ€, •ŖŽq¶•ØŠw‚Ģ–¢—ˆ. 2006, 12, –¼ŒĆ‰®.
  51. Œ““cŒ’‰E:’`”’, ƒAƒ~ƒmŽ_‘ćŽÓ‚Ģˆź”ŹŒŸø. ‘ę28‰ńNST •×‹­‰ļ. 2006, 7, •xŽR.
  52. Œ““cŒ’‰E:’įƒŠƒ“ŒŒĒ‚ĘRefeeding Syndrome. ‘ę33‰ńNST •×‹­‰ļ. 2006, 12, •xŽR.

‚»‚Ģ‘¼

  1. –k“‡ŒM:•ŖŽq•a‘Ō‰šĶ–@‚š—p‚¢‚½“Œ—mˆćŠwf’f–@‰š–¾. ćŒ“‹L”O¶–½‰ČŠwą’cŒ¤‹†•ńW19: 65-67, 2005.
  2. –k“‡ŒM:‘ę18‰ńŒ¤‹†‰ļ•ń. ƒtƒH[ƒ‰ƒ€•xŽRu‘n–ņvNews No6: 6-7, 2006.
  3. ‘å’Ė–«‹v:_Œo‰ń˜H‚ĢƒƒJƒjƒYƒ€‚š•ŖŽqƒŒƒxƒ‹‚ʼnš–¾. ŽĄ‹Ę”V•xŽRNo8: 40-42, 2006.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2005”N

’˜‘

  1. –k“‡ŒM:ƒgƒƒ“ƒrƒ“AŽ_‰»ƒXƒgƒŒƒXƒiƒrƒQ[ƒ^[(‘q—ѐ³•FAŽRŠŻ¹ˆź•Ņ)AƒƒfƒCƒJƒ‹ƒŒƒrƒ…[ŽŠAp90-91A2005
  2. –k“‡ŒM:SIRS‚Ģ—Տ°ŒŸø-“]ŽŹˆöŽq‚É‚ę‚é•a‘Ō‰šĶBˆćŠw‚Ģ‚ ‚ä‚Ż:ŒŒ‰tŽ¾Š³-state of arts (ā“c—mˆźA¬ąVŒ[–ē•Ņ)@ˆćŽ•–ņo”ÅŠ”Ž®‰ļŽŠAp272-273A2005
  3. –k“‡ŒM:ŒŒ‰tE‹ĆŒÅü—nŒŸø(“ś–{“œ”A•aŠw‰ļ@•Ņ)A“œ”A•aŠw‚Ģi•ą2005Af’f‚ĘŽ”—ĆŽŠAp50-52A2005
  4. –k“‡ŒM:50l‚Ģź–åˆć‚Ŗ‹³‚¦‚é•a‹C‚ĘŒŸø‚Ģ‚Ķ‚Č‚µB(“ś–{—Տ°ŒŸøˆć‰ļ@ŠÄC)A(ŽŠ)“ś–{‰q¶ŒŸøŠ‹³‰ļA(Š”)Æ‰_ŽŠAp60-62A2005

Œ“’˜

  1. Wang J, Tokoro T, MatsuiK, Higa S, Kitajima I: Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-Akt pathway in endothelial cells. Life Siences 76(19):2257-2268, 2005
  2. Sugimori K, Matsui K, Motomura H, Tokoro T, Wang J, Kimura T, Kitajima I: BMP2 prevents apoptosis of N1511 chodrocytic cells through PI3K/Akt-mediated NF-κB activation. J. Bone Miner. Metab. 23:411-419, 2005
  3. Terauchi R, Arai Y, Takahashi KA, Inoue A, Tonomura H, Asada H, Kishida T, Imanishi J, Mazda O, Kitajima I, Kubo T: The effect of apoptosis signal-regulating kinase 1 gene transfer on rat collagen induced arthritis. J Rheumatol 32(12):2373|2380, 2005
  4. Tanaka Y., Ueda K., Ozawa T., Kitajima I., Okamura S., Morita M., Yokota S., and Imanaka T. :Mutation study of antithrombin: the role of disulfide bonds in the intracellular accumulation and formation of Russell body-like structures. J. Biochem, 137(3):273-285, 2005
  5. Takayama K, Hashimoto N, Tanaka Y, Ozawa T, Emi Y, Ikeda T, Katayama M, Nomura S, Kitajima I, Nakano T, Imanaka T: Identification of a novel aminoacid deletion mutation and a very rare single nucleotide variant in a Japanese family with type 1 antithrombin deficiency. Thromb. Res 116:215-221, 2005
  6. Michino J, Hata Y, Matsui K, Takizawa H, Kominato Y, Tabata S, Nishino K, Yasumura S, Kitajima I: Demonstration of a antigen and a allele ofABOhisto-blood group in nail in a case with the absence of a antigen and anti-A antibody in blood. Legal Medicine 7:194-197, 2005
  7. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A: TGF-b and Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transcription. Mol. Biol. Cell. 16(4):1987-2002, 2005
  8. Kakunaga S, Ikeda W, Ito S, Deguchi-Tawarada M, Ohtsuka T, Mizoguchi A, Takai Y: Nectin-like molecule-1/TSLL1/SynCAM3: a novel tissue-specific immunoglobulin-like cell-cell adhesion molecule localizing at non-junctional contactsites of presynaptic nerveterminals, axons and glia cell processes. J Cell Sci 118:1267-1277, 2005
  9. Inagaki M, Irie K, Ishizaki H, Tanaka-Okamoto M, Morimoto K, Inoue E, OhtsukaT, Miyoshi J, Takai Y: Roles of cell-adhesion molecules nectin 1and nectin 3 in ciliary body develoment. Development 132:1525-1537, 2005
  10. Hagiwara A, Fukagawa Y, Deguchi-Tawarada M, Ohtsuka T, Shigemoto R: Differentiatial distribution of release-relatedproteins in the hipocampal CA3 area as revealed by freeze-fracture replica labeling. J Comp. Neurol. 489:195-216, 2005
  11. Ohhara-Imaizumi M, Ohtsuka T, Matsushima S, Akimoto Y, Nishiwaki C, Nakamichi Y, Kikuta T, Nagai S, Kawakami H, Watanabe T, Nagamatsu S: ELKS, a protein structurally related to the active zone-associated protein CAST, is expressed in pancreatic β cells and functions in insulin exocytosis: Interaction of ELKS with exocytotic machinery analyzed by total internal reflection fluorescence microscopy. Mol. Biol. Cell. 16:3289-3300, 2005
  12. Deguchi-Tawarada M, @Inoue@E, Takao-Rikitsu E, Unoue M, Kitajima I, @Ohtsuka, T., and Takai Y: The active zone protein CAST is a component of conventional and ribbon synapses in mouse retina. J. Comp. Neurol. 495:480-96, 2006.
  13. ā–{ƒŽqAŠp“c”ü—éA–k“‡ŒM:–«ŠĢŽ¾Š³‚É•¹”­‚µ‚½“œ”A•a‚É‚Ø‚Æ‚éƒOƒŠƒRƒAƒ‹ƒuƒ~ƒ“‚Ģ—Տ°“I•]‰æB“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‰ļŽ30(1):85-88A2005
  14. ŽÄ‘„ŽqAX“c”üA‘å–å—Ē’jA–k“‡ŒM:“œ”A•a•a‘Ō”cˆ¬‚É‚Ø‚Æ‚éƒAƒfƒCƒ|ƒlƒNƒ`ƒ“‘Ŗ’č‚ĢˆÓ‹`\ƒAƒfƒCƒvƒlƒNƒ`ƒ“’lAƒgƒŠƒOƒŠƒZƒ‰ƒCƒh’lA‚Š““xCRP’l‚Ø‚ę‚ѐ¶Šˆ—š‚Ę‚Ģ‘ŠŠÖ‰šĶ\B“ś–{—Տ°ŒŸøŽ©“®‰»‰»Šw‰ļ‰ļŽ@30(2):172-176A2005
  15. –ģŽč—Ē„AŠāé—L‰ĄAX“c–¢A‘½‰ź—R‹IŽqA‹g“cˆčŽqA‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒM:‰@“ąŠ“õ‘Īō‚É‚Ø‚Æ‚éˆā“`ŽqŒŸø‚Ģ—L—p«B‘Ļ«ˆā“`Žq‚ĢŒŸo‚Ęˆā“`ŽqŒ^•Ź‚É‚Ā‚¢‚āB“ś–{õF‘Ģˆā“`ŽqŒŸøŠw‰ļŽ23(1):28-36A2005
  16. ‹ąXŽu’ĆŽqA’†‰Ķ—³–ēAŠāé—L‰ĄA‹g“cˆčŽqA•Ä“cˆčŽqA•Ä“c^ŠģŽqA’Ņ“c—R‰Į—˜A—ŃŠģ‘ćŽuA’†‘ŗ­—YA²X–ŲŽūˆźAł“ˆˆĄŠóŽqAĪ‹“ŽjŽqA¬˜H‘”üA¼–ģˆź”üAˆź’J—SŽqAć–ģŸA”–Ų‘¼ŠģŽqA‘O“cŒb”ü:•xŽRŒ§“ą‚ɂ؂Ƃ郁ƒ^ƒ-β-ƒ‰ƒNƒ^ƒ}[ƒ[ŽY¶‹Ū’²ø(‘ę2•ń)B•xŽRŒ§‹ZŽt‰ļ•ń165:A2004
  17. ‰œ“c’‰sAŒKŒ“‘ģ”üAģ“‡–ŅŽuA–ģŽč—Ē„A‘å–å—Ē’jA–k“‡ŒM:S”•Ļ“®ƒXƒyƒNƒgƒ‰ƒ€‰šĶ‚É‚Ø‚ę‚Ś‚·‰e‹æ(‚Ę‚­‚É“śķs“®‚É‚Ā‚¢‚Ä)•xŽRŒ§—Տ°‰q¶ŒŸø‹ZŽt‰ļ‰ļ•ń168:7-9A2005

‘ą

  1. –k“‡ŒM:“]ŽŹˆöŽqNuclear Factor-kappa B (NF-κB)‚©‚ēŽa‚鎾Š³•ŖŽq•a‘Ō‰šĶ\“]ŽŹˆöŽqŠˆ«‰»ŒŸø‚ĢŽ©“®‰»‚ÉŒü‚Ƃā|B“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‰ļŽ 2005;30(1):3-17.
  2. –k“‡ŒM:Ž_‰»ƒXƒgƒŒƒXƒ}[ƒJ[Œ¤‹†‚Ę—Õ°ŒŸø‚Ģ”­“WB—Տ°ŒŸø. 2005;49(2):119-120.
  3. –k“‡ŒM:LPO‚Ę‚»‚ĢŒŸø–@B—Տ°ŒŸø. 2005;49(2):188-91.
  4. –k“‡ŒMAŽÄ‘„Žq:ŒŒ’†ƒAƒfƒBƒ|ƒlƒNƒ`ƒ“‘Ŗ’č‚É‚ę‚é2Œ^“œ”A•a‚Ģ•a‘Ō”cˆ¬BMedical Practice. 2005;22(8):1428.
  5. –k“‡ŒMA•x‰i^‹ÕA‘Oģ^l:ŒŸøŽŗ‚©‚ēŒĀl‚Ę’nˆęBModern Media. 2005;51:1-21.
  6. “c’†—zŽqA–k“‡ŒM:ŒŒŠĒ“ą”ē‹@”\AŒŒ¬”Ā‚Ę‹ĆŒÅü—nŒn:Ś’…•ŖŽqBMedical Technology. 2004;32:1506-10.
  7. ¬ąV“N•vA–k“‡ŒM:ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RĒE‘ę‡ZˆöŽqŒ‡–RĒ(ę“V«ŒŒ‰t‹ĆŒÅˆŁķĒ)B“ś–{—Տ°. 2005;63(3):408-12.
  8. ŽRŒūŒjŽiA–k“‡ŒM:ŒŒšĒ‹}«Šś‚Ģ•a‘Ō”cˆ¬‚É—L—p‚Č‹ĆŒŒ•ŖŽqƒ}[ƒJ[AƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘ĢBŒŸø‚Ę‹Zp 2005;33(8):785-8.
  9. ī’J»ŽqA–k“‡ŒM:RƒKƒ‰ƒNƒgƒVƒ‹IgGR‘ĢB“ś–{—Տ°. 2005;63:469-71.
  10. ŽRŒūŒjŽiA“c’†—zŽqA‚X‰fŽqA–k“‡ŒM:•xŽRˆć‰Č–ņ‰Č‘åŠw•‘®•a‰@ŒŸø‚ę‚ė‚ø‘Š’kŽŗŠJŻ1”N‚ĢŒo‰ß‚Ę‚»‚Ģ–šŠ„B“ś–{—Տ°ŒŸøˆćŠwŠw‰ļŽ. 2005;53(7):609-16.
  11. ‘å’Ė–«‹v:ƒvƒŒƒVƒiƒvƒXƒAƒNƒeƒBƒuƒ][ƒ“‚Ģ\‘¢‚Ę‚»‚Ģ•ŖŽqŠī”ÕCAST‚š‰ī‚µ‚½‹‘å•ŖŽq•”‡‘Ģ‚Ģ‰šĶB×–EHŠw. 2005;24(1):66-71.
  12. ˆĄ‘ŗ•qA–k“‡ŒMA”óŒū“”Ž:—AŒŒŽ–‹Ę‚ĢŒ»ó‚Ę”½ČBŠO‰Č. 2004;66:931-6.

Šw‰ļ•ń

ŠCŠO”­•\

  1. Matsui K, Tsukada K, Sugimori K, Tokoro T, Higa S, Motomura H, Kitajima I: Ets gene PEA3 cooperates with c-Jun in regulation of HER2/neu transcription in breast cancer cell. Keystone Symposia Cancer and Development, Feb5-10, 2005, Banff, CANADA
  2. Ohtuka T: Molecular mechanisms of the presynaptic active zone atructure and function. Max-Plank Institute Dr Nils Brose’s Lab Invited seminar, May17, 2005, Gottingen, Germany
  3. Ohtuka T: Molecular mechanisms of the presynaptic active zone atructure and function. Max-Plank Institute Dr. Suzanne tom Dieck’s Invited seminar, May18, 2005, Frankfrut, Germany
  4. Ohtsuka T: The active zone protein CAST is component of conventional and ribbon synapses in mouse retina. Molecular Anatomy and Physiology of Ribbon Synapses Symposium. Sept. 23-24, 2005, Gottingen, Germany
  5. Tokoro T, Kitajima I: The bihabial abnormality of ATRX hypomorpholic mutant mice. Novartis Institute for Biomedical research, En Li lab meeting. Augst 26, 2005, Boston, USA

‘“ąŠw‰ļ

  1. –k“‡ŒM:ˆÕŒŒš«‚š”cˆ¬‚Å‚«‚é‹ĆŒŒ•ŖŽqƒ}[ƒJ[B‘ę39‰ń“œ”A•aŠw‚Ģi•ąB•½¬17”N2ŒŽ19“ś(å‘ä)
  2. –k“‡ŒM:dĒŠ“õĒ‚É‚Ø‚Æ‚é“]ŽŹˆöŽqNF-κBŠˆ«‰»‚ĢˆÓ‹`‚ʐv‘¬f’f–@ŠJ”­A‚»‚µ‚Ä‚»‚Ģ§Œä‚É‚ę‚鎔—Ɛķ—ŖB‘ę32‰ń“ś–{W’†Ž”—ĆˆćŠw‰ļŠwpW‰ļA•½¬17”N2ŒŽ24“ś(“Œ‹ž)
  3. –k“‡ŒM:—Տ°ŒŸø‚Ģ“Ē‚Ż•ūA—Տ°ŒŸø‚ĢƒsƒbƒgƒtƒH[ƒ‹B‘ę1‰ń“Æ—F‰ļt“śƒNƒŠƒjƒbƒNŒŸfƒZƒ~ƒi[B•½¬17”N6ŒŽ10“ś(“Œ‹ž)
  4. –k“‡ŒM:ŒŒšĒ‹}«Šś‚š‘Ø‚¦‚é‹ĆŒŒ•ŖŽqƒ}[ƒJ[A‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ‚ĢˆÓ‹`‚Ę—Õ°‰ž—pBVŠƒŒŒ—\–hŒ¤‹†‰ļB•½¬17”N6ŒŽ17“ś(VŠƒ)
  5. –k“‡ŒM:ŒŸø’l‚Ģ³‚µ‚¢‰šŽß‚ĢƒgƒŒ[ƒjƒ“ƒOAƒŠƒo[ƒXCPC‚ĢŽĄ‘HA–k—¤’n‹ęˆćŠw¶‡“ƕ׋­‰ļƒZƒ~ƒi[B•½¬17”N7ŒŽ3“ś(•xŽR)
  6. –k“‡ŒM:•xŽRˆć‰Č–ņ‰Č‘åŠwŒŸø‚ę‚ė‚ø‘Š’kŽŗŠJŻ1”N”¼‚ɂ؂Ƃ錟ø‘Š’kŠˆ“®‚Ę‚»‚ĢˆÓ‹`B‘ę30‰ń–k—¤—Տ°•a—W’k‰ļA‘ę13‰ń“ƃZƒ~ƒi[B•½¬17”N9ŒŽ10“ś(‹ą‘ņ)
  7. –k“‡ŒM:SNPs‚š—p‚¢‚½ŒĀ‚ĢŒŸø‚ĘƒI[ƒ_[ƒƒCƒhˆć—ƁB•½¬17”N“x’m“IƒNƒ‰ƒXƒ^[‘n¬Ž–‹Ęu‚Ę‚ā‚܈ć–ņƒoƒCƒIƒNƒ‰ƒXƒ^[v‘ęˆź‰ńBMEŒ¤‹†‰ļE‘ę1‰ńŽ–‹Ę‰»ŒŸ“¢ˆĻˆõ‰ļB•½¬17”N9ŒŽ26“ś(•xŽRŽs•xŽR‹ZpŒš—¬ƒZƒ“ƒ^[)
  8. –k“‡ŒM:“Ę—§s­–@l‰ŗ‚É‚Ø‚Æ‚é‘åŠw•‘®•a‰@ŒŸøŽŗ‚Ģ•Ļ‰»‚ʍ”Œć‚Ģ“W–]B“ś—§ƒnƒCƒeƒNƒmƒƒW[ƒYƒZƒ~ƒi[A•½¬17”N10ŒŽ4“ś(“ś—§“߉ĻŽs)
  9. ‘å’Ė–«‹v:Scaffolding proteins and the active zone funtion:ƒvƒŒƒVƒiƒvƒXŒ¤‹†‚ĢV“WŠJ\•ŖŽq\‘¢‚Ę‚»‚Ģ‹@”\\The Cutting Edge of Presynaptic Research:Molecular mechanisms of presynaptic structure and function. ‘ę28‰ń“ś–{_Œo‰ČŠwŠw‰ļ‘å‰ļA•½¬17”N7ŒŽ26-28“ś@(‰”•l)
  10. ‘å’Ė–«‹v:Scaffolding proteins and the active zone funtion. •xŽR‘åŠwEƒuƒŠƒeƒbƒVƒ…ƒRƒƒ“ƒrƒA‘åŠw_Œo‰ČŠwƒWƒ‡ƒCƒ“ƒgƒ~[ƒeƒ“ƒO2005. •½¬17”N11ŒŽ24“ś(•xŽRŽs)
  11. Šp“c”ü—éAā–{ƒŽqA“c’†—zŽqA–k“‡ŒM:“–‰@‚É‚Ø‚Æ‚éNSTŠˆ“®‚É‚Ā‚¢‚āB‘ę44‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļA•½¬17”N3ŒŽ6“ś(•Ÿˆä)
  12. ŠŻ“c‚Ż‚©A‘½Šģ”Ž•¶A•½–ģPŽiA“”‰ŗ—²AŠā“cŽĄA²“”Œ[AŽRčŸ–ēA‰Y•—‰ėtA¬—ѐ³A¬ąV“N•v:2Œ^“œ”A•a‚ĢŽ”—Ć’†‚É”­Œ©‚³‚ź‚½ˆā“`«‹…óŌŒŒ‹…Ē‚ʐę“V«‘ę5ˆöŽqŒ‡–RĒ‚Ģ‡•¹—įB‘ę102‰ń“ś–{“ą‰ČŠw‰ļu‰‰‰ļB•½¬17”N4ŒŽ9“ś(‘åć)
  13. ™XˆźmA–k“‡ŒMA¼ˆäPŽuAŒ³‘ŗ‘ńAŠ’A‰¤‹e—EA”ä‰ĆiA–Ų‘ŗ—FŒś:“īœ×–EŠ”‚É‚Ø‚Æ‚éBMP-2‚ĢƒAƒ|ƒg[ƒVƒX—}§‹@\B‘ę37‰ń“ś–{Œ‹‡‘gDŠw‰ļŠwp‘å‰ļB•½¬17”N5ŒŽ26“śA•xŽR
  14. ¼–ģŽå^AˆĄ‘ŗ•qA“¹–ģ~ŽqA‘½—t“cĖ‘ćA‹{—ѐē’ߎqA‰„–ģ^‹|A–k“‡ŒM:I&AŽóŒŸ‚É‚ę‚č‰ü‘P‚³‚ź‚½“–‰@‚Ģ—AŒŒ‹Ę–±‚É‚Ā‚¢‚āB‘ę53‰ń“ś–{—AŒŒŠw‰ļ‘‰ļB•½¬17”N5ŒŽ27“śA“Œ‹ž
  15. ‰„–ģ^‹|A“¹–ģ~ŽqA‘½—t“cĖ‘ćA¼–ģŽå^AˆĄ‘ŗ•qA–k“‡ŒM:PeGŽ©ŒČR‘Ģ‹zŽū–@‚Ŗ“ÆŽķR‘Ģ‚É‹y‚Ś‚·‰e‹æB‘ę53‰ń“ś–{—AŒŒŠw‰ļ‘‰ļB•½¬17”N5ŒŽ27“śA“Œ‹ž
  16. –ģŽč—Ē„Aī’J»ŽqAX“c–¢A‘½‰ź—R‹IŽqAā–{ƒŽqA‹g“cˆčŽqA‘å–å—Ē’jAmˆäŒ©‰pŽ÷A–k“‡ŒM:PCR–@‚š—p‚¢‚½v‘¬‚Č×‹Ū“Æ’čƒVƒXƒeƒ€\’zB‘ę30‰ń–k—¤—Տ°•a—W’k‰ļA‘ę13‰ń“ƃZƒ~ƒi[B•½¬17”N9ŒŽ10“ś(‹ą‘ņ)
  17. ī’J»ŽqA–ģŽč—Ē„AmˆäŒ©‰pŽ÷AŠŻ“c‚Ż‚©A–k“‡ŒM:ˆā“`«‹…óŌŒŒ‹…Ē‚ʐę“V«‘ęVˆöŽqŒ‡–RĒ‚Ģ‡•¹—įB‘ę30‰ń–k—¤—Տ°•a—W’k‰ļA‘ę13‰ń“ƃZƒ~ƒi[B•½¬17”N9ŒŽ10“ś(‹ą‘ņ)
  18. ā–{ƒŽqA–k“‡ŒMA–ģ‘ŗŒbŽqA‹ąŒ“O˜a:œ‘ˆŚAŒćBKƒEƒCƒ‹ƒXŠ“õ‚É‚ę‚č”A’†ƒEƒCƒ‹ƒXŠ“õ×–E‚Ŗ”F‚ß‚ē‚ź‚½ˆźĒ—įB‘ę30‰ń–k—¤—Տ°•a—W’k‰ļA‘ę13‰ń“ƃZƒ~ƒi[B•½¬17”N9ŒŽ10“ś(‹ą‘ņ)
  19. ‰œ“c’‰sAć–ģ’q_A‘å–å—Ē’jA–k“‡ŒMA‰Į“”‹P—²:W‡Z‘ī‚É‚Ø‚Æ‚é‘›‰¹B‘ę30‰ń–k—¤—Տ°•a—W’k‰ļA‘ę13‰ń“ƃZƒ~ƒi[B•½¬17”N9ŒŽ10“ś(‹ą‘ņ)
  20. ’J‚Ż‚ĖŽqA”öģ’q”üAģ“‡–ŅŽuA‘å–å—Ē’jA–k“‡ŒM:ƒGƒsƒg[ƒv‚ĢˆŁ‚Č‚é“ńŽķ—Ž‚ĢR‘Ģ‚É‚ę‚éƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ’l˜Ø—£‚Ģ–ā‘č‚Ę‚»‚Ģ—Տ°“IˆÓ‹`B“ś–{—Տ°ŒŸøŽ©“®‰»‰»Šw‰ļ‘‰ļB•½¬17”N9ŒŽ29“ś(‰”•l)
  21. ŽRŒūŒjŽiA–k“‡ŒM:‹Ł‹}ŒŸø‚ĢƒsƒbƒgƒtƒH[ƒ‹B³‚µ‚¢‹Ł‹}ŒŸø‚ĢŽg‚¢•ūB‘ę8‰ń•xŽR‘åŠw•‘®•a‰@Œ¤CˆćƒCƒuƒjƒ“ƒOƒZƒ~ƒi[B•½¬17”N10ŒŽ6“ś(•xŽR)
  22. Y‘ņ˜a•FA—яƒˆźA“y“cŒj‘ :VŠƒ’†‰z’nk”ķŠŽŅ‚É‚Ø‚Æ‚éĆ–¬ŒŒšĒšĒ‚Ę‹ĆŒŒ•ŖŽqƒ}[ƒJ[B‘ę12‰ń”xĒšŒ¤‹†‰ļEŠwpW‰ļB•½¬17”N11ŒŽ5“ś(“Œ‹ž)
  23. Žß‰i“ŽuAa’JLŽqAŽRŒūŒjŽiA’J‚Ż‚ĖŽqA–k“‡ŒMAŽRčŒõĶ:lH•GŠÖß’uŠ·p‚Ģ‹ģŒŒ‘ŃŠJ•ś‚É‚ę‚é‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ‚Ģ•Ļ‰»B‘ę3‰ń–k—¤DICŒ¤‹†‰ļB•½¬17”N11ŒŽ12“ś(‹ą‘ņ)
  24. ŽRŒūŒjŽiA“c’†—zŽqA‚X‰fŽqA–k“‡ŒM:—Տ°ŒŸøˆć‚ĢƒRƒ“ƒTƒ‹ƒeƒBƒ“ƒO‹Ę–±Šˆ“®‚Ģź‚Ę‚µ‚Ä‚Ģ‘åŠw•a‰@ŒŸø•”“ą‚ę‚ė‚ø‘Š’kŽŗŠJŻ1”N‚ĢlŽ@B‘ę52‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB•½¬17”N11ŒŽ18“ś(•Ÿ‰Ŗ)
  25. ‚X‰fŽqA“c’†—zŽqAŽRŒū”ü—éAā–{ƒŽqA–k“‡ŒMB‘ę52‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB•½¬17”N11ŒŽ19“ś(•Ÿ‰Ŗ)
  26. ‰œ“c’‰sA‘å–å—Ē’jA²“”Œ[A–k“‡ŒM:ŠeŽ¾Š³(“œ”A•aA‚ŒŒˆ³A‹N—§«’įŒŒˆ³‹^‚¢)‚É‚Ø‚Æ‚éS”EŒŒˆ³•Ļ“®ƒXƒyƒNƒgƒ‹‰šĶ‚ĢŒŸ“¢B‘ę52‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB•½¬17”N11ŒŽ20“ś(•Ÿ‰Ŗ)
  27. ‘½—t“cĖ‘ćA“¹–ģ~ŽqA¼–ģŽåįĮA‹{—ѐē’ߎqAˆĄ‘ŗ•qA–k“‡ŒM:“–‰@‚ÅŽŽ‚Ż‚½—AŒŒ‚É‚ę‚éCŒ^ŠĢ‰ŠŠ³ŽŅ‚ĢŒ@‚č‹N‚±‚µ‚É‚Ā‚¢‚āB‘ę23‰ń“ś–{—AŒŒŠw‰ļ–k—¤Žx•”‘‰ļA•½¬17”N11ŒŽ19“ś(‹ą‘ņ)
  28. ¼–ģŽåįĮA‘½—t“cĖ‘ćA“¹–ģ~ŽqA‹{—ѐē’ߎqAˆĄ‘ŗ•qA–k“‡ŒM:I&A‚Ģ”FŲ‚šŽó‚ƂāB‘ę23‰ń“ś–{—AŒŒŠw‰ļ–k—¤Žx•”‘‰ļA•½¬17”N11ŒŽ19“ś(‹ą‘ņ)
  29. ‹{—ѐē’ߎqAˆĄ‘ŗ•qA‘½—t“cĖ‘ćA“¹–ģ~ŽqA]”¦˜a”üA¼–ģŽåįĮA–k“‡ŒM:“–‰@—AŒŒE×–EŽ”—Ć•”‚É‚Ø‚Æ‚éŠÅŒģŽt‚Ģ–šŠ„B‘ę23‰ń“ś–{—AŒŒŠw‰ļ–k—¤Žx•”‘‰ļA•½¬17”N11ŒŽ19“ś(‹ą‘ņ)
  30. ‘å’Ė–«‹v:ƒvƒŒƒVƒiƒvƒXƒAƒNƒeƒBƒuƒ][ƒ“‚ɂ؂Ƃ郊ƒ“Ž_‰»ƒvƒƒeƒI[ƒ€B•½¬17”N“x¶—ŠwŒ¤‹†ŠŒ¤‹†‰ļ@ƒVƒiƒvƒX‚Ģˆź¶:’a¶EˆŪŽEœ‹Ž‰ß’ö‚Ģ“‡“I—‰š‚ÖŒü‚ƂāB•½¬17”N12ŒŽ1|2“ś(‰Ŗč)
  31. –k“‡ŒM:—ā‚¦‚Ę’É‚Ż‚É‘Ī‚·‚é˜aŠæ–ņ‚Ģ’TõB˜aŠæ–ņEƒoƒCƒIƒeƒNƒmƒƒW[Œ¤‹†¬‰Ź”­•\‰ļB•½¬17”N12ŒŽ6“ś(•xŽR)
  32. –k“‡ŒM:•xŽR‘åŠw‚Ģ“Œ¼ˆćŠw—Z‡Œ¤‹†‚ĘƒJƒIƒX–¬”gŒv‚š—p‚¢‚½–¬”g‰šĶ‚ĢŽę‚č‘g‚ŻB•½¬17”N“x‰ČŠw‹ZpU‹»’²®”ļu‰ČŠw‹Zp‚É•K—v‚Č’²øŒ¤‹†:Šæ•ūu–¬fvf’f–@‚ĢƒJƒIƒX‰šĶ‚ʉȊw‰»Œ¤‹†•ń‰ļB•½¬17”N12ŒŽ16“ś(Ž­Ž™“‡)

‚»‚Ģ‘¼

  1. –k“‡ŒM:HTLV-TŠÖ˜AŽ¾Š³”­Ē‚É‚Ø‚Æ‚éƒvƒƒEƒCƒ‹ƒXŠ“õ—Ź‚ĘHTLV-I Taxˆā“`Žq•ĻˆŁ‚ĢŠÖ˜A‚ÉŠÖ‚·‚錤‹†B•ZˆćŠwŒ¤‹†U‹»ą’cŒ¤‹†‹ĘŃW:75A2005
  2. –k“‡ŒM:—ā‚¦‚Ę’É‚Ż‚É‘Ī‚·‚é˜aŠæ–ņ‚Ģ’TõBŠÖßƒŠƒEƒ}ƒ`‚É–ņŒų‚šŽ¦‚·“]ŽŹˆöŽqŠˆ«’²ß‹@\‰š–¾B•½¬16”N“xŽó‘õŒ¤‹†˜aŠæ–ņEƒoƒCƒIƒeƒNƒmƒƒW[Œ¤‹†Œ¤‹†¬‰Ź•ń‘:1-14A2005
  3. –k“‡ŒM:˜aŠæ–ņ‚É‚ę‚錌ŠĒV¶“]ŽŹˆöŽq‚ĢŠˆ«‰»§Œä-˜aŠæ–ņ‚ĢV‚µ‚¢Žg‚¢•ū-@•½¬16”N“xŽó‘õŒ¤‹†˜aŠæ–ņEƒoƒCƒIƒeƒNƒmƒƒW[Œ¤‹†Œ¤‹†¬‰Ź•ń‘:69-72A2005
  4. –k“‡ŒM:–{•Ø‚šŒ©‹É‚ß‚éŠįBModern Media 51(February 2):24, 2005
  5. –k“‡ŒM:•½¬17”N“x•ŅWŒć‹LB—Տ°•a—@53(12):1206, 2005

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2004”N

’˜‘

  1. –k“‡ŒM:ƒŠƒsƒbƒhƒp[ƒIƒLƒVƒh(LPO)BL”ĶˆĶŒŒ‰tE”A‰»ŠwŒŸøA–ʉuŠw“IŒŸøy‘ę6”Łz“ś–{—Տ°62Ap530-532A“ś–{—Տ°ŽŠ, “Œ‹žA2004
  2. “c’†—zŽqA–k“‡ŒM:IŒ^ƒRƒ‰[ƒQƒ“C––’[ƒeƒƒyƒvƒ`ƒh(ICTP)BL”ĶˆĶŒŒ‰tE”A‰»ŠwŒŸøA–ʉuŠw“IŒŸøy‘ę6”Łz“ś–{—Տ°62Ap240-243A“ś–{—Տ°ŽŠ, “Œ‹žA2004
  3. “c’†—zŽqA–k“‡ŒM:IŒ^ƒvƒƒRƒ‰[ƒQƒ“C––’[ƒvƒƒyƒvƒ`ƒh(PICP)BL”ĶˆĶŒŒ‰tE‰»ŠwŒŸøA–ʉuŠw“IŒŸøy‘ę6”Łz“ś–{—Տ°62Ap244-246A“ś–{—Տ°ŽŠ, “Œ‹žA2004
  4. ¬ąV“N•vA–k“‡ŒM:ƒ‚ƒfƒ‹“®•ØŠe˜_@ŒŒ¬”Ā. uƒ‚ƒfƒ‹“®•Ø‚Ģģ»‚ĘˆŪŽvX˜e˜a˜Y‘¼•Ņ, 286-292, ƒGƒ‹EƒAƒCEƒV[,“Œ‹ž,2004

Œ“’˜

  1. Wang J, Tokoro T, MatsuiK, Higa S, Kitajima I. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-Akt pathway in endothelial cells. Life Siences 2005;76:2257-68.
  2. Kainuma M, Sakai S, Sekiya N, Mantani N, Ogata N, Shimada Y, Terasawa K. The effects of a harbal medicine (Mao-to) in patients with chronic hepatitis C after injection of IFN-β. Phytomedicine 2004;11:5-10.
  3. Tokoro T, Wang J, Kitajima I. The novel HMG-CoA reductase inhibitor, Pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO). Yakugaku Zasshi. 2004;124:121-6.
  4. Katayama K, Hashimoto N, Tanaka Y, Ozawa T, Emi Y, Ikeda T, Katayama M, Nomura S, Kitajima I, Nakano T, Imanaka T. Identification of a novel amino acid deletion mutation and a very rare single nucleotide variant in a Japanese family with type I antithrombin deficiency. Thromb Res. 2005;116:215-21.
  5. Tanaka Y, Ueda K, Ozawa T, Kitajima I, Okamura S, Morita M, Yokota S, Imanaka T. Mutation study of antithrombin: the role of disulfide bonds in the intracellular accumulation and formation of Russell body-like structures. J Biochem. 2005;137:273-85.
  6. —ŃŽj˜NA“”–Ų–¾A›¶¹‚A²’|ˆÉ’ĆŽqA×’JFŽqAˆäć”Ž:24ŽžŠŌƒzƒ‹ƒ^[S“d}‚š—p‚¢‚½V‚µ‚¢QTŽžŠŌ‚Ģ’č—Ź•]‰æ–@B“ś–{S“d}Šw‰ļŽ2004;24:199-207.
  7. ’†“ˆ»ŽqAŽÄ‘„ŽqA‘å–å—Ē’jA–k“‡ŒM:ŒŒ’†”]«Na—˜”Aƒyƒvƒ`ƒh(BNP)‚Ģ•a‰@ŒŸøŽŗ“±“ü‚É‚Ž‚Æ‚Ä-RIA–@‚©‚ēEIA–@‚Ö‚Ģ“]Š·‚É‚ę‚郋[ƒ`ƒ“‰»\. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‰ļŽ2004;29:617-20.
  8. Šp“c”ü—éA‘å–å—Ē’jA–k“‡ŒMA‘å–ģ‰ėŒ›A–Ų‰ŗ—ĒŽ”:‘’`”’EŽ‰Žæ‰ńŽū—¦Œüć‚š‚ß‚“‚µ‚½’†‹óŽ…–Œ—˜—pƒv[ƒ‹ŒŒ“ģ»•ū–@BˆćŠwŒŸø 2004;53:43-6.
  9. ‘½‰ź—R‹IŽqAŠāé—L‰ĄAX“c”üA‹g“cˆčŽqA—ŃŠģ‘ćŽuA’†‘ŗ­—YA‹ąXŽu’ĆŽqA–k“‡ŒM:•xŽRŒ§“ą14Ž{Ż‚ɂ؂Ƃ郁ƒ^ƒ-β-ƒ‰ƒNƒ^ƒ}[ƒ[ŽY¶‹Ū‚ĢŒŸoó‹µ. ˆćŠwŒŸø2004;53:882-5.
  10. Ōˆä‘ģ–ē, ŽR–{ŒŖ“ń, ”Ń’ĖG–¾, ģćd•F, Š`ĄG–¾, ¬ąV“N•v:“ŖŠWœ‘Šś–ü‡Ē‚Ę”­’B’x‘Ų -FGFRˆā“`ŽqˆŁķ‚ĢŒŸ“¢-. ¬Ž™‚Ģ”]_Œo, 2004;29:224-8.
  11. Sakai M, Kitagawa Y, Yoshida I, Nakagawa T, Mizushima Y, Ochiai H. Bacteriological study on the contamination of flow vase water. •xŽRˆć‰Č–ņ‰Č‘åŠwŠÅŒģŠwŽGŽ. 2003;5:41-8.

‘ą

  1. –k“‡ŒM:ˆćŠw•”‚ĢŠw¶‹³ˆē‰üŠvBLab. Clin. Pract., 22(1):68-76A2004
  2. –k“‡ŒM:•xŽR‚ĢŽYŠw‹¤“ÆŒ¤‹†‚Ķ‚Ē‚±‚܂Ői‚ń‚Å‚¢‚é‚©B-‚ą‚¤ˆź‚Ā‚ĢuƒT[ƒYv\BŽĄ‹Ę”V•xŽR4ŒŽ†:38-40A2004
  3. –k“‡ŒM:“]ŽŹˆöŽq‚ʉŠĒB—Տ°ŒŸø48(3):315-325A2004
  4. –k“‡ŒM:ƒVƒOƒiƒ‹“`’BŒnˆŁķ‚ĘŽ¾Š³B—Տ°‰»Šw33:163-176A2004
  5. –k“‡ŒM:ƒVƒOƒiƒ‹“`’B•a‚Ę‚µ‚Ä‚ĢŒŒšĒBŒŒŠĒˆćŠw5(2):19-28A2004
  6. –k“‡ŒM:‚Š““xCRP‚É‚ę‚鍘’Å’ÅŠŌ”Āƒwƒ‹ƒjƒA‚Ģ•]‰æBMedical Practice 21(11):1923, 2004
  7. Š’A–k“‡ŒM:ƒTƒCƒgƒJƒCƒ“B—Տ°ŒŸø47(13):1687-1692, 2003
  8. ŽRŒūŒjŽiA–k“‡ŒM:ƒgƒƒ“ƒrƒ“EƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“•”‡‘Ģ(TAT)BŒŒšĒŒŸøƒKƒCƒhƒuƒbƒNBŒŒš‚ʏzŠĀ12(4):76-79A2004
  9. ŽRŒūŒjŽiA–k“‡ŒM:FDPAFgDP, @FDP-EBŒŒšĒŒŸøƒKƒCƒhƒuƒbƒNBŒŒš‚ʏzŠĀ12(4):101-104A2004
  10. ŽÄ‘„Žq:ƒAƒfƒBƒ|ƒlƒNƒ`ƒ“‚š‚²‘¶’m‚Å‚·‚©B•xŽRŒ§—Տ°‰q¶ŒŸø‹ZŽt‰ļ‰ļ•ń:7-11, 2004
  11. ‘å–å—Ē’j:Šw‰ļˆóŪ‹L@ˆćŠwŒŸøƒtƒH[ƒ‰ƒ€B@ƒƒfƒBƒJƒ‹ƒŠƒXƒNƒ}ƒlƒWƒƒ“ƒg@Medical Technology 32:868-869, 2004

Šw‰ļ•ń(“Į•Źu‰‰A‹³ˆēu‰‰AƒVƒ“ƒ|ƒWƒEƒ€‚Ģ‚Ż)

  1. Isao Kitajima: Upregulation of Toll-like receptor 2 gene expression in macrophage response to high concentration of lipopolysaccharide is involved in NF-κB activation. Keystone symposia NF-κB: Biology and Pathology, 2004, Jan 19, Solt Lake City, USA
  2. Tokoro T, Kitajima I: Behavioral analyses and molecular pathogenesisi of ATRX mutant mice. Cardiovascular Research Center/MGH Kenneth D. Boch’s Lab Meeting, 2004, 10, 25
  3. –k“‡ŒM:‰F’ˆˆćŠwAŒ¤‹†‚Ģi‚ß•ūBƒX[ƒp[ƒTƒCƒGƒ“ƒXƒnƒCƒXƒN[ƒ‹(SSH)–k—¤’n‹ęŒš—¬‰ļA•½¬16”N2ŒŽ15“śA(•xŽRŽsA•xŽRŒ§—§•xŽR‚Z)
  4. –k“‡ŒM:”xŒŒšĒšĒ‚Ę‹ĆŒŒƒ}[ƒJ[BONOƒXƒvƒŠƒ“ƒOƒtƒH[ƒ‰ƒ€inŽRŒ`B•½¬16”N6ŒŽ23“ś(ŽRŒ`)
  5. –k“‡ŒM:ƒiƒmƒeƒNƒmƒƒW[‚šŠˆ—p‚µ‚½21¢‹IŒ^—Տ°ŒŸø\’zB•½¬15”NŒś¶˜J“­‰ČŠwŒ¤‹†:ƒiƒmƒƒfƒVƒ“ƒtƒH[ƒ‰ƒ€NMF2003(III)Aƒiƒmƒ}ƒCƒNƒƒCƒ[ƒWƒ“ƒO‚Ģˆć—Ɖž—pB•½¬16”N3ŒŽ18“ś(“Œ‹žƒrƒbƒOƒTƒCƒg)
  6. –k“‡ŒM:“Ę—§s­–@l‰»‚É‚Ø‚Æ‚é‘åŠw•a‰@ŒŸø•”B•½¬16”N“x‘S‘ŒŸø‹ZŽt‰ļ‘å‰ļB•½¬16”N5ŒŽ13“ś(•xŽRŽs)
  7. –k“‡ŒM:ˆā“`Žqī•ń‚š‘g‚Żž‚ń‚¾21¢‹IŒ^—Տ°ŒŸø‚Ģ\’zB‘ę53‰ń“ś–{ˆćŠwŒŸøŠw‰ļB•½¬16”N5ŒŽ15“ś(•xŽRŽs)
  8. –k“‡ŒM:ƒƒRƒ‚[ƒVƒ‡ƒ“ƒTƒCƒGƒ“ƒX‚Ę‚Ģ•ą‚ŻB‹ß‹E’ß—Ė‰ļ‘‰ļA•½¬16”N6ŒŽ12“ś(‘åć)
  9. –k“‡ŒM:“Ę—§s­–@l‰»‚šŒ}‚¦‘Å‚Ā‘åŠw•a‰@ŒŸø•”B‘ę23‰ń“ś–{—Տ°‰»Šw‰ļ‰ÄŠśƒZƒ~ƒi[B•½¬16”N7ŒŽ15“ś(Ž­Ž™“‡Žs)
  10. –k“‡ŒM:•a‰@ŒŸø•”‚šŠˆ—p‚µ‚½‘²‘OE‘²ŒćŒŸø‹³ˆē‚Ģ‚ ‚č•ūB‘ę23‰ń“ś–{—Տ°‰»Šw‰ļ‰ÄŠśƒZƒ~ƒi[B•½¬16”N7ŒŽ15“ś(Ž­Ž™“‡Žs)
  11. –k“‡ŒM:ŒŒš‹}«Šśf’f‚É‘Ī‰ž‚Å‚«‚éƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•”‡‘Ģ‚ĢPOCT“±“ü‚ÉŒü‚ƂāB‘ę51‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļƒCƒuƒjƒ“ƒOƒZƒ~ƒi[B•½¬16”N9ŒŽ4“ś(“Œ‹ž)
  12. –k“‡ŒM:“Ę—§s­–@l‰ŗ‚É‚Ø‚Æ‚é21¢‹I‘Ī‰žŒ^ŒŸø•”‚É‚Ž‚ƂāB–kŠC“¹‘åŠw•‘®•a‰@ŒŸø•”ƒZƒ~ƒi[B•½¬16”N11ŒŽ5“ś(ŽD–y)
  13. –k“‡ŒM:•xŽRˆć‰Č–ņ‰Č‘åŠw•a‰@‚É‚Ø‚Æ‚éNST—§‚æć‚°‚ʍ”Œć‚Ģ“W–]:•a‰@ŒŸø•”‚Ģ—§ź‚©‚ēB‘ę2‰ń–kŠC“¹‘åŠwNSTu‰‰‰ļB•½¬16”N11ŒŽ5“ś(ŽD–y)
  14. –k“‡ŒM:ŒŒšŒ`¬‹}«Šś‚š”½‰f‚·‚é‹ĆŒŒ•ŖŽqƒ}[ƒJ[‚š’T‚éB‘ę7‰ń“ś–{šŽqŒŸo‚ĘŽ”—ĆŠw‰ļ‘å‰ļB•½¬16”N12ŒŽ5“ś(‰”•l)

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2003”N

’˜‘

  1. –k“‡ŒM:•›bó‘B‹@”\ŒŸøAˆćŠw‘‰@ˆćŠw‘厫“T(ˆÉ“”³’jAˆä‘ŗ—T•vA‚‹vŽj–›•Ņ)A“Œ‹žAˆćŠw‘‰@pp2138A2003
  2. ¬•ū‘„•v:ƒfƒ‹ƒ^(DŒ^)ŠĢ‰ŠƒEƒCƒ‹ƒXƒQƒmƒ€:“ĮˆŁ“I‚ČƒQƒmƒ€\‘¢E•”»‚Ę•aŒ“«‚Ę‚ĢŠÖ˜ABV¢‹I‚ĢŠ“õĒŠw(‰ŗŠŖ):ƒQƒmƒ€EƒOƒ[ƒoƒ‹Žž‘ć‚ĢŠ“õĒƒAƒbƒvƒf[ƒgB(ŽRŒūŒbŽOAŠā–{ˆ¤‹g•Ņ)A“ś–{—Տ°ŽŠA“Œ‹žApp634-639, 2003
  3. ¬•ū‘„•vA“‡–Ų‹M‹vŽqAŒKŽē”üē‘ćA‚“‡C‘¾˜YA“n•Ó–¾Ž”:ƒEƒCƒ‹ƒXŠĢ‰Š‘Īō:ˆć—ĆŒnŠw¶‚ĢBŒ^ŠĢ‰ŠƒƒNƒ`ƒ“ŚŽķó‹µ‚Ø‚ę‚ŃŠl“¾HBsR‘Ģ•]‰æ‚Ģ–ā‘čBCAMPUS HEALTH‘ę40ŠŖA‘S‘‘åŠw•ŪŒ’ŠĒ—‹¦‰ļA‹ž“sApp252-253, 2003

Œ“’˜

  1. Shibakura M, Niiya K, Kibuchi K, Kitajima I, Niiya M, Asaumi N, Huh N-K, Nakata Y, Harada M, Tanimoto M. Induction of interleulin-8 and monocyte chemoattractant protein-1 by doxorubicin in human small-cell lung cartinoma cells. Int J Cancer. 2003;103:380-6.
  2. Sarker KP, Biswas KK, Yamakuchi M, Lee KY, Hashiguchi T, Kuracht M, Kitajima I, Maruyama I. ASK-1-p38 MAPK/JNK signaling cascade mediates anandamide-ondeced PC12 cell death. J Neurochem. 2003;85(1):50-61.
  3. Arisato T, Sarker KP, Kawahara K, Nakata M, Hashiguchi T, Osame M, Kitajima I, Maruyama I. The agonist of the protease-activated receptor1- (PAR) but not PAR3 mimics@thrombin-inducedvascular endothelial growth factor release in human smooth muscle cells. Cell Mol Life Sci. 2003;60(8):1716-24.
  4. Sugimori K, Kawaguchi Y, Morita M, Kitajima I, Kimura T. High-sensitive analysis of serum C-reactive protein in young patients with lumbar disc herniation. J Bone Joint Surg Br. 2003;85(8):1151-4.
  5. Ogata N, Ichida T, Aoyagi Y, Kitajima I. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC). Direct sequencing method for detecting lamivudene-resistant hepatitis B virus (HBV) variants with high sensitive and specificity. J Jpn Soc Lab Med. [Rinsho Byori] 2003;51:313-9.
  6. Ogata N, Takashima S, Shimaki K, Kuwamori M, Kitajima I, Watanabe A. Antibody to hepatitis B surface antigen (anti-HBs) induced by recombinant hepatisis B vaccine consisting of subtype adr antigen is underestimayed on the World Health Organization (WHO)-standardized assay. Inter Med. 2003;42(5):446-7.
  7. Okoshi S, Ogata N, Ichida T: The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5 year observation. Hepatol Res. 2003;27:13-7.
  8. ˆĄ‘ŗ•qA”óŒū“”ŽA‘½—t“cĖŽqA“¹–ģ~ŽqA¼–ģŽåįĮAŽOč‘ń˜YA–k“‡ŒMA“nē²–¾Ž”A‰–Œ“NŽiA•½ˆä”£A¼–ģŽ”gA’bŽ”—Fŗ:RIgAR‘Ģ•Ū—LŽŅ‚ĢR‘Ģ‰æ‘Ŗ’č‚ĢˆÓ‹`‚Ę—AŒŒć‚Ģ‘Ī‰žB“ś–{—AŒŒŠw‰ļŽGŽ49(5)646-652A2003
  9. Šāé—R‰ĄAX“c–¢A‘½‰ź—R‹IŽqA–ģŽč—Ē„A‹g“cˆčŽqA¬ąV“N•vA–k“‡ŒM:Serratia marcescens‚Ģnuclease‚É‚ę‚éPCRŽY•Ø‚Ģ•Ŗ‰š. ŒŸø‚Ę‹Zp. 2003;13:468-9.
  10. ‰œ“c’‰sA¼ˆäĖŽqAŽÄŒ“’¼—˜AŠÖŖ“¹˜aAć–ģ’q_A‘å–å—Ē’jA–k“‡ŒM:ŒŒ‰tƒKƒX•ŖĶ‹@Šķ‚Ģ‘Šˆį‚É‚ę‚éPaCO2’l˜Ø—£‚ĢŒŸ“¢. —Տ°ŒŸø 2003;47:553-8.
  11. ‰„–ģ^‹|¤Šp“c”ü—餗юj˜N¤‘å–å—Ē’j¤–k“‡ŒM¤‘å–ģ‰ė”Ķ¤–Ų‰ŗ—ĒŽ”:‘Ca‘Ŗ’č‚É‚Ø‚Æ‚é–ā‘č“_‚Ę‚»‚Ģ‰ü—Ē–ņ-uƒGƒXƒpECav-‚Ģ—L—p«@ˆć—Ć‚ĘŒŸø‹@ŠķEŽŽ–ņ. 2003;26(3):235-9.
  12. ‰œ“c’‰s¤–ģŽč—Ē„AŒKŒ“‘ģ”üAģ“‡–ŅŽuA‘å–å—Ē’jA”~–ģŽg:Žs–ƃ‰ƒ“ƒi[‚š‘ĪŪ‚Ę‚µ‚½D‹C“IEŒ™‹C“IƒgƒŒ[ƒjƒ“ƒOŒų‰Ź‚Ģ•]‰æ\Ž©Šo“IÅ‘åŽ_‘fŪŽę—Ź(peakVO2)AŒ™‹C“I‘ćŽÓˆę’l(AT)‚Ø‚ę‚ѐ¶‰»Šw•ŖĶ‚ę‚č[•xŽRŒ§—Տ°ŒŸ‰q¶ŒŸø‹ZŽt‰ļŽ. 2003;29:9-11.
  13. ‘½‰ź—R‹IŽqAŠāé—R‰ĄA, X“c–¢A–ģŽč—Ē„A‹g“cˆčŽqA¬ąV“N•vA–k“‡ŒM:ƒƒ^ƒ[β-ƒ‰ƒNƒ^ƒ}[ƒ[ŽY¶‹Ū‚Ģ•Ū—L’²øB•xŽRŒ§—Տ°‰q¶ŒŸø‹ZŽt‰ļŽ. 2003;29:16-9.
  14. ŒKŒ“‘ģ”üAā–{ƒŽqAī’J»ŽqA“c‘ŗ‚Č‚Ø‚ŻA¬ąV“N•vA–k“‡ŒM:ITP‚Ŗˆā“`‚·‚éBę“V«ŒŒ¬”ĀŒø­ĒBMedical Tecnology. 2003;31:893-6.

‘ą

  1. –k“‡ŒM:œ‹zŽūƒ}[ƒJ[;ƒfƒIƒLƒVƒsƒŠƒWƒmƒŠƒ“AIŒ^ƒRƒ‰[ƒQƒ“‰Ė‹“N-ƒeƒƒyƒvƒ`ƒh(NTTx)AIŒ^ƒRƒ‰[ƒQƒ“Cƒeƒƒyƒvƒ`ƒh(ICTP). ‘‡—Տ°. 2003;52:101-7.
  2. –k“‡ŒM:ˆćŠw‹³ˆēŽĄ‘H‚Ģź‚Ę‚µ‚Ä‚Ģ‘åŠwŒŸø•”‚Ģ–šŠ„. JACLaP News 2003;68:4-5.
  3. –k“‡ŒM:ƒVƒŠ[ƒYÅVˆćŠwuĄ„II. ƒVƒOƒiƒ‹“`’BŠT—v. —Տ°ŒŸø 2003;47(1):89-101.
  4. –k“‡ŒM¤“Ž—ĒM—YAać‰ėŽjA‘Oģ^l:V‚µ‚¢ŒŒ“ƒ}[ƒJ[. Medico. 2003;34(4):16-30.
  5. –k“‡ŒM:—Տ°ŒŸøˆćŠw‚ĢƒRƒAEƒJƒŠƒLƒ…ƒ‰ƒ€‚Ö‚Ģ‘Ī‰ž(‘—§‘åŠw). —Տ°•a—. 2003;51:357-61.
  6. –k“‡ŒM:‘²‘O‚ĢŒŸøˆćŠw‹³ˆē‚É‚Ø‚Æ‚éŽĄK‚Ģ‚ ‚č•ū. —Տ°•a—. 2003;51:983-94.
  7. –k“‡ŒM:‘å‘Śœ“Ŗ‰óŽ€‚ĘƒAƒ|ƒg[ƒVƒX. ˆćŠw‚Ģ‚ ‚ä‚Ż. 2003;205(10):824-8.
  8. –k“‡ŒM:ˆā“`Žqī•ń(SNPsAƒVƒOƒiƒ‹“`’B)‚šŠˆ—p‚µ‚½Ž¾Š³•ŖŽq•a‘Ō‰šĶŒŸø. “ś–{—Տ°‰»Šw‰ļ‹ćBŽx•”—į‰ļŽ. 2003;13:1-10.
  9. ¬•ū‘„•v:SIRS. sespsis‚Ę”sŒŒĒ:’č‹`‚ĢˆÓ‹`‚ʍ”Œć. ‰»Šw—Ć–@‚Ģ—Ģˆę. 2003;19:941-6.
  10. ‰„–ģ^‹|A–k“‡ŒM:‚MgŒŒĒ‚š‚Ż‚½‚ēCa‘Ŗ’č–@‚É’ˆÓ. Medical Practice. 2003;20:695.
  11. ī’J»Žq¤–k“‡ŒM:ŠÖßƒŠƒEƒ}ƒ`f’f‚ɂ؂Ƃ郊ƒEƒ}ƒgƒCƒhˆöŽq‚ĘMMP3“ÆŽž‘Ŗ’č‚Ģ—L—p«. Medical Practice. 2003;20(8):1417.
  12. ā–{ƒŽqA–k“‡ŒM:–«ŠĢŽ¾Š³‚É•¹”­‚µ‚½“œ”A•a‚ĢŒŒ“œƒRƒ“ƒgƒ[ƒ‹Žw•W‚ɉ½‚ŖÅ“K‚©. Medical Practice. 2003;20(11):1955.

Šw‰ļ•ń(“Į•Źu‰‰A‹³ˆēu‰‰AƒVƒ“ƒ|ƒWƒEƒ€‚Ģ‚Ż)

  1. –k“‡ŒM:ŠÖßƒŠƒEƒ}ƒ`‚Ģœ”j‰ó‚ʍœ‘e頏Ē”­ĒƒƒJƒjƒYƒ€. ‘ę1‰ńŒF–{œ‘e頏ĒŒ¤‹†‰ļ@2003”N2ŒŽ15“ś(ŒF–{)
  2. –k“‡ŒM: ˆā“`ī•ń(SNPs, ƒVƒOƒiƒ‹“`’B)‚šŠˆ—p‚µ‚½Ž¾Š³•ŖŽq•a‘Ō‰šĶ. ‘ę13‰ń—Տ°‰»Šw‹ćBŽx•”‘‰ļ@2003”N2ŒŽ22“ś(•Ÿ‰Ŗ)
  3. –k“‡ŒM:¶ŠˆKŠµ•a‚É‚Ø‚Æ‚é“]ŽŹˆöŽq’²ßˆŁķ‚Ę•ŖŽq•a‘Ō‰šĶ. ‘ę47‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‹ćB’n•ū‰ļ@2003”N2ŒŽ22“ś(•Ÿ‰Ŗ)
  4. –k“‡ŒM:ˆā“`ī•ń‚š‚¢‚©‚Ɉć—ĆŒ»ź‚É“`‚¦‚é‚©. “ś—§ƒnƒCƒeƒNƒmƒƒW[ƒYEƒ‰ƒCƒtƒTƒCƒGƒ“ƒXƒZƒ~ƒi[@2003”N3ŒŽ6“ś(“ś—§“߉ĻŽs)
  5. –k“‡ŒM::‚Ē‚¤‚·‚éE‚Ē‚¤‚Č‚é—Տ°ŒŸø. ‘ę26‰ń“ś–{ˆćŠw‰ļ‘‰ļ•Ŗ‰Č‰ļ‘ę7‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“Į•Ź—į‰ļ@2003”N4ŒŽ3“ś(•Ÿ‰Ŗ)
  6. –k“‡ŒM:ƒ|ƒXƒgƒV[ƒPƒ“ƒXŽž‘ć‚Ģ—Տ°ŒŸøˆćŠw‚Ę“Ę—§s­–@l‰»Œć‚ĢŒŸø•”‚šl‚¦‚é. MB‘åŠwŒŸø•”ƒZƒ~ƒi[@2003”N10ŒŽ14“ś(¼–{)
  7. –k“‡ŒM:ŒŒšĒ—\’mƒ}[ƒJ[‚Ę‚µ‚Ä‚Ģ‰Ā—n«ƒtƒBƒtƒŠƒ“ƒ‚ƒmƒ}[‘Ŗ’č‚Ģ—L—p«B‘ę50‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļƒ‰ƒ“ƒ`ƒZƒ~ƒi[@2003”N10ŒŽ30“ś(L“‡)
  8. –k“‡ŒM::œ‘ćŽÓˆŁķ‚©‚ē‚Ż‚½ŠÖßƒŠƒEƒ}ƒ`‚Ģ•a‘ŌB‘ę12‰ń‹ž“sœ‘ćŽÓŒ¤‹†‰ļB2003”N11ŒŽ6“ś
  9. –k“‡ŒM:œ‘ćŽÓˆŁķ‚©‚ē‚Ż‚½ŠÖßƒŠƒEƒ}ƒ`‚Ģœ”j‰ó‹@˜B‘ę76‰ń“ś–{®Œ`ŠO‰ČŠw‰ļŠwpW‰ļB2003”N5ŒŽ25“ś(‹ą‘ņ)
  10. –k“‡ŒM:Į‰»ŠķŽ¾Š³‚É‚Ø‚Æ‚éReversed CPCB•½¬15”N“x•xŽRˆć‰Č–ņ‰Č‘åŠwŒöŠJuĄ@2003”N8ŒŽ3“ś(•xŽR)
  11. –k“‡ŒM:“®–¬d‰»Up to date. @‘ę17‰ń’†•”’n‹ę¶—ŒŸøŒ¤C‰ļB2003”N11ŒŽ15“ś(‚‰ŖŽs)
  12. ¬•ū‘„•v:ĒŒó‚©‚ē‚Ż‚½• •”’“‰¹”gf’f‚Ģ‚·‚·‚ß•ūB•½¬15”N“x•xŽRˆć‰Č–ņ‰Č‘åŠwŒöŠJuĄ@2003”N8ŒŽ3“ś(•xŽR)
  13. Ozawa T., Tanaka Y., Imanaka T., Kitajima:Intracellular behavior of antithrombin Morioka (Cys95Arg), a mutant protein causing type I deficiency: escape from intracellular protein degradation systems and accumulation within newly formed Russell Body-like structures. The International Society on Thrombosis and haemostasis, XIX Congress, Oral Communication, July 2003, Birmingham, UK
  14. Kitajima I: Development of Laboratory testing systems and Research for new biomarker. Seminar of Pathology Core Lab and Biomarker Discovery Center, Johns Hopkins Medical Institutions. 2003, 12, 1
  15. Tokoro T, Kitajima I: The novel HMG-CoA reductase inhibitor, Pitavastatin. Induce a protective action in vascular endothelial cells through the production of nitric oxide. Cardiovascular Research Center/MGH Kenneth D. Boch’s Lab Meeting, 2003, 11, 24
  16. Tokoro T, Kitajima I: Behavioral analyses of ATRX mutant mice. Novaritis Institutes for BioMedical Research. En Li lab Meeting. 2003, 11, 25

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2002”N

’˜‘

  1. –k“‡ŒMA—«•FAŠŪŽRŖ˜Y:ƒ}ƒNƒƒtƒ@[ƒW‚É‚Ø‚Æ‚éToll-like receptor 2. 4‚Ģˆā“`Žq”­Œ»’²ß‹@\ ƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†5(–]ŒŽ‰p—¤A¬–ģ‘A¬‹Ź³’qA‰”’n‚ŽuA’J“OA•Ņ) ˆćŠw}‘o”ÅŠ”Ž®‰ļŽŠA“Œ‹žA2002Ap152-159
  2. ¬•ū‘„•v:Peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)‚ĢŠJ”­E‰ž—p‚É‚Ø‚Æ‚éYMDDƒ‚ƒ`[ƒt‰–Šīƒ_ƒCƒiƒ~ƒNƒX‚Ģ‰šĶ(’Jģ‹vˆź, ‘¼)ŠĢŽ¾Š³Œ¤‹†‚ĢV‚µ‚¢“WŠJ‘ę‡WŠŖAƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽŠA‘åćA2002A8

Œ“’˜

  1. Shoji Y, Noguchi A, Shoji Y, Matsumori M, Takasago Y, Takayanagi M, Yoshida Y, Ihara K, hara T, Yamaguchi S, Yoshino M, Kaji M, Yamamoto S, Nakai A, Koizumi A, Hokezu Y, Nagamatsu K, Mikami H, Kitajima I, Takada G. Five novel SLC7A7 variants and y+L gene-expression pattern in cultured lymphoblasts from Japanese patients with lysinuric protein intolerance. Hum Mutat. 2002;20(5):375-81.
  2. Yamahata H, Takeshima H, Kuratsu J, Sarker KP, Tanioka K, Wakimaru N, Nakata M, Kitajima I, Maruyama I. The role of thrombin in the neo-vascularization of malignant gliomas: An intrinstic modulator for the up-regulation of vascular endothelial growth factor. Int J Oncol. 2002;20(5):921-8.
  3. Obara S, Nakata M, Takeshima H, Kuratsu J, Maruyama I, Kitajima I. Inhibition of migration of human cells by ceribastatin in association with focal adhesion kinase (FAK). Cancer Lett. 2002;185(2):153-61.
  4. Nishimura S , Nakata M, Matsuo K, Nakajima T, Kitajima I, Saito H, Maruyama I. Human lactiferous mammary gland cells produce vascular endothelial growth factor (VEGF) and express the VEGF receptors, Flt-1 and KDR/Flk-1. Cytokine. 2002;18(4):191-8.
  5. Tezono K, Sarker KP, Kikuchi H, Nasu M, Kitajima I, Maruyama I. Bioactivity of the vascular endothelial growth factor trapped in fibrin clots: production of IL-6 and IL-8 in monocytes by fibrin clots. Haemostasis. 2002;31(2):71-9.
  6. Kainuma M, Ogata N, Kogure T, Kohta K, Hattori N, Mitsuma T, Terasawa K. The efficacy of a herbal medicine (Mao-to) in combination with intavenous natural interferon-beta for patients with chronic hepatitis C genotype 1b and high viral load: a pilot study. Phytomedicine. 2002;9:365-72.
  7. Ohkoshi S, Igarashi M, Suda T, Ogata N. Remote development of hepatocellular cartinoma in patients with liver cirrhosis type B serologically cured for HBs antigenemia with long-standing normalization of ATL values. Dig Dis Sci. 2002;47:2002-6.
  8. Tanaka Y, Ueda K, Ozawa T, Sakuragawa N, Yokota S, Sato R, Okamura S, Morita M, Imanaka T. Intracellular Accumulation of Antithrombin Morioka (Cys95Arg), A Novel Mutation Causing Type I Antithrombin Deficiency. J Biol Chem. 2002;277, 51058-67.
  9. Akai T, Iizuka H, Kishibe M, Kawakami S, Kobayashi A, Ozawa T. A Case of Beare-Stevenson Cutis gyrata Syndrome Confirmed by Mutation Analysis of the Fibroblast Growth Factor Receptor 2 Gene. Pediatr Neurosurg. 2002;37:97-9.
  10. –k“‡ŒMA—«•FAŠŪŽRŖ˜Y. Toll like receptor (TLR)‚š‰ī‚·‚é“]ŽŹˆöŽqNF-κBŠˆ«‰»•ŖŽq‹@\‚ĘƒAƒ“ƒ`ƒZƒ“ƒXNF-κB‚É‚ę‚éƒGƒ“ƒhƒgƒLƒVƒ“ŒŒĒŽ”—Ć–@ŠJ”­. ƒGƒ“ƒhƒgƒLƒVƒ“ŒŒĒ‹~–½Ž”—ĆŒ¤‹†‰ļŽ. 2001;5:173-7.
  11. ¬ąV“N•v. ŒŒš«Ž¾Š³‚Ģ—\’mEf’f‚É–š—§‚Ā‹ĆŒÅEü—nŒŸø\ˆā“`ŽqŒŸø‚šŠÜ‚Ž-B“ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‰ļŽ 2002;27:131-4.
  12. ‰œ“c’‰sA²“”Œ[A‘åŠp½Ž”AŠÖŖ“¹˜aA–k“‡ŒM. Œ’ķ¬l‚É‚Ø‚Æ‚é’j—•Ź‚ĢŒŒˆ³ES”•Ļ“®ƒXƒyƒNƒgƒ‹‰šĶ‚Ģ‰Į—ī‚ĢŒŸ“¢. —Տ°•a—. 2001;50:186-90.
  13. ‰œ“c’‰sA‹g“c–«Aģéŗ‘ćAŽO“śŽsœØŽqA–k“‡ŒMA•Ÿ‰iŽõ°. •xŽRŒ§‚É‚Ø‚Æ‚é12”NŠŌ‚ĢŒŒ‰tƒKƒX•ŖĶƒRƒ“ƒg[ƒ‹ƒT[ƒxƒC‚Ģ•]‰æ. —Տ°ŒŸø. 2002;46:1051-7.
  14. ’J‚Ż‚ĖŽqAģ“‡–ŅŽuA‘å–å—Ē’jA¬ąV“N•vA•½ˆä’‰˜aA–k“‡ŒM. V‚µ‚¢‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[ŽŽ–ņƒI[ƒgLIA FM‚ĢŒŸ“¢:¶SŽØŒŒšĒf’f‚Ģ—L—p«. ˆćŠw‚Ę–ņŠw. 2002;48(4):600-5.

‘ą

  1. –k“‡ŒM:21¢‹I‚ĢƒGƒ“ƒhƒgƒLƒVƒ“ŒŒĒBƒGƒ“ƒhƒgƒLƒVƒ“ŒŒĒ‹~–½Ž”—ĆŒ¤‹†‰ļŽ. 2001;5:184-194.
  2. –k“‡ŒM:ŒJ‚č•Ō‚·ˆÓŽÆįŠQ”­ģ‚ʐ¬l”­ĒŒ^ƒŠƒWƒ“”A«’`”’•s‘ĻĒBMedical Practice. 2002;19:505.
  3. –k“‡ŒM:ƒ|ƒXƒgƒV[ƒPƒ“ƒXŽž‘ć‚Ģ—Տ°ŒŸøÅ‘OüB•xŽRŒ§—Տ°‰q¶ŒŸø‹ZŽt‰ļŽ. 2002;28(1):2-11.
  4. –k“‡ŒM:One Point Meno No182: ŒŒ‰tA”A‚Å‚Ģœ‘e頏Ē‚Ģf’f‚ʏdĒ“x‚Ģ”»’č. @ƒ‚ƒ_ƒ“ƒƒfƒCƒA. 2002;48(4):20-6.
  5. –k“‡ŒM:ƒ|ƒXƒgƒQƒmƒ€Žž‘ć‚É‚Ø‚Æ‚éV‚µ‚¢ŒŸø•”E—Տ°ŒŸøˆćŠw‚Ö‚Ģ’§ķ. •xŽRˆć‰Č–ņ‰Č‘åŠwˆćŠw‰ļŽ. 2002;14(1):27-31.
  6. –k“‡ŒM:“]ŽŹˆöŽq‰šĶ‚šŠī”Õ‚É‚µ‚½Ž¾Š³•ŖŽq•a‘Ō‰šĶŒŸø‚Ö‚Ģ’§ķ. Laboratory and Clinical Practice. 2002;20:79-84.
  7. –k“‡ŒM:“īœ×–E‚ĘƒƒJƒjƒJƒ‹ƒXƒgƒŒƒXBRheumatology. Clinical Update. 2002;8:37-9.
  8. –k“‡ŒM:ˆā“`ŽqŽ”—ƁB—Տ°‚É—L—p‚Čˆā“`ŽqŒŸø. —Տ°•a—ƒŒƒrƒ…[. @2002;123:207-13.
  9. ™XˆźmA–k“‡ŒM:yŠÖßƒŠƒEƒ}ƒ`‚É”ŗ‚¤œ‘e頏Ē‚Ģ•a‘Ō‚ĘŽ”—ƁzƒXƒeƒƒCƒh—U”­«œ‘e頏Ē. ƒŠƒEƒ}ƒ`‰Č. 2002;28(1):24-30.
  10. ¬•ū‘„•v:˜aŠæ–ņ‚É‚ę‚é–ņ•Ø«ŠĢįŠQ\ŒŸø‘Of’f‚Ģ–ā‘č‚ʏ«—ˆ. —Տ°ŒŸø. 2002;46:197-200.
  11. ¬•ū‘„•v:“ą‰Č100”N‚Ģ‚ ‚ä‚Ż(Š“õĒ):”sŒŒĒ. “ś–{“ą‰ČŠw‰ļŽGŽ. 2002;91:2975-82.
  12. ¬ąV“N•v@ŒŒš«Ž¾Š³‚Ģ—\’mEf’f‚É–š—§‚Ā‹ĆŒÅEü—nŒŸø-ˆā“`ŽqŒŸø‚šŠÜ‚Ž-. “ś–{—Տ°ŒŸøŽ©“®‰»Šw‰ļ‰ļŽ. 2002;27:131-4.
  13. –k“‡ŒM:V‚µ‚¢—Տ°ŒŸøˆćŠw‚Ö‚Ģ’§ķ. ’ß—Ė‰ļ‰ļ•ń. 2001;30:18-9.
  14. –k“‡ŒM:EBM(Evidence based medicine)ŽĄŽ{‚É‚Ø‚Æ‚é—Տ°ŒŸøˆć‚Ģ–šŠ„. ˆć•ń‚Ę‚ā‚Ü. 2002;1314:6-7.
  15. –k“‡ŒM:ŽĄŒ±Žŗ‚ɂ؂Ƃ鎊•Ÿ‚ĢuŠŌ. “ą“”‹L”Oą’cŽž•ń. 2002;70:25.

Šw‰ļ•ń

  1. Isao Kitajima, Akihiro Iguchi, Ikuro Maruyama: Molecular role of angiogenesis in hepatocellular cartinoma cells through constitutive interleukin-8 gene expression. Angiogenesis in Cancer and Other Diseases: From Genes to Function to Therapy. Keystone Symposia, 2002, Feb8-13, Banff, Canada.
  2. Isao Kitajima: Topics of angiogenesis in cancer and other diseases. The 18th International Congress of Clinical Chemistry and Laboratory Medicene, 2002 Oct 20-25, Kyoto
  3. Tetsuo Ozawa, Yuki Tanaka, Tsuneo Imanaka, and Isao Kitajima. Antithrombin Morioka (Cys95Arg) Is Accumulated in the Newly Formed Intracytoplasmic Membrane Structures Without Degradation: An Experimental Study. The 29th World Congress of the International Society of Hematology, August 24 - 28, 2002, Seoul.
  4. Isao Kitajima: Molecular role of tumor angiogenesis through constitutivr interleukin-8 gene expression. 5 th Endothelome Conference. 2002, Feb 2, (Okayama)
  5. –k“‡ŒM:ŒŒ‰t‹ĆŒÅ‚Ę“®–¬d‰»i“W‚ĢƒNƒƒXƒg[ƒNB‘ę26‰ńSŒŒŠĒŒn‚Ģ’²ß‚ÉŠÖ‚·‚錤‹†‰ļB2002”N2ŒŽ15“śA“Œ‹ž
  6. –k“‡ŒM:“]ŽŹˆöŽqNF-κBŠˆ«‰»‘Ŗ’čDNAƒ`ƒbƒvŠJ”­‚É‚ę‚éƒGƒ“ƒhƒgƒLƒVƒ“ƒVƒ‡ƒbƒNv‘¬f’fB‘ę18‰ń’†’J“dŽqŒv‘Ŗ‹ZpU‹»ą’cŒ¤‹†•¬u‰‰‰ļB2002”N2ŒŽ22“ś
  7. –k“‡ŒM:ƒGƒ“ƒhƒgƒLƒVƒ“ƒVƒ‡ƒbƒNV‹Kf’f–@ŠJ”­BƒVƒXƒƒbƒNƒbƒXŽŠŒ¤‹†ŠŒ¤‹†ƒZƒ~ƒi[B2002”N3ŒŽ4“śA_ŒĖ
  8. –k“‡ŒM:“]ŽŹˆöŽq‰šĶ‚šŠī”Õ‚É‚µ‚½Ž¾Š³•ŖŽq•a‘ŌŒŸø‚Ö‚Ģ’§ķB‘ę12‰ń“ś–{—Տ°ŒŸøˆć‰ļt‹G‘å‰ļB2002”N4ŒŽ20“śA•Ÿ‰Ŗ
  9. –k“‡ŒM:–«ŠÖßƒŠƒEƒ}ƒ`‚ĢŠÖß”j‰ó‚Ę‚»‚ĢŒŸøŽŽ–ņŠJ”­B‘ę7‰ńƒtƒH[ƒ‰ƒ€•xŽRu‘n–ņvB2002”N5ŒŽ23“śA•xŽR
  10. –k“‡ŒM:‘åŠw•a‰@ƒ}ƒl[ƒWƒƒ“ƒg‰üŠv‚Ę—Õ°ŒŸøˆćŠwuĄEŒŸø‚Ģ«—ˆBŽ­Ž™“‡‘åŠw—Տ°ŒŸøˆćŠwuĄ10Žü”N‹L”O‰ļB2002”N6ŒŽ1“śAŽ­Ž™“‡
  11. –k“‡ŒM:–«ŠÖßƒŠƒEƒ}ƒ`‚Ģœ”j‰ó‹@\B‘ę19‰ń—§ŽRƒZƒ~ƒi[B2002”N7ŒŽ6“śA•xŽR
  12. –k“‡ŒM:‚±‚ź‚©‚ē‚Ģ—Տ°ŒŸø‚Ŗ‚ß‚“‚·‚ą‚ĢBˆā“`Žqī•ń‚š‚¢‚©‚ɗՏ°ŒŸø‚ɉž—p‚µ‚Ä‚ä‚­‚©B‘ę41‰ń’†•”ˆćŠwŒŸøŠw‰ļB2002”N10ŒŽ5“śA•xŽR
  13. –k“‡ŒM:—Տ°ŒŸøˆćŠw‚ĢƒRƒAEƒJƒŠƒLƒ…ƒ‰ƒ€‚Ö‚Ģ‘Ī‰ž(‘—§‘åŠw)B‘ę49‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB2002”N11ŒŽ22“śA‘åć
  14. ģ“‡–ŅŽuAŒKŒ“‘ģ”üA’J‚Ż‚ĖŽqAā–{ƒŽqA‘å–å—Ē’jA–k“‡ŒM:ŒŸø•]‰æƒVƒXƒeƒ€‚Ģ\’zB•½¬13”N“x‘—§‘åŠw•‘®•a‰@ˆć—Əī•ńˆ—•”–å˜A—‰ļ‹cB2002”N1ŒŽO‘O
  15. –ī–ģŹŽqA‰„–ģ^‹|AX“c–¢AŠp“c”ü—éA‘å–å—Ē’jA–k“‡ŒM:ƒfƒ^ƒ~ƒi[LPO‚š—p‚¢‚½‰ßŽ_‰»Ž‰Žæ‚Ģ—Տ°“I—L—p«‚É‚Ā‚¢‚Ä‚ĢŒŸ“¢B‘ę41‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļB2002”N3ŒŽ10“śA‹ą‘ņ
  16. ‰„–ģ^‹|AX“c–¢AŠp“c”ü—éA‘å–å—Ē’jA–k“‡ŒM:‚MgŒŒĒ‚É‚Ø‚Æ‚éƒAƒ‹ƒZƒiƒ]IIIF‘f‚š—p‚¢‚½V‹KƒJƒ‹ƒVƒEƒ€ŽŽ–ņ‚Ģ—L—p«B‘ę41‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļB2002”N3ŒŽ10“śA‹ą‘ņ
  17. ŠpŒū—ŒbAŽÄ‘„ŽqA–ģŽč—Ē„A¬ąV“N•vA–k“‡ŒM:“ń•ō«ƒAƒ‹ƒuƒ~ƒ“‚š’ꂵ‚½1‰ĘŒn‚ĢˆŁķƒAƒ‹ƒuƒ~ƒ“’`”’‰šĶB‘ę41‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļB2002”N3ŒŽ10“śA‹ą‘ņ
  18. ī’J»ŽqAŽÄ‘„ŽqAŠpŒū—ŒbA‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒM:RA‚Ø‚ę‚ŃäPŒ“•aŠ³ŽŅ‚É‚Ø‚Æ‚éƒKƒ‰ƒNƒg[ƒXŒ‡‘¹IgGR‘Ģ‘Ŗ’č‚Ģ—Տ°“I—L—p«‚ĢŒŸ“¢B‘ę41‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļB2002”N3ŒŽ10“śA‹ą‘ņ
  19. —ŃŽj˜NA²’|ˆÉ’ĆŽqA×’JFŽqA“c‘ŗ‚Č‚Ø‚ŻA‘å–å—Ē’jA–k“‡ŒMA›¶–`‚A“”–Ų–¾:ƒzƒ‹ƒ^[S“d}‚É‚Ø‚Æ‚éRR‚ĘQTŽžŠŌ‚Ģ‘ŠŠÖ•ŖĶ‚Ģ•]‰æB‘ę41‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ“ŒŠCE–k—¤Žx•”‘‰ļB2002”N3ŒŽ10“śA‹ą‘ņ
  20. X“c–¢A‰„–ģ^‹|AŠp“c”ü—éA—ŃŽj˜NA‘å–å—Ē’jA–k“‡ŒM:“œ”A•a‚ɂ؂Ƃ鍂Š““xCRP‚Ģ—L—p«B‘ę51‰ńˆćŠwŒŸøŠw‰ļB2002”N5ŒŽ16“śAå‘ä
  21. Šp“c”ü—éA‘å–å—Ē’jA–k“‡ŒMA‘å–ģ‰ė”ĶA–Ų‰ŗ—ĒŽ”:‘ę51‰ńˆćŠwŒŸøŠw‰ļB2002”N5ŒŽ16“śAå‘ä
  22. ī’J»ŽqAŽÄ‘„ŽqAŠpŒū—ŒbA‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒM:RƒKƒ‰ƒNƒg[ƒXŒ‡‘¹IgGR‘Ģ‘Ŗ’č‚É‚Ø‚Æ‚éRA‚ĘäPŒ“•a‚ĢŠÓ•ŹB‘ę33‰ń•xŽRŒ§—Տ°‰q¶ŒŸøŠw‰ļB5ŒŽ22“śA•xŽR
  23. ‰„–ģ^‹|AX“c–¢AŠp“c”ü—éA‘å–å—Ē’jA–k“‡ŒM:O-CPO–@‚Ę”äŠr‚µ‚½ƒAƒ‹ƒZƒiƒ]IIIF‘f‚š—p‚¢‚½V‹KCaŽŽ–ņ‚Ģ—L—p«B‘ę33‰ń•xŽRŒ§—Տ°‰q¶ŒŸøŠw‰ļB5ŒŽ22“śA•xŽR
  24. –k“‡ŒMA¬Œ“‘sˆźAŠŪŽRŖ˜Y:ƒXƒ^ƒ`ƒ“Œn–ņÜ‚Ķ_ŒoäP‰čŽī×–E‚ĢZ‚š—}§‚µAƒAƒ|ƒg[ƒVƒX‚š—U“±‚·‚éB‘ę43‰ń“ś–{_ŒoŠw‰ļ‘‰ļB2002”N5ŒŽ30“śAŽD–y
  25. ģ“‡–ŅŽuAŒKŒ“‘ģ”üA’J‚Ż‚ĖŽqAā–{ƒŽqAī’J»ŽqA‘å–å—Ē•vA–k“‡ŒMBŒŸø•]‰æƒVƒXƒeƒ€‚Ģ‹@”\•]‰æB“ś–{ŒŸøŒŒ‰tŠw‰ļ2002”N7ŒŽ6“śA“Œ‹ž
  26. ’J‚Ż‚ĖŽqAģ“‡–ŅŽuAā–{ƒŽqAī’J»ŽqAŒKŒ“‘ģ”üA‘å–å—Ē•vA–k“‡ŒMA•½ˆä’‰˜a:@V‚µ‚¢‰Ā—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[ŽŽ–ņ‚ĢŠī‘bŒŸ“¢B“ś–{ŒŸøŒŒ‰tŠw‰ļ2002”N7ŒŽ6“śA“Œ‹ž
  27. –k“‡ŒMAņ³˜a:ŒŸø•”–å‚Ģ“WŠJAŠe—Ģˆę‚É‚Ø‚Æ‚é“WŠJB‘ę21‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļA“ŒŠCE–k—¤Žx•”—į‰ļB2002”N8ŒŽ31“śA–¼ŒĆ‰®
  28. –k“‡ŒM¤@–ģ“‡F”V:—Տ°ŒŸø‚Ęˆć—ƉüŠv@?ˆć—Ć‚ĢŽæ‚ĢŒüć‚ĘŠ³ŽŅ’†S‚Ģˆć—Ć‚š–ŚŽw‚µ‚āB‘ę10‰ń–k—¤—Տ°•a—ƒZƒ~ƒi[B2002”N9ŒŽ8“śA•xŽR
  29. ģ“‡–ŅŽuAŒKŒ“‘ģ”üA’J‚Ż‚ĖŽqAā–{ƒŽqAī’J»ŽqA‘å–å—Ē’jA–k“‡ŒM:ŒŸø•]‰æƒVƒVƒeƒ€‚ĢŠˆ—pB‘ę27‰ń–k—¤—Տ°•a—W’k‰ļA2002”N9ŒŽ8“śA•xŽR
  30. ā–{ƒŽqA‰œ“c’‰sA–k“‡ŒMAŽRčŸ–ē:–«ŠĢŽ¾Š³‚É•¹”­‚µ‚½“œ”A•a‚É‚Ø‚Æ‚éƒOƒŠƒRƒwƒ‚ƒOƒƒrƒ“‘Ŗ’č‚Ģ–ā‘č“_‚ĘŒ»óB‘ę27‰ń–k—¤—Տ°•a—W’k‰ļA2002”N9ŒŽ8“śA•xŽR
  31. ™XˆźmAģŒū‘PŽ”A–k“‡ŒMAX“c–¢A‘åXˆź¶A‹ąX¹•FAĪŒ“—T˜aA–Ų‘ŗ—FŒś:®Œ`ŠO‰Č—Ģˆę‚ɂ؂Ƃ鍂Š““xCRPB‘ę27‰ń–k—¤—Տ°•a—W’k‰ļA2002”N9ŒŽ8“śA•xŽR
  32. ī’J»ŽqAŽÄ‘„ŽqA‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒM:RA‚É‚Ø‚Æ‚éMMP-3ƒeƒXƒguBSv‚ĘƒpƒiƒNƒŠƒAMMP-3uƒvƒŒ[ƒgv‚Ę‚Ģ—Տ°“I—L—p«‚Ģ”äŠrŒŸ“¢B‘ę27‰ń–k—¤—Տ°•a—W’k‰ļA2002”N9ŒŽ8“śA•xŽR
  33. ‹g“cˆčŽqAX“c–¢A‘½‰ź—R‹IŽqAŠāé—R‰ĄA–ģŽč—Ē„A‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒM:AŒQ—nƒŒƒ“‹Ū‚É‚ę‚é‰óŽ€«‹Ų–Œ‰Š‚Ģ‹N‚±‚µ‚½2Ē—įB‘ę27‰ń–k—¤—Տ°•a—W’k‰ļA2002”N9ŒŽ8“śA•xŽR
  34. ŒKŒ“‘ģ”üAā–{ƒŽqAī’J»ŽqAģ“‡–ŅŽuA’J‚Ż‚ĖŽqA‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒM:ŒŒ¬”ĀŒø­Ē‚ĢŠÓ•Źf’f‚Ę—Õ°ŒŸøB-ę“V«ŒŒ¬”ĀŒø­Ē‚Ģ1‰ĘŒn‚š—į‚É-B‘ę27‰ń–k—¤—Տ°•a—W’k‰ļA2002”N9ŒŽ8“śA•xŽR
  35. –ģŽč—Ē„AŠāé—L‰ĄAX“c–¢‰ĄB‘½‰ź—R‹IŽqA‹g“cˆčŽqA‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒM. ‘ę41‰ń’†•”ˆćŠwŒŸøŠw‰ļA2002”N10ŒŽ6“śA•xŽR
  36. –k“‡ŒM¤–Ų‘ŗ—FŒś¤ę®’‰l:œŠÖßŽ¾Š³‚É–ņŒų‚šŽ¦‚·Šæ•ū–ņ’Tõ‚Ę‚»‚Ģ“]ŽŹˆöŽq’²ß‹@\‰š–¾. •½¬13”N“x‹³ˆēŒ¤‹†Šw“ą“Į•ŹŒo”ļŽĄŽ{•ń‰ļA2002”N10ŒŽ15“śA•xŽR
  37. ¬•ū‘„•vA–k“‡ŒM:PMPC-DS–@‚É‚ę‚é‹t“]ŽŹy‘fYMDD‰–Šī‰šĶŒn‚ĢŠJ”­‚ʉž—p:HBVEHIV‚Ģ‘Šˆį‚Ę–ņÜ‘Ļ«ƒeƒXƒg. ‘ę49‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB2002”N11ŒŽ22“śA‘åć
  38. ī’J»ŽqAŽÄ‘„ŽqA‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒM:RŠjR‘Ģ—z«Š³ŽŅRA‹y‚ŃäPŒ“•aŠ³ŽŅ‚É‚Ø‚Æ‚éMMP-3ACA. RFŒŸø‚Ģ—Տ°“IˆÓ‹`B‘ę49‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB2002”N11ŒŽ24“śA‘åć
  39. ¬ąV“N•vAŌˆä‘ģ–ēA–k“‡ŒM:“ŖŠWœ‘Šś–ü‡Ē‚É‚Ø‚Æ‚éFGFRˆā“`Žq‰šĶ‚Ģ—Տ°“I—L—p«‚É‚Ā‚¢‚Ä. ‘ę49‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB2002”N11ŒŽ23“śA‘åć
  40. X“c–¢A‰„–ģ^‹|AŠp“c”ü—éA‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒM:“œ”A•aŠ³ŽŅ‚ɂ؂Ƃ鍂Ž‰ŒŒĒ‚ĘCRP’l‚Ę‚ĢŠÖ˜AB‘ę49‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB2002”N11ŒŽ23“śA‘åć
  41. ‰„–ģ^‹|AX“c–¢AŠp“c”ü—éA‘å–å—Ē’jA–k“‡ŒMA‘å–ģ‰ė”ĶA–Ų‰ŗ—ĒŽ”B‚”Z“xMgŒŸ‘Ģ(ŒŒ“‹y‚Ń”A)‚É‚Ø‚Æ‚éƒAƒ‹ƒZƒiƒ]III–@‚š—p‚¢‚½Ca‘Ŗ’č‚Ģ—Տ°“I—L—p«B‘ę49‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB2002”N11ŒŽ23“śA‘åć
  42. ‰œ“c’‰sA¼ˆäĖŽqAŽÄŒ“’¼—˜AŠÖŖ“¹˜aAŽÄ‘„ŽqAć–ģ’q_A‘å–å—Ē’jA–k“‡ŒM:ŒŒ‰tƒKƒX•ŖĶ‚ɂ؂Ƃ鍂PCO2‚Ģƒ[ƒJ[ŠŌ·‚ĢŒŸ“¢(ƒ‰ƒWƒIƒ[ƒ^[ŽŠ vs BayerŽŠ)‘ę49‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB2002”N11ŒŽ24“śA‘åć
  43. ¬•ū‘„•vA–k“‡ŒMA’©‘q‹Ļ:ˆā“`ŽqŒ^CEHBVŠ“õĒ‚É‘Ī‚·‚郉ƒ~ƒuƒWƒ“Ž”—ĆŒų‰Ź‚ÉŠÖ—^‚·‚é—vˆö:HBVƒJƒCƒlƒeƒBƒNƒXAYMDD—Ģˆę”ń–ģ¶Œ^‰–ŠīA‹t“]ŽŹy‘fˆā“`ŽqˆŸŒ^‚Ģ‰šĶB‘ę38‰ń“ś–{ŠĢ‘ŸŠw‰ļ‘‰ļB2002”N6ŒŽA‘åć
  44. ¬•ū‘„•vA“‡–Ų‹M‹vŽqAŒKŽē”üē‘ćA‚“ˆC‘¾˜YA“n•Ó–¾Ž”:ƒEƒCƒ‹ƒXŠĢ‰Š‘Īō:BŒ^ŠĢ‰ŠƒƒNƒ`ƒ“ŪŽęó‹µ‚Ø‚ę‚ŃHBsR‘Ģ•]‰æ‚Ģ–ā‘č“_B‘ę40‰ń‘S‘‘åŠw•ŪŒ’ŠĒ—Œ¤‹†‘‰ļA2002”N10ŒŽA“Œ‹ž
  45. ‘å‰zĶŒįA‚‹“’BAŽs“c—²•¶A¬•ū‘„•v:BŒ^–«ŠĢ‰Š‚É‘Ī‚·‚郉ƒ~ƒuƒWƒ“1”NŠŌ“Š—^—į‚Ģ’·Šś—\Œć:’·Šś“Š—^—į‚Ę‚Ģ”äŠrB‘ę88‰ń“ś–{Į‰»Šķ•aŠw‰ļ‘‰ļA2002”N4ŒŽAˆ®ģ

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2001”N

’˜‘

  1. –k“‡ŒM:Ž~ŒŒEŒŒšAŒŒŠĒ“ą‰Č(]“ŖŒ’•ćA‹v•Ä“TŗA‘q—ѐ³•FAŒIŒ“—TŠīA–x“ą³ŽkAX‰ŗ—³ˆź•Ņ)AƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽŠA“Œ‹žApp95-104A2001
  2. –k“‡ŒM:ŒŒŠĒ“ą”ē×–EAÅVäPŒ“•aEƒŠƒEƒ}ƒ`Šw@(‹{āM”V•Ņ)A’©‘q‘“XA“Œ‹žApp6-13, 2001
  3. ŽRŒū@ˆźA–k“‡ŒM:LPS, Vascular Biology ƒiƒrƒQ[ƒ^[. (ŠŪŽRŖ˜YAˆĄ“”÷“ńA²“”–õŽj•Ņ)AƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽŠA“Œ‹žApp362-363A2001
  4. ¬•ū‘„•v:ć‘ŗ’©‹PA”©ŽRdH. DŒ^ŠĢ‰Š. Žs“c•¶OA‘¼A•ŅA—Տ°ŠĢ‘Ÿ•aApp 64-68, “ś–{ƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, “Œ‹ž, 2001.

Œ“’˜

  1. Kubo T, Kitajima I, Makinodan A, Nirastuka S, Inoue S, Otsuka G, Ohashi S, Ueshima K, Hirasawa Y. Fibrin Monomer would be useful predictor of pulmonary embolism following total hip arthropathy. -preliminary report- J Orthopaedic Sci. 2001;6:119-22.
  2. Yoneda T, Maruyama Y, Uji Y, Motomiya Y, Hashiguchi Y, Miura M, Kitajima I, Mariyama I. A possible role of leptin in the normo or hypoparathyroidism uremic bone in postmenopausal dialysis women. J Bone Miner Metab. 2001;19:119-24.
  3. Sarker KP. Nakata M, Kitajima I, Nakajima T, Maruyama I. Inhibition of caspase-3 activation by SB203580, p38 Mitogen-activated protein kinase inhibitor in nitric oxide induced apoptosis of PC12 cells. J Mol Neurosc. 2001;15:243-50.
  4. Saker KP, Uchimura T, Nakajima T, Sorimachi M, Kitajima I, Maruyama I. Epinephrine prevents oxide-/peroxynitrite induced apoptosis of neural cell death through b-adrenergic receptor activation. Neurosci Res Commun.
  5. Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, Yamakuchi M, Shimizu H, Matsu S, Imaizumi H, Maruyama I. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: Increase in endogenous cannabinoids in the seraof patients with endotoxin shock. Anal Biochem. 2001;249:73-82.
  6. Liu Y, Wang Y, Yamakuchi M, Masuta S, Tokioka T, Yamaoka S, Maruyama I, Kitajima I. Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type-1 tax. Oncogene. 2001;20:2514-26.
  7. Iguchi A, Kobayashi R, Yoshida M, Kobayashi K, Matsuo K, Kitajima I, Maruyma I. Vascular endothelial growth factor (VEGF) is one of the causative and predictive cytokines of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplantation. 2001;27:1173-80.
  8. Kishida A, Matsuyam T, Kitajima I, Maruyama I. Study of cell-material interaction by estimating NF-κB activation in HeLa S3 cells adhered on to hydrophilic substrates, Biomaterials. 2001;22:541-6.
  9. Liu Y, Wang Y, Yamakuchi M, Iwasaki S, Nagata E, Kanmura Y, Kitajima I, Maruyama I. Upregulation of toll-like receptor 2 gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is involved in NF-κB activation. Infect Immun. 2001;69:2788-96.
  10. Kubo T, Arai Y, Takahashi K, Ikeda T, Ohashi S, Kitajima I, Mazda O, Takigawa M, Imanishi J, Hirasawa Y. Expression of transduced HSP70 gene protects chondrocytes from stress. J Rheum. 2001;28:330-5.
  11. ¬•ū‘„•vA–k“‡ŒMAŽs“c—²•¶A’©‘q‹ĻA‚‹“‘„•FA–Ų‰ŗ·•q. ƒ‰ƒ~ƒuƒWƒ“‘Ļ«BŒ^ŠĢ‰ŠƒEƒCƒ‹ƒX:peptide nucleic acid mediated PCR clamping (PMPC)–@‚É‚ę‚éƒ|ƒŠƒƒ‰[ƒ[YMDDƒ‚ƒ`[ƒt‰–Šī•ĻˆŁ‚Ģ‚Š““xŒŸo. ŠĢ‘Ÿ. 2001;42:223-4.

Ē—į•ń

  1. Niimi H, Arimura K, Jonosono M, Hashiguchi T, Kawabata M, Osame M, Kitajima I: VEGF is causative for pulmonary hypertension in apatients with Crow-Fukase (POEMS) syndrome. Internal Medicine. 39:1101-1104, 2000.

‘ą

  1. –k“‡ŒM:ŒŸ‘ĢƒTƒ“ƒvƒŠƒ“ƒOAŒŒ‰t•Ū‘¶‚ʍ‚KŒŒĒBMedical Practice 18: 317, 2001
  2. –k“‡ŒM:‘½”­«œ‘Žī‚ʐŌ’¾BMedical Practice 18:1028, 2001
  3. –k“‡ŒM:ƒ|ƒXƒgƒQƒmƒ€Žž‘ć‚É‚Ø‚Æ‚é‘åŠwf—Ć•”‚Ģ‰Ź‚½‚·‚ׂ«–šŠ„Bˆā“`Žqf—Ć‚Ģd—v«BŽ­Ž™“‡‘åŠwˆćŠw•”ˆā“`ŽqŽ”—ĆŒ¤‹†‰ļ”N‰ļŽB4-6A2001
  4. –k“‡ŒM:ˆā“`Žqˆć–ņ•iŠJ”­‚Ę‚»‚Ģ—Տ°‰ž—p‚š–ŚŽw‚µ‚Ä:HTLV-IŠ“õĒ‚ĢŽ”—Ɖž—pAŒŒŠĒV¶—}§–@‚Ö‚Ģ‰ž—pBŽ­Ž™“‡‘åŠwˆćŠw•”ˆā“`ŽqŽ”—ĆŒ¤‹†‰ļ”N‰ļŽB8-9A2001
  5. –k“‡ŒM:ƒXƒeƒƒCƒh—U”­«œ‘e頏ĒBCLINICAL CALCIUM 11:34-40, 2001
  6. –k“‡ŒM:—Տ°ŒŸøˆćŠw‚ĢV‚µ‚¢ƒ`[ƒY‚šŠy‚µ‚ą‚¤BJACLaP NEWS 60:5A2001
  7. –k“‡ŒM:ƒ|ƒXƒgƒQƒmƒ€Žž‘ć‚Ģ—Տ°ŒŸøÅ‘OüB‘ę8‰ń’†•”’n‹ę—Տ°ŒŸøŒ¤C‰ļŽ:27-28, 2001
  8. –k“‡ŒM:ŒŒŠĒV¶‚É‚Ø‚Æ‚é“]ŽŹ’²ß‹@\BŒŒŠĒˆćŠw2:553-560, 2001
  9. –k“‡ŒM:comments for the paper of “Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Medicine, 2001;7:425-429”. Chugai Selected Cardiovascular Evidence, Excerpta Media. 10:2, 2001
  10. –k“‡ŒM:Molecular pathomechanisms of human T-cell leikemia virus type I (HTLV-I) rax-mediated tumorgenesis. @ē—tH‹Ę‘åŠwƒnƒCƒeƒNƒŠƒT[ƒ`ƒZƒ“ƒ^[@•½¬12”N“xuƒAƒ“ƒ`ƒZƒ“ƒXŠjŽ_‚Ģ•ŖŽqŻŒvvŒ¤‹†¬‰Ź•ń‘:26A2001
  11. ŽRŒū@ˆźA–k“‡ŒM:‰ŠĒ‚ɂ؂Ƃ錌ŠĒV¶‚ÉŠÖ‚·‚éÅ‹ß‚Ģi•ąB—Տ°–ʉu33:544-540, 2000
  12. ‹v•ŪrˆźA–k“‡ŒM:”xĒš—\‘Ŗ‚ɃtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[‘Ŗ’čBMedical Practice 18:1727, 2001
  13. ¬•ū‘„•v:˜aŠæ–ņ‚É‚ę‚é–ņ•Ø«ŠĢįŠQ:ŒŸøŽŗf’f‚Ģ–ā‘č‚ʏ«—ˆ. —Տ°ŒŸø

Šw‰ļŠˆ“®

‘ŪŠw‰ļ

  1. Kabata@T, @Kubo@T, @Matshumoto@T, @Nishino@M, @Horii@T, Kitajima@I, @Tomota@K:Apoptotic@cell death in steroid-induced osteonecrosis: an experimental study in rabbits. The 46th Annual Meeting of Orthopaedic Research Society. 2001, 3, SanFransico, USA
  2. Kabata@T, @Kubo@T, @Matshumoto@T, @Nishino@M, @Horii@T, Tomota@K, Kitajima I:Apoptotic@cell death in steroid-induced osteonecrosis in rabbits. The 4th Korea-Japan Combined Meeting of Rheumatology, 2001, 3, Tokyo

‘“ąŠw‰ļ

ƒVƒ“ƒ|ƒWƒEƒ€

  1. –k“‡ŒMA—«•FAŠŪŽRŖ˜Y:Toll like receptor (TLR)‚š‰ī‚·‚é“]ŽŹˆöŽqNF-κBŠˆ«‰»•ŖŽq‹@\:ƒAƒ“ƒ`ƒZƒ“ƒXNF-κB‚É‚ę‚éƒGƒ“ƒhƒgƒLƒVƒ“ŒŒĒŽ”—Ć–@ŠJ”­B‘ę5‰ńƒGƒ“ƒhƒgƒLƒVƒ“ŒŒĒŽ”—ĆŒ¤‹†‰ļA2001”N1ŒŽA‰”•l
  2. –k“‡ŒM:21¢‹I‚ĢƒGƒ“ƒhƒgƒLƒVƒ“ŒŒĒŽ”—ƁB‘ę5‰ńƒGƒ“ƒhƒgƒLƒVƒ“ŒŒĒŽ”—ĆŒ¤‹†‰ļA2001”N1ŒŽA‰”•l
  3. –k“‡ŒM: ŒŒŠĒV¶A‰ŠĒ‚š•W“I‚É‚µ‚½ˆā“`Žqˆć–ņ•i‚ĢŠJ”­B‘ę44‰ń“ś–{t‘Ÿ•aŠw‰ļ2001”N5ŒŽA“Œ‹ž
  4. –k“‡ŒM:ƒEƒCƒ‹ƒXŠ“õĒŽ”—Ć‚Ģi•ą‚Ę“W–]BŠ“õĒ•a‘ŌŒ`¬‰ß’ö‚šl—¶‚µ‚½ˆā“`Žqˆć–ņ•i‚ĢŠJ”­B‘ę73‰ń“ś–{¶‰»Šw‰ļ‘å‰ļ@2001”N10ŒŽA‹ž“s
  5. –k“‡ŒM:ƒGƒ“ƒhƒgƒLƒVƒ“ŒŒĒ‚É‘Ī‚·‚éV‚µ‚¢Ž”—Ɛķ—Ŗ:‚”Z“xLPSŽhŒƒó‘Ō‚Å‚ĶNF-κBŠˆ«‰»‚š‰ī‚µ‚ÄToll-like receptor 2‚Ģ”­Œ»—U“±‚Ŗ¶‚¶‚éB‘ę7‰ń“ś–{ƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†‰ļB2001”N11ŒŽ‘å‹{
  6. –k“‡ŒM:œ‘e頏Ē‚Ģf’f‚ĘŽ”—ƁB‘ę16‰ń“ś–{—Տ°ƒŠƒEƒ}ƒ`Šw‰ļ‘‰ļB2001”N11ŒŽA–¼ŒĆ‰®

µćŁu‰‰

  1. –k“‡ŒM:“®–¬d‰»i“W‚Ęƒvƒ‰[ƒNƒ‰ƒvƒ`ƒƒ[‚ɂ؂Ƃ錌ŠĒ“ą”ē×–EŠˆ«‰»‚Ģd—v«A‘ę2‰ńS‹Ų‹•ŒŒŒ¤‹†‰ļ2001”N5ŒŽA‘åć
  2. –k“‡ŒM:–«ŠÖßƒŠƒEƒ}ƒ`‚Ģœ”j‰ó‚ʍœ‘ćŽÓˆŁķ‚É‚Ā‚¢‚āB‹ą‘ņ®Œ`ŠO‰Č‰ÄŠśƒZƒ~ƒi[B2001”N7ŒŽA‹ą‘ņ
  3. –k“‡ŒM:ƒ|ƒXƒgƒQƒmƒ€Žž‘ć‚Ģ—Տ°ŒŸøÅ‘OüB‘ę8‰ń’†•”’n‹ę—Տ°‰»ŠwŒŸøŒ¤C‰ļB2001”N9ŒŽA•xŽR
  4. ¬•ū‘„•v: HBVŠ“õĒ‚É‘Ī‚·‚郉ƒ~ƒuƒWƒ“Ž”—Ć‚ĘHBVƒ|ƒŠƒƒ‰[ƒ[•ĻˆŁ@‘ę87‰ń“ś–{Į‰»Šķ•aŠw‰ļ‘‰ļƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[, 2001”N4ŒŽA“Œ‹ž(“śŒoƒƒfƒBƒJƒ‹ŽŠŽęŽ‹L˜^:Nikkei Medical 2001”N6ŒŽ†App 102-105. )
  5. ¬•ū‘„•v: HBV YMDDƒ‚ƒ`[ƒt‰–Šī•ĻˆŁ‚Ģ‚Š““xŒŸo
  6. ‘ę3‰ńƒ[ƒtƒBƒbƒNƒXŽ”—ĆŒ¤‹†‰ļ, 2001”N7ŒŽAVŠƒ
  7. ¬•ū‘„•v:‚aŒ^ŠĢ‰ŠƒEƒCƒ‹ƒXŠ“õĒ‚É‘Ī‚·‚郉ƒ~ƒuƒWƒ“Ž”—Ɓ@‘ę1‰ńŠĢŽ¾Š³Ž”—ĆƒJƒ“ƒtƒ@ƒŒƒ“ƒXA2001”N12ŒŽA•xŽR

ˆź”Ź‰‰‘č

  1. ²“”Œ[AĪ–ŲŠwAŽRčŸ–ēA’†‘ŗ“T—YA‰Y•—‰ėtA‘åŠp½Ž”A¬—ѐ³A‰œ“c’‰s:ŒŒˆ³’·•Ļ“®ƒXƒyƒNƒgƒ‹‚É‚ę‚é“œ”A•aŽ©—„_ŒoįŠQ‚Ģ•]‰æB‘ę9‰ń•xŽR“œ”A•a‡•¹ĒŒ¤‹†‰ļB2001”N2ŒŽ15“ś@•xŽRŽs
  2. ’·ąV’qŽqA—ŃŽj˜NAŠp“c”ü—éAX“c–¢A‘å–å—Ē’jA–k“‡ŒM:‹}«S‹Ų[Ē‚Ģ—Տ°Œo‰ß‚É‚Ø‚Æ‚éƒgƒƒ|ƒjƒ“T—L—p«‚ĢŒŸ“¢B‘ę40‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļA“ŒŠC–k—¤Žx•”‘‰ļB2001”N3ŒŽ11“śAĆ‰Ŗ
  3. ‰œ“c’‰sA–k“‡ŒMA²“”Œ[A‘åŠp½Ž”AŠÖŖ“¹˜a:S”EŒŒˆ³•Ļ“®ƒXƒyƒNƒgƒ‹‰šĶ‚É‚Ø‚Æ‚éŽQl³ķ’l‚É‚Ā‚¢‚āB‘ę40‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļA“ŒŠC–k—¤Žx•”‘‰ļB2001”N3ŒŽ11“śAĆ‰Ŗ
  4. –k“‡ŒMA‘å–å—Ē’j:‘åŠw¶‚ĢˆłŽšKŠµ‚Ęaldehyde dehydrogenese 2 ˆā“`Žq‘½Œ^‚Ę‚ĢŠÖ˜AB‘ę12‰ń“ś–{—Տ°‰»Šw‰ļ“ŒŠC–k—¤Žx•”‘‰ļB2001”N6ŒŽ23“ś
  5. ŒKŒ“‘ģ”üAģ“‡–ŅŽuA’J‚Ż‚ĖŽqAā–{ƒŽqA‘å–å—Ē’jA–k“‡ŒMA‰Į“”‹Ī:ŒŒ‰t×–E‰ę‘œƒtƒ@ƒCƒŠƒ“ƒOƒVƒXƒeƒ€‚Ģ\¬‚Ø‚ę‚Ń‚»‚ĢŠˆ—pB‘ę2‰ń“ś–{ŒŸøŒŒ‰tŠw‰ļŠwpW‰ļB2001”N6ŒŽA‘åć
  6. –k“‡ŒM:: –«ŠÖßƒŠƒEƒ}ƒ`‚ĢŠÖß”j‰ó‹@˜(œ‰č×–E‚ĢƒAƒ|ƒg[ƒVƒX—U“±•ŖŽq‹@\‚É‚Ā‚¢‚Ä)B‘ę31‰ń•xŽRƒŠƒEƒ}ƒ`‚ʖʉuŒ¤‹†‰ļB2001”N8ŒŽA•xŽR
  7. –k“‡ŒMA‰Į”Ø‘½•¶A‹v•Ūrˆź:ƒXƒeƒƒCƒh—U”­œ“Ŗ‰óŽ€‚É‚Ø‚Æ‚éƒAƒ|ƒg[ƒVƒX‚ĢŠÖ—^B‘ę19‰ń“ś–{œ‘ćŽÓŠw‰ļB2001”N8ŒŽA•xŽR
  8. ‰œ“c’‰sA‘å–å—Ē’jA–k“‡ŒMA²“”Œ[A‘åŠp½Ž”AŠÖŖ“¹˜a:ŒŒˆ³•Ļ“®ES”•Ļ“®ƒXƒyƒNƒgƒ‰ƒ€‰šĶ‚ɂ؂Ƃ鎾Š³(“œ”A•aA‚ŒŒˆ³)‚Ę‚ĢŠÖŒWB‘ę48‰ń“ś–{—Տ°ŒŸøˆćŠw‰ļ‘‰ļB2001”N8ŒŽA‰”•l
  9. ’·ąV’qŽqA‘½‰ź—R‹IŽqA¬–ģ—TŽqA–ģŽč—Ē„A‹g“c“sŽqA‘å–å—Ē’jA–k“‡ŒM:Haemophilus—Ž‚Ģ–ņÜŠ“Žó«ŽŽŒ±‚É‚Ā‚¢‚āBƒfƒCƒXƒN–@‚ĘMIC–@‚Ģ”äŠrB‘ę26‰ń–k—¤—Տ°•a—W’c‰ļB2001”N9ŒŽA‹ą‘ņ
  10. ‘å–å—Ē’jA‰œ“c’‰sAŒKŒ“‘ģ”üA–k“‡ŒM:Š³ŽŅƒT[ƒrƒXŒüć‚š–ŚŽw‚µ‚½‘åŠw•a‰@ŒŸø•”“ą‰üŠv‚ĢŽę‚č‘g‚Ż:ŒŸø•”“ąŠˆ«‰»‚ĘŽžŠŌŠO‹Ł‹}ŒŸø®”õB‘ę26‰ń–k—¤—Տ°•a—W’c‰ļB2001”N9ŒŽA‹ą‘ņ
  11. ŽÄ‘„ŽqA—ŃŽj˜NA–ģŽč—Ē„A‘å–å—Ē’jA¬ąV“N•vA–k“‡ŒMB¬Ž™RŠjR‘Ģ‚É‚Ā‚¢‚Ä‚ĢŒŸ“¢B‘ę26‰ń–k—¤—Տ°•a—W’c‰ļB2001”N9ŒŽA‹ą‘ņ
  12. ’J‚Ż‚ĖŽqAī’J»ŽqAā–{ƒŽqAģ“‡–ŅŽuAŒKŒ“‘ģ”üA‘å–å—Ē’jA–k“‡ŒMA“n•Óˆ»‰ĄAŒIŒ“^‹IŽqA–ģ‘ŗœØŽqA‹ąŒ“O˜aA–{‹½˜a‹vA”Ŗ–ŲMˆźA‹{˜e—˜’j:––½ŒŒƒŠƒ“ƒp‹…‚Ģ‹ó–EŒ`¬‚ʍDŽ_‹…‚ĢˆŁķ‰Ź—±oŒ»‚šŒ_‹@‚ɐf’f‚³‚ź‚½GM1ƒKƒ“ƒOƒŠƒIƒVƒh[ƒVƒX‚Ģ1—įB‘ę26‰ń–k—¤—Տ°•a—W’c‰ļB2001”N9ŒŽA‹ą‘ņ
  13. •Ÿ‰iŽõ°A’†‘ŗ³lA‰œ“c’‰sAŠā²ˆź˜YA’JĀA”~–{‰ė•vAŒKŽ•F:ŒŒ‰tƒKƒX‘Ŗ’č—p•W€•ØŽæ‚É‚ę‚é•W€‰»‚ĢŽŽ‚Ż(‘ę3•ń)B‘ę33‰ń“ś–{—Տ°ŒŸøŒŸøŽ©“®‰»Šw‰ļB2001”N9ŒŽA‰”•l
  14. ²“”Œ[AĪ–ŲŠwAŽRčŸ–ēAŠā“cŽĄA‘é“c”ü’qŽqA‰Y•—‰ėtAŠŻ“c‚Ż‚©AŒÜ\—’•ŪŽjAł‰Ŗ—˜ˆĄA‘åŠp½Ž”A‰œ“c’‰sA–k“‡ŒMA¬—ѐ³:ŒŒˆ³•Ļ“®ƒXƒyƒNƒgƒ‰ƒ€‰šĶ‚É‚ę‚é“œ”A•a«SŒŒŠĒŒnŽ©—„_ŒoĒŠO‚Ģ•]‰æB‘ę16‰ń“ś–{“œ”A•a‡•¹ĒŠw‰ļB2001”N10ŒŽA‘åć
  15. ŠLĄ–ĪŽO˜YA¬•ū‘„•vA䯒J’¼Ž÷A‘¼. “ļŽ”«CŒ^–«ŠĢ‰Š‚É‘Ī‚·‚éƒCƒ“ƒ^[ƒtƒFƒƒ“‚Ę–ƒ‰©“’‚Ģ•¹—p—Ć–@‚É‚Ā‚¢‚Ä. ‘ę34‰ń“ś–{ŠĢ‘ŸŠw‰ļ¼•”‰ļA2001”N12ŒŽA‚’m

‚»‚Ģ‘¼(u‰‰AŒ¤‹†‰ļA•×‹­‰ļ“™)

  1. –k“‡ŒM:‰F’ˆ—·s‚©‚ēœ‚ĢŒ’N‚šl‚¦‚éB@•½¬13”N“x•xŽRˆć‰Č–ņ‰Č‘åŠwŒöŠJuĄB6ŒŽ16“śA•xŽR
  2. ¬•ū‘„•v: u‚aŒ^ŠĢ‰Š‚ĢŽ”—Ɓv MutationŒŸoŒn@‘ę6‰ń Otsuka Liver Symposium, 2001”N11ŒŽA‘åć

Œ¤‹†”ļ

  1. ‰ČŠwŒ¤‹†”ļ•ā•‹ą(Šī”ÕŒ¤‹†C2):uŠąi“W‚É‚Ø‚Æ‚éƒCƒ“ƒ^[ƒƒCƒLƒ“8Pķ”­Œ»‹@\‰š–¾‚Ę”­Œ»—}§‚É‚ę‚錌ŠĒV¶—}§—Ć–@vŒ¤‹†‘ć•\ŽŅ(–k“‡ŒM)
  2. •¶•”Č‘åŠw‰@“Į•ŹŒo”ļ:•Ŗ’SŽŅ@(–k“‡ŒM)
  3. “ś–{Šæ•ūˆćŠwŒ¤‹†ŠŒ¤‹†•¬:u–«ŠÖßƒŠƒEƒ}ƒ`‚É–ņŒų‚šŽ¦‚·˜aŠæ–ņ‚Ģ“]ŽŹˆöŽqNF-κB)Šˆ«’²ß‹@\‰š–¾BŒ¤‹†‘ć•\ŽŅ(–k“‡ŒM)
  4. “ą“”‹L”O‰ČŠwU‹»ą’c:uŒŒŠĒˆā“`Žq‚Ģ“]ŽŹ’²ß‹@\‰š–¾‚ĘŒŒŠĒV¶•a‚ĢV‹Kˆā“`Žqˆć–ņ•iŠJ”­BŒ¤‹†‘ć•\ŽŅ(–k“‡ŒM)
  5. •½¬13”N“x‹³ˆēŒ¤‹†Šw“ą“Į•ŹŒo”ļ:uœEŠÖßŽ¾Š³‚É–ņŒų‚šŽ¦‚·Šæ•ū–ņ’Tõ‚Ę‚»‚Ģ“]ŽŹˆöŽq’²ß‹@\‰š–¾vŒ¤‹†‘ć•\ŽŅ(–k“‡ŒM)

ŽŠ‰ļ“IŠˆ“®

  1. –k“‡ŒM:—Տ°ŒŸøø“xŠĒ—‹¦‹c‰ļŒŚ–ā
  2. –k“‡ŒM:Ž­Ž™“‡‘åŠwˆćŠw•””ńķ‹ĪuŽt
  3. –k“‡ŒM:ˆć—ĆŠÖ˜AƒT[ƒrƒX’²øŽw“±ˆõ
  4. –k“‡ŒM:—Տ°•a—ø“ĒˆĻˆõ
  5. –k“‡ŒM:“ś–{œ‘ćŽÓŠw‰ļ•]‹cˆõA“ś–{—Տ°ŒŸøŠw‰ļ•]‹cˆõ
  6. Isao Kitajima: membership of New York Academy of Science
  7. ¬•ū‘„•v:‘Š’kˆõ. ŠĢ‚Ŗ‚ń–o–ŃtƒH[ƒ‰ƒ€2001 uŠĢ‰Š110”Ōv|ŠĢ‘Ÿ•a“d˜b‘Š’kŽŗA2001”N5ŒŽ, •xŽR@(–k“ś–{V•·ŽŠŽęŽ‹LŽ–:•½¬13”N5ŒŽ21“ś)

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é

2000”N

Šw‰ļŠˆ“®

‘ŪŠw‰ļ

symposium

  1. Isao Kitajima:Molecular pathomechanisms of human T cell leukemia virus type I (HTLV-I) Tax mediated tumorigenesis. Antisense, ribozyme development for HTLV-I related diseases 1st symposium of Chiba High Technology Research Center. Drug Discovery for Virus. (September 6-7, 2000) (Chiba, JAPAN)

‘“ąŠw‰ļ

ƒVƒ“ƒ|ƒWƒEƒ€

  1. –k“‡ŒM:ˆā“`Žqˆć–ņ•i‚É‚ę‚鎾Š³Ž”—Ć‚Ö‚ĢV‚½‚ČŒ¤‹†“WŠJ:ˆā“`Žqˆć–ņ•i‚ĢˆŁ‚Č‚éģ—p“_‚š—˜—p‚µ‚½ŒŒŠĒV¶‚Ö‚Ģ‰ž—p, ‘ę73‰ń“ś–{¶‰»Šw‘å‰ļ@10ŒŽ23“ś2000”N(‰”•l)

µćŁu‰‰

  1. –k“‡ŒM:ƒ|ƒXƒgƒV[ƒNƒGƒ“ƒXŽž‘ć‚É‚Ø‚Æ‚é—Տ°ŒŸøˆćŠw‚Ģ“W–], ‘ę6‰ńƒvƒƒWƒFƒNƒgƒtƒH[ƒ‰ƒ€ƒCƒ“”ņ’¹ 12ŒŽ2“ś2000”N(•xŽR)
  2. –k“‡ŒM:ŒŒŽī‚Ģ–šŠ„‚ĘŒŒŠĒV¶‚Ģ§Œä‚ÉŠÖ‚·‚éÅ‹ß‚ĢŒ¤‹†
    ‘ę3‰ń Cardiovascular Research Forum 12ŒŽ9“ś2000”N(“Œ‹ž)

ˆź”Ź‰‰‘č

  1. –k“‡ŒMAˆäŒū»—TAŒü“c’¼ŽjAŠŪŽRŖ˜Y:ŠĢ‘ŸŠą‚É‚Ø‚Æ‚éƒCƒ“ƒ^[ƒƒCƒLƒ“8‚ĢPķ“I”­Œ»•ŖŽq‹@\‚Ę‚»‚Ģ§Œä‚É‚ę‚錌ŠĒV¶—}§—Ć–@ŠJ”­, ‘ę47‰ń“ś–{—Տ°•a—Šw‰ļ‘‰ļ@11ŒŽ3“ś2000”N(ŒSŽR)
  2. ˆäŒū»—TA–k“‡ŒMAŽRŒū@ˆźAć–ģ^ˆźAˆ¤bFA¼“‡jŽ”AŒü“c’¼ŽjAŠŪŽRŖ˜Y:The transcription factor, PEA3 and AP-1 are required for constitutive Il-8 gene expression in human hepatoma cells. ‘ę23‰ń“ś–{•ŖŽq¶•ØŠw‰ļ”N‰ļ@12ŒŽ13“ś2000”N(_ŒĖ)

Œ“’˜

  1. Yamakuchi M, Higuchi I, Masuda S, Ohira Y, Kubo T, Kato Y, Maruyama I:Type I muscle atrophy caused by microgravity-induced decrease of myocyte enhancer factor 2C (MEF2C) protein expression. FEBS Lett. 2000;477:135-140.
  2. Saker KP, Obara S, Nakata M, Kitajima I, Maruyama I:Anandamide induced apoptosis of PC12 cells. Involvement of superoxide and caspase-3. , FEBS Lett. 2000;472:39-44.
  3. Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I. :Polymyxin B binds to anandamide and inhibits its cytotoxic effect., FEBS Lett. 2000;470:151-5.
  4. Kabata T, Kubo T, Matsumoto T, Nishino M, Tomita K, Katsuda S, Horii T, Nuto N, Kitajima I. :Apoptotic cell death in steroid-induced osteonecrosis: An experimental study in rabbits., J. Rheumatol. 2000;27:2166-71.
  5. Kabata T, Matsumoto T, Nishio M, Horii T, Kubo T, Kitajima I, Tomita K. :Histopathological and immunohistochemical study of femoral bone and bone marrow tissue in steroid treated rabbit. J., Neurol Orthop Med Surg. 2000;20:41-6.
  6. Ogata N:J. Gastroenteol Hepatol. 2000;15:100.
  7. Hayakawa Y, Hayashi T, Jung-Bum Lee, Ozawa T, Sakuragawa N.:Activation of heparin cofactor II by calcium spirulan. J., Biol. Chem. 2000;275:11379-82.
  8. Ozawa T, Sakuragawa N.:A thymine base is missed out of the published nucleotide sequence data of the antithrombin gene.,Br J Haematol. 2000;110:493.
  9. Ohta S, Ozawa T, Izumino K, Sakuragawa N, Fuse H.:A novel missense mutation of the WT1 gene causing Denys-Drash syndrome with exceptionally mild renal manifestations., J. Urology 2000;163:1857-8.
  10. Ohta S, Ozawa T, Shirage H, Fuse H. Genetic analysis of two female patients with incomplete Denys-Drash syndrome., Endocrine J. 2000;47:683-7.

‘ą

  1. –k“‡ŒM:ƒŠƒ{ƒUƒCƒ€‚Ģˆā“`ŽqŽ”—Ć‚Ö‚Ģ‰ž—pBˆćŠw‚Ģ‚ ‚ä‚Ż. 2000;129:240-1.
  2. –k“‡ŒM:ŒŒšĒB21¢‹I‚Ģ•ŖŽqˆćŠwBSŒŒŠĒ•a‚ĢŽ•ž‚š‚ß‚“‚µ‚āB•ŖŽqŒŒŠĒ•a. 2000;1:63-71.
  3. —«•FA–k“‡ŒM:ƒGƒ“ƒhƒgƒLƒVƒ“‚ĢŽó—e‘Ģ‚ĘƒVƒOƒiƒ‹“`’BBŒŒ‰tƒtƒƒ“ƒeƒA. 2000;10:27-32.
  4. X‰ŗ—³ˆźAĪ‹“•qKA–k“‡ŒM:‹}«Š„ĒŒóŒQ‚Ę‚»‚ĢƒŠƒXƒNƒtƒ@ƒNƒ^[. Pharma Medica. 2000;18:155-164.
  5. ¬ąV“N•v:ę“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“IIIŒ‡–RĒ‚Ø‚ę‚ŃˆŁķĒBŒŒ‰tƒtƒƒ“ƒeƒCƒA. 2000;10:13-9.
  6. ¬ąV“N•v:ŸNģM’j:DICŽ”—Ć–ņ‚Ģ–ņ—|ƒwƒpƒŠƒ“‚ĘƒvƒƒeƒA[ƒ[ƒCƒ“ƒqƒrƒ^[‚Ķ‚Č‚ŗŒų‚­‚Ģ‚©|.Medical Practice. 2000;17:237-9.

ƒy[ƒW‚Ģę“Ŗ‚Ö–ß‚é